Immune modulation in gene therapy studies by Aerts Kaya, F.S.F. (Fatima) et al.
Immune modulation in 
gene therapy studies
Points to consider for Environmental Risk Assessment
 
FSF Aerts Kaya     
2010   
Immune modulation in 
gene therapy studies
Points to consider for Environmental Risk Assessment
 
FSF Aerts Kaya     
2010   
Dr. Fatima S.F. Aerts Kaya
Dr.  Leonie C.M. Kaptein
Prof. Dr. Gerard Wagemaker
This report represents the ideas of the authors and does not necessarily represent the opinion of the Ministry of 
Housing, Spatial Planning and the Environment (VROM).
ISBN: 978-94-6169-011-1
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Immune modulation in gene therapy studies
Points to consider for Environmental Risk Assessment
Project execution
This project was executed by Dr. Fatima S.F. Aerts Kaya under supervision of Dr. Leonie C.M. Kaptein and  
Prof. Dr. Gerard Wagemaker, department of Hematology, Erasmus Medical Center, Rotterdam, at the request of 
the National Institute for Public Health and the Environment (RIVM).
Supervisory Committee
Regular meetings were organized to assess the progress and to provide feedback on the contents of the report.
We gratefully acknowledge the members of the supervisory committee:
•Prof.Dr.RobHoeben,DepartmentofMolecularCellBiology,LUMC,Leiden,TheNetherlands
•Prof.Dr.TonSchumacher,DepartmentofImmunology,NetherlandsCancerInstitute,Amsterdam, 
The Netherlands
•Dr.PiterBosma,LiverCenter,AMC,Amsterdam,TheNetherlands
•Dr.EricvandenAkker,GMOoffice,RIVM,Bilthoven,TheNetherlands
•Dr.RikBleijs,Genetherapyoffice,RIVM,Bilthoven,TheNetherlands
•Drs.ImkeHaenen,MinistryofHousing,SpatialplanningandtheEnvironment(VROM),TheNetherlands
This report represents the ideas of the authors and does not necessarily represent the opinion of the Netherlands 
National Institute for Public Health and the Environment (RIVM).
Contact
Dr. F.S.F. Aerts Kaya
Department of Hematology,
Erasmus Medical Center,
Rotterdam, The Netherlands
f.aerts@erasmusmc.nl
Publication year: 2010
P0
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Contents
CONTENTS 
 
Management Samenvatting 7
Summary  7
1  Introduction 9
 1.1  Rationale of the report 9
 1.2  Lessons from vaccination and non-gene therapy transplantation studies 9
 1.3  Overview of this report 10
2  Effects of immune modulation 11 
 2.1 Persistence of viral vectors 11
 2.2  Biodistribution 12
 2.3  Recombination events in unmodified viruses and viral vectors 13
  2.3.1  Recombination and mutation of wild type viruses 13
  2.3.2  Recombination in replicating and replication-defective vectors 14
  2.3.3  Recombination of non-human/artificial vectors 16
  2.3.4  Effects of immune modulation on recombination risk 16
 2.4  Shedding 16
 2.5 Translationofdatafromanimalmodelstotheclinic 18
  2.5.1 Gene therapy animal models using immune modulation 18
  2.5.2  The use of immune deficient preclinical animal models 19
  2.5.3  Conclusions from preclinical animal models 20
3  Environmental Risk Assessment (ERA) 23
 3.1  Factors and variables determining environmental risk 23
 3.2  Background information for the ERA 26
 3.3  ERA sample clinical trial 42
 3.4  ERA sample animal study 54
4  Conclusions and recommendations 58
 4.1  Introduction 58
 4.2  General conclusions 58
  4.2.1  Indications for immune modulation 58
  4.2.2  Risks of immune modulation 58
  4.2.3  Relevance regulatory affairs 59
 4.3  Recommendations 59
  4.3.1  Preclinical animal studies and readout systems 59
  4.3.2 Clinical studies & Immune modulation 59
  4.3.3 Precautionary measures 60  
  4.3.4  Regulatory aspects and risk assessment 60
 4.4  Future expectations and developments 61
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Contents
Appendix A Immune response against vectors 62
 Immune response against viruses, viral vectors and transgenes 63
  Adenoviruses 63
  Adeno-associated virus 65
  Herpes Viruses 67
  Vaccinia virus 69
  Retroviruses 70
  Other viruses 71
 Viral evasion mechanisms 73
  Evasion of the innate immune response 73
  Evasion of the humoral immune response 74
  Modulation of the cellular immune response 74
Appendix B Immune modulation and induction of tolerance 75
 Immune modulation 75
  Systemic immune suppression 75
  Inhibition of specific immune responses 76
 Induction of tolerance 80
  RegulatoryT-cells 80
  Hepatic gene transfer 80
  Muscle gene transfer 81
  Prevention of binding of Ad to clotting factors 81
 Prevention of immune detection 82
  Stealth-mechanisms 82
 Prevention of early vector clearance 82
  Complement depletion 82
Appendix C Lessons from the past 83
 Viral infections in patients with impaired immunity 83
  Immune deficiencies 83
  Transplantationpatients 83
 Recombination and shedding of live-attenuated vaccine viruses 84
  Gene therapy vector vaccines 84
  Non-gene therapy vaccines 85
Appendix D Project execution 88
 List of interviews with experts 88
 Meetings with the supervisory committee and project progress 88
 Attended meetings and publications 88
 Keyreferences 88
List of abbreviations 89 
Figures and Tables 90
References  105
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 7
Management Samenvatting / Summary
ManageMent SaMenvatting
Immuunmodulatie kan het milieurisico beinvloeden door 
twee mechanismen: langduriger vectorpersistentie zorgt 
voor een potentieel langduriger interactie met wildtype 
virussen en mogelijke recombinatie en kan de kans op en/
of duur van shedding van de toegediende virale vectoren 
en de eventuele milieurisico’s die daarmee samenhangen 
verhogen; immuun-gecompromiteerde individuen zijn 
gevoeliger voor infecties, met als gevolg een toegenomen 
kans op co-infectie met wildtype virussen. Huidige data 
uit dierstudies zijn onvoldoende om een voorspellende 
milieu risicoanalyse te doen voor de klinische situatie. 
Gebruik van immuunmodulatie in het klinische genther-
apieveld moet daarom nauwgezet worden bijgehouden 
en data zouden makkelijk(er) toegankelijk moeten zijn 
om klinische protocollen vlug te kunnen bijwerken in 
antwoord op nieuwe ontwikkelingen. 
Hier stellen wij het gebruik van een checklist voor om 
huidige milieurisico’s binnen het gebruik van immuun-
modulatie bij gentherapie onder de aandacht te brengen 
in de verwachting dat dit rapport zal kunnen dienen als 
een leidraad bij de risicobeoordeling en beleidsvorming 
bij gentherapiestudies. 
Trefwoorden: Milieu Risicobeoordeling, Virale vector, 
Gentherapie, Immuunmodulatie
SuMMary
Host immune responses play a major role in clearance of 
viral infections from the body, and may limit long-term 
expressionandclinicalefficacyofviralvectors.Methods
to prevent these immune responses may also increase 
the risk for infections, recombination with wild type 
virus and affect biodistribution, persistence, shedding 
and transmission. The study described in this report was 
initiated to assess possible environmental risks associated 
with the use of immune modulation in combination with 
gene therapy and set up as a literature study, by perform-
ing PubMed searches for certain keywords, by interview-
ing experts and by attending selected meetings. Lack of 
availability of clinical data combining gene therapy and 
immune modulation and limited animal data warranted 
additional exploration of relevant non-gene therapy 
studies from closely related fields such as stem cell and 
organ transplantation, and vaccination studies with live 
attenuated vaccines.
Adenovirus-based (Ad) vectors induce a rapid im-
mune response, resulting in the formation of neutralizing 
antibodies (NAb) and clearance by cytotoxic T-cells
(CTL). Immune responses against Adeno-associated
viruses (AAV) are considerably less robust, and largely 
dependent on the presence of helper virus, state of im-
mune activation and the immunogenicity of the trans-
gene.ClearanceismediatedbyaCTLandNAbresponse.
Herpes Simplex Virus (HSV) vectors are highly immuno-
genic and induce a rapid activation of complement and a 
robustNAbandCTLresponse.Rapidcapsidturnoverof
Lentivirus (LV) vectors prevents effective recognition of 
immunogenicepitopesbyactivatedeffectorT-cells,but
immune responses against LV may still occur in presence 
of an antigenic transgene. Clearance is predominantly 
NAb mediated.
Currently, a broad variety of immune modulatory 
agents is used in the (pre)clinical setting to prevent or 
dampen the immune response against viral vectors. 
Immune modulation with Cyclophosphamide (CY), 
an alkylating chemotherapeutic agent, was shown to 
result in a diminished formation of NAb and prolonged 
transgene expression when used with Ad, AAV and HSV 
vectors;CTLA4Ig isa fusionproteinof thecytotoxicT
lymphocyteantigen-4(CTLA4,CD152)andanantibody
and was able to decrease NAb and prolong transgene 
expression of Ad, AAV, and LV vectors, the use of Cy-
closporin A (CsA), an immune suppressive agent, and 
Mycophenolate Mofetil (MMF), an inhibitor of purine 
biosynthesis in lymphocytes, showed variable results, but 
was in general only moderately or not effective. However, 
animal studies used different doses, different combina-
tions, different time of administration, different routes 
of administration of the immune modulating agents, as 
well as different types and generations of viral vectors. In 
addition, differences in persistence, biodistribution and 
shedding were not systematically measured. Neverthe-
less, immune modulation appeared to affect biodistribu-
tion to some extent with more off-target transduction 
of the liver due to the potentially prolonged presence of 
vectors in the circulation in case of replication-deficient 
viral vectors, and a broader biodistribution pattern (ie to 
extratumoral tissue) for replication-competent oncolytic 
viral vectors. 
Gene therapy animal models show a great discrepancy 
in the choice and timing of immune modulation and gen-
erally lack systematically obtained data on biodistribution 
and shedding.BothCYandCTLA4Ig can (transiently)
prolong transgene expression, but increased risks for 
shedding or transmission were not reported in any study. 
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Future animal studies using immune modulation should 
include these data in their experimental setup to allow for 
a proper risk assessment. 
Carefull reviewing of vaccinination studies with live 
attenuated viruses demonstrated that 1) albeit possible, 
adults are unlikely to transmit to other adults 2) high 
vaccine vector titers in pre-immune young children may 
increase the risk of transmission to other young children 
or even adults, 3) shedding and secondary or even tertiary 
transmission most often occur via direct contact with the 
site of vaccine inoculation of the vaccinee, 4) the risks 
of transmission depend on other environmental factors 
including frequent contact with excreta from other young 
children and the level of immune competence, and 5) 
transmission may occur due to breeches in precautionary 
measures despite written instructions.
Similarly, it is anticipated that the risks of recombina-
tion between recombinant viral vectors and related wild 
type viruses will be the highest in the pediatric pre-im-
mune population. The risk of shedding is likely affected 
by additional handling, such as modification of vectors, 
affecting replication competentence and immune eva-
sion mechanisms, immune modulation, the route of 
administration; the delivered viral vector load (single 
dose or/re-administration) and may remain unaltered in 
cases where expression of the transgene and transgenic 
proteins is increased, but duration of persistence of the 
viral vector remains unchanged.
Immune suppression or modulation can possibly 
affect the environmental risk by two mechanisms, i.e. 
longer persistence of the vector may increase the duration 
of interaction with wild type viruses and recombination 
and potentially increase the risk and/or duration of shed-
ding of administered viral vectors and consequently the 
environmental risks; immune suppressed individuals 
are more susceptible to infections, thus increasing the 
chances of interaction with specific wild type viruses. 
Currentdatafromanimalstudiesarenotsufficienttodo
a predictive environmental risk assessment for the clini-
cal situation. Applications of immune modulation in the 
clinical gene therapy field therefore need to be followed 
carefully and access to data should be open and (more) 
readily accessible to be able to adjust clinical protocols 
quickly in response to new developments. 
Finally, we propose the use of a checklist to assess 
current environmental risks in the use of immune modu-
lation during gene therapy. This report is expected to 
provideguidancetoriskassessorsandregulatoryofficers
as well as to applicants for a gene therapy licence.
Keywords: 
Environmental Risk Assessment, Viral Vector, Gene 
Therapy, Immune modulation
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Introduction
1 introduCtion
1.1 rationale of the report
Host immune responses play a major role in the clear-
ance of viral infections from the body.  The induction 
of these immune responses are now being used to our 
advantage in the treatment of certain cancers, such as 
malignant melanoma, lung cancer, prostate cancer etc, 
by boosting the immune response against malignant 
cells, carrying viral antigens. However, for the treatment 
of monogenetic diseases, such as enzyme deficiencies, 
storage disorders, muscle diseases and immune deficien-
cies, the same (acquired) host immune response plays a 
crucial role as a determinant of long-term expression and 
clinicalefficacy.
Viral gene products as well as transgene products, 
viral proteins, CpG DNA in plasmids and the transduced 
cells themselves all play an important role in inducing the 
host immune responses upon transfer into the targeted 
tissues. A key concern in the treatment of inherited pro-
tein or enzyme deficiencies by gene therapy is the risk for 
an immune response against the foreign therapeutic pro-
tein, which is distinct from the mutant protein produced 
by the patient. These immune responses may result in 
decreasedefficacyandefficiencyofgenetherapy,leading
totransientexpressionoftherapeuticgene,non-efficient
re-administration of the same vectors, and possibly (se-
vere) side-effects in clinical trials.
As the potential success of gene therapy for chronic 
types of diseases depends fundamentally on long-term 
transgene expression to either cure or slow down the 
progression of a disease, immune modulation to dampen, 
eradicate or ideally prevent an immune response could 
increase the therapeutic benefits of gene therapy. 
Currently employed techniques to decrease immune 
responses include, among other, systemic immune sup-
pression, blockade of co-stimulatory molecules, the use 
of anti-inflammatory cytokines, as well as (structural) 
modification of viral vectors. These methods to suppress 
the (acquired) immune response or to reduce the im-
munogenicity of vectors and transgenic proteins are used 
with the aim to have a more effective treatment. In cases 
where this leads to longer persistence of viral vectors the 
risk of interaction or recombination with wild type 
viruses and shedding subsequently increases, thereby 
possibly imposing an unintended environmental risk. 
This study was initiated by the National Institute for 
Public Health and the Environment (RIVM)in a response 
to an increased demand of the governmental regulatory 
institutions 1) to assess the possible environmental risks 
associated with the use of immune modulation in combi-
nation with gene therapy; 2) to generate an overview of 
relevant data to assess new applications for future clinical 
trials involving immune modulation; and 3) to provide 
research groups with some background information on 
the immunology of gene therapy and the availability, 
possibilities, risks and advantages of current immune 
modulatory agents.
In this study, we evaluate the effects of immune mod-
ulation on the efficacy of gene therapy and provide an
overall assessment of the environmental risk of recombi-
nation with wild type viruses and possible shedding. The 
study was designed as a literature study, using PubMed 
searches for various keywords, including immune sup-
pression, immune modulation, gene therapy, immune 
reponses, tolerance and others. Additional information 
was obtained by attending relevant conferences and 
through personnal communications with experts in the 
field (for more information see Appendix D).
1.2 Lessons from vaccination and non-gene therapy 
transplantation studies 
Data from preclinical and clinical gene therapy studies 
can be used for making risk assessments. However, these 
data are still limited and risk assessment could be further 
supported by making use of the experience from related 
fields, including (stem cell) transplantation and viral vac-
cination studies.
A major environmental safety concern for the use of 
a vector of viral origin for gene therapy is the potential 
spreading of the vector into the environment via excreta 
from the patient. This phenomenon is called shedding. 
Shedding of viral vectors does not per se result in person-
to-person transmission and generally requires the pres-
ence of considerable levels of virus in multiple excreta 
and, more importantly, requires that treated individuals 
shed vector in an amount that is equal to or greater 
than a human infectious dose. In order to obtain better 
insight in the occurrence of viral spread to other persons 
viral vaccination studies were  analysed for assessing the 
likelihood of horizontal transmission and furthermore to 
determine which factors are of influence. 
Many of the agents currently tested for immune 
modulation in gene therapy, have been used as immune 
suppressive drugs in cancer treatment as well as in stem 
cell and solid organ transplantation to prevent GvHD 
and graft rejection. Reciprocally, these agents all carry the 
intrinsic risk of increasing the susceptibility to distinct in-
fections, depending on the modes of action and duration 
of use. Patients with primary immune deficiencies and 
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with acquired immune deficiencies are also highly sus-
ceptible to a wide range of (viral) infections. Here, we give 
an overview of the different immune modulatory drugs 
currently used and their relation with the occurrence 
of viral infections and an outline of most common viral 
infections observed in immune compromised patients. 
Using these four categories of immune compromised
patients as a “worst case” scenario for attracting virus 
infections, we will attempt to make a prediction of the 
risk of viral infections that might occur in gene therapy 
trials using immune modulation to prevent immune 
reactions against the viral vectors, viral proteins and 
transgenes. Based on this risk assessment, a risk estima-
tion of recombination between wild type viruses and viral 
vectors, and possible shedding and transmission to health 
care personnel and relatives will be approximated and 
presented as a flow chart depicting relative risks of the 
use of immune modulation in combination with specific 
viral vectors. This flow chart can be used by governmental 
organizations, ethics committees and other advisory bod-
ies to assess environmental risks for immune modulation 
gene therapy, but is also intended as a reference guide for 
clinicians during the planning, monitoring and reporting 
of new gene therapy trials. 
1.3 overview of this report
Data presented not only include gene therapy studies, but 
also all relevant non-gene therapy, clinical studies from 
related fields, including (stem cell) transplantation and 
viral vaccination studies, and all preclinical gene therapy 
studies using any type of immune modulation. This re-
port consists of an introduction to the subject (chapter 1), 
the effects of immune modulation (chapter 2) and a list 
of points to consider when to assess the risks of immune 
modulation (chapter 3). Background information is 
provided in appendices: on immunogenicity of currently 
used viral vectors (appendix A), immune modulation 
currently used in the clinics (appendix B), lessons from 
vaccination studies with live attenuated vaccine strains 
(appendix C) and some lists of relevant literature and/or 
meetings (appendix D). 
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Effects of immune modulation
2 effeCtS of iMMune ModuLation
2.1 Persistence of viral vectors
In ongoing clinical trials, the use and choice of immune 
modulatory agents, is usually dictated by the underlying 
disease (genetic versus malignant disorder) and may 
be a requirement for the gene transfer procedure (e.g. 
hematopoietic stem cell transplantation). For genetic 
disorders this is done with the aim to obtain longlasting 
persistence of the transduced cells. For cancer there are 
increasingly more studies that want to make use of the 
host immune system in order to attack the cancer cells. 
Furthermore, in animal studies for genetic disorders, the 
focus has been on methods to decrease the host immune 
response against vector or transgene; whereas in preclini-
cal studies for malignant disorders, the focus has been on 
methods to stimulate the specific anti-tumor response. 
To this purpose, a wide range of immunemodulatory
agents have been tested, including the use of different 
animal models, doses of the agents, administration regi-
mens (before gene therapy, after gene therapy, multiple 
or single treatment), as well as combinations between 
immune modulatory agents. These data have been sum-
marizedinTableIImmunesuppressionusedinclinical
trials and animal studies with ex vivo gene transfer and 
Table II (A) Immunemodulationused in animal stud-
ies using in vivo delivery of replicaton deficient vectors 
and (B) replication competent vectors, (C) Structural 
modications used in animal studies using in vivo delivery 
of replication competent vectors, (D) Immunodeficient 
animal studies using in vivo delivery of replication defec-
tiveand(E)replicationcompetentvectors.TableIshows
immune suppression is used in order to provide space in 
the hematopoietic compartment for the transduced cells, 
which is especially needed when no growth advantage 
overnon-transducedcellsistobeexpected.InTableII,
it is shown that the most commonly used immune sup-
pressive therapy was blockade of co-stimulatory signals, 
particularly by usingCTLA4Ig, a fusion protein of the
cytotoxicTlymphocyteantigen-4(CTLA4,CD152)and
an antibody, which blocks CD80 and CD86, followed by 
therapy with monoclonal antibodies. In addition, not 
only are almost all data concerning the effects of immune 
modulatory agents in combination with gene therapeutic 
procedures from animal studies, the majority of these 
studies involve either adenoviral (Ad) vectors or adeno-
associated virus (AAV) vectors and an occasional study 
involves retroviral (RV) vectors. None of the studies used 
immune modulatory agents in combination with Herpes 
Simplex Virus (HSV)-based vectors, which is interesting 
considering the vast immune responses induced by HSV. 
This could be explained by the fact that HSV is mostly 
used in cancer therapy and that this property of HSV 
is taken as an advantage by enhancing the effect of the 
immune system in attacking the cancer cells. Therefore, 
theneedtoimprovetheefficacyofthetherapybyusing
immune modulatory agents is more critically needed in 
cases where Ad and AAV-derived vectors are used for 
long-term gene correction. Upon administration, Ad
induces a rapid and robust immune response due to 
binding to several blood components (complement, red 
blood cells, macrophages, etc) and clearance is mediated 
by apredominantlyCD8+CTL response.The immune
response against AAV is generally moderate, but the slow 
uncoating of AAV capsid proteins allows for the induc-
tionofananti-AAV-capsidCTLresponseandclearance
of the vector by neutralizing antibodies. Clearance of 
AAV serotypes 1-9 from the circulation to <1% of the 
inoculated dose occurs typically within 48 hours1. In 
addition, widespread pre-existing immunity against both 
Ad and AAV necessitates the use of immune modulation, 
either through (transient) immune suppression or by 
vector modifications using stealth technology. Herpes 
virus and some retroviruses are known to pass from cell 
to cell by direct entry through and budding from the 
cell membrane of the cells. Viral antigen presentation is 
particularly abundant in cells infected by the latter type 
of viruses, marking these cells as ‘infected’ and rendering 
themsusceptibletoattackbycytotoxicT-cells.However,
as in most cases RV and lentiviral (LV) vectors are used in 
ex vivo transduction procedures resulting in integration 
in the genome, from a shedding perspective these type of 
vectors become less relevant, since the vectors by itself are 
not expected to enter the circulation. When viral vectors 
such as Ad, RV/LV and HSV are used in vivo, immune 
suppressants affecting lymphocyte function or numbers, 
such as Cyclosporin, which specifically inhibits prolifera-
tionofT cells;ATG,which isused todeplete lympho-
cytes;andCampath,whichisusedtolyseCD52+Tcells,
B cells and monocytes, could interfere here, and specifi-
cally prolong the presence of vectors, as well as mutant 
viruses, formed by recombination. In contrast, viruses 
that are predominantly cleared through formation of 
virus-specific neutralizing antibodies, such as AAV and 
Reovirus (Reo), could benefit from immune modulatory 
agents affecting B cell number and/or function or other 
interventions delaying or attenuating the development 
of neutralizing antibodies, eg Rituximab or Cyclophos-
phamide. Selective anti-B cell immune modulation could 
even enhance the effect of reovirus gene therapy, since the 
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oncolytic reovirus requires a certain level of functional 
TcellstoascertainkillingofReovirus-infectedmalignant
cells. 
2.2 Biodistribution
Biodistribution of the most commonly used gene therapy 
vectors in immune-competent animals is reviewed by 
Gonin and Gaillard (2004)2. Below you can find further 
information on (1) immune deficient animal models (Ad 
and Vaccinia Virus, VACV); (2) serotype-switching, cir-
cumventing pre-exisiting immunity (AAV); and (3) ac-
tive immunomodulation (reovirus). Biodistribution (this 
paragraph) and shedding (paragraph 2.4) are discussed as 
separate entities here, but are clearly dependent on each 
other. Therefore some overlap in the discussions below 
cannot be avoided. 
adenovirus
Administration of replication-deficient human Ad5 
(HAd5) based vectors to Severe Combined Immune 
Deficiency (SCID) mice resulted in whole body bio-
distribution, with the highest number of vector copy 
numbers in liver and spleen after intravenous injections, 
in prostate and liver after intraperitoneal injection and 
in draining lymph nodes after injection into paws and 
subcutaneous tissue3. Replication-deficient vectors based 
on non-human Ad serotypes, such as bovine Ad3 (BAd3) 
and porcine Ad3 (PAd3) can be used to circumvent pre-
existing immunity and were found to distribute to the 
liver, spleen, lung, heart and kidney when intravenously 
injected into healthy FVB/n mice, with similar (PAd3) 
or even higher (BAd3) vector copy numbers than HAd5, 
detectable up to 16 days after intravenous injection3.
In an athymic mouse xenograft tumor model, it was 
demonstrated that after a single intravenous injection of 
ONYX-015, 90% of the virus could be recovered from the 
liver within 3-6 hours, with 250 fold less infectious parti-
cles per gram tissue being found in the tumors. However, 
following tumorselective replication for 3 days, no infec-
tious virus could be recovered from liver, while titers had 
increased 100-fold in tumor tissue, demonstrating the 
possibilities of systemic infusion in an immune deficient 
mouse model and the feasibility of this procedure for 
future clinical applications3. Evidence for viral replication 
within human tumor tissue and shedding of ONYX-015 
into the circulation was found in patients receiving doses 
exceeding 2x1012 particles with 2.5 to 10 fold increased 
levels of viral genome detected in the plasma at 48 hrs 
after infusion in comparison to levels at 6 hrs. ONYX-
015 has been used in many clinical trials sinds 1996, 
demonstratingsafety,butlimitedefficacy.H101,another
oncolytic adenovirus with an E1B-55 kDa deletion, was 
recently approved for marketing in China based on 
promising results in head and neck cancers4. After intra-
tumoral injection into nasopharyngeal carcinomas, virus 
could be detected in blood, urine and the oropharynx. 
Combination treatment of H101 with cisplatin resulted 
despite leucopenia in an antibody response against H101 
at day 22 after treatment4.
adeno-associated virus
AAV2 is the most commonly used serotype for gene 
therapy and has been used in a variety of clinical trials. 
Pre-existing neutralizing anti-AAV2 antibodies limit the 
efficacyoftreatmentandtheuseofalternativeserotypes
or pseudotyping may circumvent these limitations. Com-
parisonoftransductionefficiencyandbiodistributionof
AAV-pseudotyped capsids 1, 5, 6 and 8 serotypes with 
single stranded (ss) or double stranded (ds) AAV2 after 
intravenous injection into immunocompetent male and 
female mice and imaging studies using luciferase as a 
marker to study biodistribution of AAV serotypes 1-9, 
demonstrated the widest biodistribution of AAV9, but 
thehighesttransductionefficiencyoflivercellsbyAAV8
in mice, independent of the gender of the mice and the 
genomic structure of the vector; AAV4 vectors showed 
the greatest number of genome copies in lung, kidney 
and heart tissue; AAV5-pseudotyped vectors showed 
no appreciatable extra-hepatic gene expression; AAV6 
vectors showed strong gene expression in the liver, the 
lower limbs skeletal muscle and heart muscle cells; both 
ssAAV1 and ssAAV8 vectors displayed significant gene 
expression in the lower abdominal area and gene transfer 
to the stromal cells of the gonads of female animals, 
but not in oocytes and gene transfer to offspring was 
not observed1,5. In C57Bl6 mice it was shown that upon 
iv injection, AAV6 vectors are shortly sequestered in 
liver (up to 72 hours) and spleen (largely cleared within 6 
hours) and persist for up to 6 hours in serum, explaining 
the relatively efficient transduction of skeletal muscle
cells6. Furthermore, it was shown that biodistribution of 
the several AAV serotypes is dependent on the route of 
delivery.
retrovirus and Lentivirus
After intravenous injection of non-targeted replication-
competent MLV-based vectors to tumor-bearing CB17 
SCID mice, vector DNA was not only found intratu-
moral, but also distributed efficiently to most organs,
appearing consecutively in spleen, liver and bone marrow 
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and to a lesser extent in the lung tissue, but not the brain7. 
Increasing PCR signal intensities and the detection of 
infectious viral particles in blood suggested continuous 
replication of MLV. In contrast, targeted MLV-based 
vectors, which are activated by matrix metalloproteinases 
(MMP) present in tumor cells, were found only in tumor 
sites, and showed no signs of extra-tumoral replication or 
biodistribution7.
Most lentiviral vectors are based on the HIV-1 virus. 
However, the HIV-1 gp120 restricts transduction of 
HIV-1 vectors to CD4+ cells and limits its usefulness 
for other gene therapy applications. VSV-G is the most 
commonly used viral envelope protein used for LV 
pseudotyping, but other envelopes including rabies, 
MLV-amphotropic, Ebola, baculovirus, and measles vi-
rus envelopes have also been used to modify transduction 
patterns8. Pseudotyping with VSV-G results in a broad 
tropism and allows transduction of hematopoietic stem 
cells, brain, muscle and liver. Intraperitoneal injection of 
VSV-G pseudotyped LV encoding  the immunomodula-
tory protein VIP in immunocompetent mice resulted 
in predominant biodistribution and transduction of the 
spleen, liver, adipose tissue and draining lymphnodes, 
but not kidney cells9. Intravenous injection of a VSV-G 
pseudotyped lentiviral vector encoding the adenosine 
deaminase (ADA) enzyme into neonatal ADA-deficient 
SCID mice resulted in primary transduction of liver 
and lung and low level transduction of peripheral blood 
leucocytes, thymus, spleen and bone marrow10. 
vaccinia
Modified Vaccinia Virus Ankara (MVA) and MVA-based 
vectors were previously shown to be safe in immune de-
ficient mice11, SIV-infected monkeys11 and HIV-infected 
humans12, with clearance of all vector DNA, including 
the injection site, within 81 days in mice and 9 weeks 
in monkeys after intradermal injection. In normal, 
healthy C57Bl/J mice, MVA was detected 6 hours after 
intraperitoneal inoculation in almost all tissues studied, 
including the lungs, spleen, lymph nodes and ovaries and 
after subcutaneous injection predominantly in draining 
lymph nodes, although low level virus was detected in 
other organs as well, but was below detection levels at 48 
hours after inoculation13.
reovirus
Wild-type Reovirus type 3 Dearing (RT3D), the most
commonly used oncolytic reovirus strain, is non-
pathogenic in healthy persons and infections are either 
asymptomatic or may result in mild respiratory or enteric 
symptoms. Clearance of the virus is predominantly medi-
ated by neutralizing anti-reovirus antibodies. In a mouse 
tumor model, treatment with Cyclophosphamide was 
shown to significantly blunt the neutralizing antibody 
response against Reovirus and allow effective infection of 
tumorcellsbyRT3D.However,highdosesofCyclophos-
phamide abrogating any formation of neutralizing anti-
bodies and complete absence of B-cells in B-cell knockout 
mice were associated with severe toxicity and distribution 
and replication of Reovirus in normal organs14. 
2.3 recombination events in unmodified viruses and 
viral vectors
Mutation events such as removal or insertion of a nucleo-
tide or a group of nucleotides (deletion or insertion mu-
tants) are not uncommon during virus replication and 
are much more frequent in RNA than in DNA viruses15. 
In fact, all RNA viruses are thought to exist as mixtures of 
countless genetic variants with slightly different genetic 
and antigenic compositions. Recombination is brought 
about by the exchange and subsequent covalent linkage 
of genome fragments from a single gene or from two 
coinfecting related viruses15 and does not generally occur 
among distantly or unrelated viruses. Recombination 
may give rise to a virus with hitherto unknown charac-
teristics and may also give it a selective advantage over 
its relatives. More often though, the recombinant will 
have properties incompatible with survival15 (personal 
communications with Ben Berkhout/Marco Schilham), 
for example the size of the recombinant genome may 
simplybetoolargeforefficientpackaging.Withcertain
RNA viruses, such as influenza (orthomyxoviridae) and 
rotaviruses (reoviridae), in which the genome exists as 
separate fragments, simple exchange of genes may occur, 
a process known as gene reassortment. Such reassortant 
viruses have characteristics that differ from those of the 
parental viruses. The frequency of such gene exchanges 
may be very high, much higher than that of true re-
combination. Such genetic reassortment can extend the 
gene pool of the virus and allow the emergence of new 
and successful variants15. In addition, in at least some 
RNA viruses, such as influenza, very few or even a single 
nucleotide modification can turn a non-virulent strain 
into a virulent strain.
2.3.1 recombination and mutation of wild type viruses
In general, RNA viruses are more prone to mutations due 
to lack of proofreading mechanisms, which cause a high 
mutation rate, and short replication times allowing RNA 
virus to rapidly adapt to a new environment. The ortho-
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retroviruses, including the gammaretroviruses (MLV, 
HTLV-1andHTLV-2)and lentiviruses (HIV-1,HIV-2
and SIV-2) replicate through a DNA intermediate, which 
is formed after virus entry and the process of reverse 
transcription. The formed double-stranded linear DNA 
is transported to the nucleus, where it is stably integrated 
into the cellular DNA of the host cell to form the provirus. 
UsuallyoneDNAcopyisgeneratedfromthetwoRNA
genome copies that are present in the virion16. During 
reversetranscription,theRTenzymecanjumpfromone
template strand to the other, thereby generating a hybrid 
transcript. If the two RNA templates are not identical, 
template switching (TS) can contribute to the overall
retroviral mutation rate16-18.TSeventscaneventakeplace
between distantly related retroviruses, provided that the 
different viruses can cross-package the heterologous viral 
genomes19. It was calculated that the rate of retroviral 
recombination, during co-infection of viruses with dis-
tinct genomic RNAs, could reach up to 2% per kilobase 
per replication cycle, resulting in recombinant progeny 
in almost 50% of the mixed infections16,17. Furthermore, 
it was shown that recombination occurred only after the 
viral RNAs had been packaged into particles and that co-
packaging of two different genomic RNAs as a heterodi-
mer is a requirement for recombination18. Importantly, 
retroviral recombination does not occur during the initial 
infection, but takes place only after a second infection by 
the progeny of the initially infected cells. This unusual 
feature stems from the diploid nature of the virion ge-
nome and its mode of replication18. This could turn out to 
be relevant at later timepoints after gene therapy studies 
using retroviral vectors and immune modulation or in 
patients otherwise susceptible to superinfection with 
HIV. Nevertheless, the risks of recombination events are 
greatly diminished due to the absence of all viral genes in 
these vectors. Thus, orthoretroviral genomes are highly 
susceptible to the introduction of mutations, most of 
which are assumed to result from the action of the viral 
RT.Incontrast,thefoamyvirusesarethemostgenetically
stable viruses among the retrovirus family20,21. Analysis of 
recombination frequency of FV genomes revealed a 27% 
probability for a template switching event per 1 kb20. 
The DNA viruses are considerably less prone to mu-
tations, as viral DNA polymerases have greater fidelity 
due to proofreading capability and viral genomes can 
remain stable under a variety of conditions. However, 
the existence of multiple (newly occurring) serotypes 
among the DNA viruses, eg adenoviruses and herpes 
viruses, suggests that some evolutionary mechanism is 
operative here as well. Homologous recombination of 
Ads was found to be restricted to closely related strains 
or serotypes within the same genus, in regions with the 
greatest homology22. For homologous recombination 
to occur, mammalian cells require an overlap of at least 
200 bp23. Serotype specificity of Ad hexon-proteins is 
determined by hypervariable regions (HVR), which 
do not present sufficient sequency homology to allow
recombination24. Illegitimate recombination resulting 
from the joining of two DNA sequence “hot spots” with 
limited homology in the HVR, as well as single base pair 
substitutions appears to play a role in the evolution of 
Ads22. Both illegitimate and homologous recombination 
events have been linked to species-diversion among the 
herpes viruses25 and recombination rate can be very high 
(up to 40%) under experimental conditions26,27, but also 
in HSV-1 natural populations, depending on local virus 
prevalence, host demography and rates of co-infection28. 
Biological properties of HSV-1 add to the likelihood of 
recombination due to high prevalence in the population, 
primary replication at muco-cutaneous sites, co-infection 
with more than one strain, rapid lytic cycles and latent 
persistence interrupted by reactivation and virus replica-
tion29. The presence of inverted repeats allows segment 
inversion through specific recombination and both intra-
specific (same strain) and interspecific (distinct strains) 
recombination has been shown to occur, with coinfection 
as the most important prerequisite for successful recom-
bination, followed by dose of virus, time interval between 
infection, distance between marker mutations, genetic 
homology, virulence and latency29. Poxviruses replicate 
in membrane-wrapped cytoplasmic structures called 
virosomes, which appear approximately 4-5 hours after 
infection30. Early virosomes display exponential growth 
lasting several hours, after which they migrate to the 
nuclear periphery. The rate of fusion between virosomes 
depends on the infecting particles, but even at high MOI 
(10PFU/cell)approximately20%ofthevirosomesnever
fuse. Furthermore, it was shown that upon fusion DNA 
mixes rather poorly, resulting in low likelihood of recom-
bination even in the event of co-infection30.
2.3.2 recombination in replicating and replication-
defective vectors 
Vector/wild-type virus recombination events may arise 
if wild-type viruses related to the vector and the vector 
virus co-localize under favorable circumstances. Inter-
change, exchange or deletions of viral sequences in the 
vector may be repaired by homologous recombination or 
by reassortment. The presence of wild type virus may also 
give support in transcomplementation of deleted func-
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tions. In addition, modifications on the vector may affect 
the risk for mutation and recombination. Also, during 
vector production in packaging cell lines, recombination 
may occur through transcomplementation of one or 
moremissing genes. Testing for replication competent
viral particles is therefore indicated.
first generation, second generation and helper-
dependent adenoviral vectors
Transcomplementationofviralgenefunctionsbyawild
type Ad may result in the completion of a single life cycle, 
rather than in the generation of a replication-competent 
adenoviral (RCA) vector and therefore the impact on the 
patient and the environment is thought to be negligible. 
TruerecombinationwithawildtypeAd,resultinginRCA
is possible and could result in prolonged viral replication 
and viral dissemination31. During production of first 
generation E1-deleted Ad vectors, the packaging cell line 
provides complementary functions and recombination 
and generation of RCAs is relatively easy. Some viruses 
cannot efficiently replicate when foreign sequences are
inserted and most of the time only a moderate increase 
in size is allowed. For the development of helper-
dependent Ad vectors, this knowledge was used to make 
the constructs safer: “stuffer” DNA, inserted to obtain a 
packageable genome size, does not prevent homologous 
recombination, but does result in genome sizes exceeding 
the packaging capacity of the Ad vectors32. In addition, 
wild type virus would have to supply multiple viral genes 
making the generation of RCA less likely. Instability 
of these viruses may result in loss of both the inserted 
sequences and sequences from the viral backbone, es-
pecially in cases of duplication of a particular sequence. 
The risks for recombination are largely dependent on the 
genetic stability of the wild-type or parental viruses. The 
possible consequences of these RCAs depend on the new 
tropism and virulence, as well as the presence or absence 
of a functional transgene.
adeno-associated vectors
AAV is naturally replication incompetent and requires 
the presence of helper virus to complete its life cycle. 
Vectors based on AAV are designed to be replication-
deficient and lack the rep and cap genes. It was previously 
shown in animal studies that replication-competent AAV 
can be generated, but this requires sequential infections 
with wild type AAV, in addition to the helper virus, and 
makes it highly improbable to occur in either cell culture 
or a clinical setting31. Since AAV is non-pathogenic and 
most adults have neutralizing antibodies against AAV, 
it is unlikely that recombination and generation of 
replication-competent AAV would result in transmission 
and human disease. The most likely scenario would be 
that the vector might cause a respiratory tract infection, 
although the total of effects may be dependent on the 
transgene31.
retroviral and lentiviral vectors
Wild type murine retroviruses are not known to infect 
humans and are not associated with any known human 
disease, possibly due to the rapidly induced innate im-
mune response and inactivation mediated by human 
complement. The murine retroviruses are rendered rep-
lication incompetent by removal of the gag, pol and env 
genes and data from cell-culture studies suggest that the 
probability of RCR generation is, although theoretically 
present, low. Recently, replication-competent retroviral 
(RCR) vectors, based on MLV, have been modified for 
cancer treatment33,34. These RCRs have a reduction in rep-
licationefficiencyduetotheexpressionofheterologous
genes, which require the elongation of the viral genome 
beyond its natural size and, similar to other RVs, are 
prone to mutations35. Deletions of the inserted foreign 
genes may give rise to replication-competent virus with a 
growthadvantageduetoincreasedreplicationefficiency,
and with a resistance to subsequent superinfection with 
the parental vector36. Furthermore, it was shown that 
the genomic stability of the RCRs is also dependent on 
the host cell37. In the third generation self-inactivating 
(SIN) lentiviral vectors, also the essential genes for 
replication, tat and rev, and(partsof) theU3regionof
the3’ long terminal repeat (LTR) aredeleted, resulting
in replication-deficient vectors. This minimizes the risk 
that replication competent lentivirus (RCL) will occur. 
But again, recombination with the necessary viral genes 
derived from the packaging cell line, may theoretically 
result in the regeneration of RCL vectors. These might, 
when administered to humans, disseminate widely 
throughout the body, due to the absence of complement 
responses against LV, in contrast to the early MLV vec-
tors31. However, in an earlier advise (CGM/090331-03) 
from the Netherlands Commission on Genetic Modifica-
tion (COGEM), the organization considered the chances 
on the occurrence of RCL negligible in third generation 
SIN lentiviral vectors38. Recombination in vivo is highly 
unlikely, unless the patient is a carrier of HIV. In these 
cases, the likelihood of recombination between the cur-
rent type of lentiviral vectors and HIV is unknown, but 
such an event may not substantially affect the degree of 
pathology of the HIV disease (personal communication 
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with Ben Berkhout), unless there is other interference 
attributable to transgene expression. 
vaccinia vectors
Vaccinia virus is a replication-competent, attenuated 
pox virus with oncolytic capacity. It causes minor disease 
in healthy persons, but may lead to severe disease and 
encephalitis in immune deficient patients. Oncolytic 
Vaccinia vectors carrying specific transgenes become 
attenuated when the transgenes are inserted in non-
essential genes, such as the thymidine kinase gene and 
display restricted tumor-specific replication. Insertion in 
theTKgeneappearstodecreasethesideeffectsofvector
administration related to central nervous system involve-
ment. Recombination with wild type Vaccinia or other 
poxviruses has been thought to be highly unlikely30,31. 
2.3.3 recombination of non-human/artificial vectors
Non-viral, plasmid-based gene therapy is the most com-
monly used type of non-infectious gene therapy. Cur-
rently, some clinical trials for peripheral vascular disease, 
and certain malignancies, such as head and neck cancer 
and melanoma are underway and certain DNA-based 
vaccinesarebeingdeveloped.However,theefficiencyof
gene transfer of naked DNA or DNA transfer through 
liposomes is low in comparison to virus-mediated trans-
fer. Thus, plasmid-based gene therapy is relatively safe if 
standard precautionary measures are used, such as disin-
fection with 10% bleach, which eliminates any measur-
able DNA spill on surfaces. Spread from person to person 
or animal to animal appears unlikely, as the vectors do 
not replicate31. Vertical transmission or transfection of 
gonadal tissue in mice was never observed. Importantly, 
studies also suggest that there is no potential for replica-
tion due to recombination with any pathogen31.
2.3.4 effects of immune modulation on recombination 
risk
Immune modulation can affect the risk of recombination 
at at least two different levels, i.e. 1) immune suppressed 
individuals may be more at risk for reactivation of latent 
infections and primary infections with certain viruses, 
and 2) reduced immune responses against the viral vector 
may allow for prolonged persistence and affect biodistri-
bution. 
Adenoviruses are endemic and most adults have 
cross-reacting neutralizing immunity against multiple 
serotypes. However, immune suppressed individuals, 
especially children, are particularly vulnerable to both 
reactivation and primary infection with wild type Ad. The 
recombination risk therefore is dependent on the patient 
age, immune status, serotype of the vector and the type of 
Ad vector (first generation, second generation, HD-Ad). 
AAV are non-pathogenic and naturally replication-
deficient and most adults have cross-reacting neutral-
izing antibodies against AAV. Recombination of AAV 
would require the simultaneous presence of the AAV 
vector, a wild type AAV and the presence of a helper 
virus, such as HSV or Ad to provide the complementary 
functions. In children with acute respiratory infections 
coinfection of Ad and AAV was found to occur in 2% 
of sampled tissues39. AAV infections are not increased or 
more pathogenic in immune suppressed individuals, and 
recombination therefore seems highly unlikely. 
Oncolytic vaccinia has been used in combination with 
several immune modulatory agents, including cyclophos-
phamide and rapamycin, resulting in increased intratu-
moral viral replication40. This could potentially increase 
the risk for recombination between viral particles, as it 
was shown to be dependent on the amount of infectious 
particles present during coinfection30. However, recom-
bination rates are also inversely dependent on the time 
between virosome appearance and fusion30. Due to the 
eradication of variola in the human population, possible 
recombination events can only occur with zoonotic non-
variola orthopoxviruses. Recombination risks of different 
vaccinia strains are therefore highly unlikely and can be 
relatively easily prevented by restricting access to possible 
carriers.   
2.4 Shedding
Shedding is defined as the dissemination of a viral vector 
into the environment via excreta from a patient treated 
with gene therapy. Recently an inventory of shedding 
data from clinical trials was published by Schenk-Braat 
et al41. They showed that shedding of vectors occurs in 
practice and is mainly determined by the type of vector 
and the route of vector administration. The risks associ-
ated with shedding depend on multiple factors, including 
the pathogenicity of the viral vector, whether the vector is 
replication deficient or competent, the immunogenicity 
of the vector, the occurrence of pre-existing neutralizing 
antibodies in the healthy population, and the possibly 
toxicity of the transgene.
adenovirus
Shedding of adenovirus may occur during administra-
tion from the site of the injection or after administration 
through droplets generated by coughing or sneezing, if 
the vector is administered as an aerosol into the lung, 
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or by fecal/oral contact, if the virus affects the gastro-
intestinal system. It is known from vaccination studies 
(see Appendix C), that shedding of Adenovirus vaccine 
strains from vaccinees occurs and that transmission may 
take place to secondary persons after close contact42. After 
vaccination of military recruits with live Ad4 or Ad7 
vaccine, it was shown that fecal shedding occurred in at 
least 30% of the vaccinees, depending on the strain and 
could last from day 7-21 after vaccination43. The current 
Ad4 and Ad7 vaccines are contraindicated for individuals 
who are immune suppressed or those who have immune-
compromised partners due to possible risks of increased 
shedding of replicating Ad44. 
In a recent clinical trial with a replication-defective 
Ad-CMV-p53 for treatment of esophageal cancer, it 
was shown that local tumor injection could result in sig-
nificant shedding through the gastrointestinal tract, with 
almost 30% of stool samples and 13% of gargling samples 
positive for adenoviral DNA fragments for up to 12 days45. 
A recent overview on biodistribution and shedding data 
of the non-replicating vector HAd5 showed that both 
biodistribution and sites of shedding were dependent on 
route of administration, but that shedding via semen was 
unlikely46.  
adeno-associated virus
In a recent trial for lipoprotein lipase deficiency with 
an AAV1 pseudotyped vector, vector sequences could 
be transiently detected after intramuscular injection in 
serum, saliva, urine, semen, and muscle biopsies using a 
sensitive quantitative PCR47. The highest vector concen-
trations were detected in the serum, with a rapid clearance 
by1–2logsperweek.Urinewasclearedfromvectorse-
quences at 1 week after treatment in patients treated with 
the lower dose of 1x1011 gc/kg AAV1-LPLS447X and only 
very low levels (at maximum 25–58 copies/mg of DNA) 
were detected in the semen for short periods of time. 
Persistent presence of high levels of vector sequences was 
only detected in injected muscle. Leakage of vector from 
the injection site was limited and the risk for germline 
transmission was considered extremely low47. In a rabbit 
model, the risk of germline transmission of AAV2 was 
found to be dependent on the route of vector adminis-
tration, with intravascular delivery of vector leading to 
dissemination in semen, but local injection in muscle not 
and infectious particles in semen could be detected up to 
a maximum of 4 days after injection and not thereafter48. 
Similarly, AAV2 sequences were detected in semen of 
AAV2-fIX vector recipients49. Data from vasectomized 
rabbits, treated with AAV2 or AAV8, however, suggest 
that not the germ cells, but the seminal fluid was the source 
of vector sequences and in the absence of germ cells, AAV 
sequences could remain present for prolonged periods, 
up to 10 weeks50. Importantly, clearance of vector from 
the semen was found to be dose- and time dependent, but 
serotype-independent50. Biodistribution and shedding of 
AAV2 vectors through other excreta were also shown to 
be dependent on the route of administration51.  
retrovirus and lentivirus
Biodistribution of retrovirus and lentiviral vectors in 
vivo is strongly dependent on the type of envelope used. 
VSV-G is the most commonly used envelope to pseudo-
type lentiviral vectors and allows transduction of a broad 
range of cells. There is little data available on shedding of 
retro- and lentiviral vectors.
vaccinia virus
Vaccinia is a naturally attenuated strain and is considered 
a minor human pathogen. Shedding may occur during 
administration and from skin lesions or body fluids for 
up to 7-10 days and transmission has been observed to 
occur in 7.4 per 100.000 primary vaccines after close 
personal contact52, as described in detail in Appendix 
C. As the virus is known to cause severe disease and 
encephalitis in immune deficient patients, patients with 
structural brain malformations and young children, this 
virus should not be used in these patient populations or 
in patients treated with immune suppressive agents. In 
addition, since the risk for shedding is considerable, fam-
ily and close contacts of the patient should be screened 
for these risk factors as well.
Measles virus
In two recent phase I clinical trials performed by Galanis 
and Dispenzieri the safety of Measles vectors carrying the 
CEA transgene and the NIS transgene, respectively, were 
tested53. In the former study 22 patients with advanced 
ovarian cancer received increasing doses of MV-CEA 
through ip delivery. Patients did not receive immune 
modulation and all had pre-existing anti-measles 
antibodies at enrollment. Fourteen patients displayed 
dose-dependent stable disease without signs of toxicity. 
No shedding was measured in any of the patients. In the 
latter study, 12 multiple myeloma patients were enrolled 
and treated with MV-NIS through intravenous injection 
at four different dose levels. All patients had received in-
tensive anti-cancer chemotherapy resulting in profound 
immune suppression and no detectable preexisting anti-
Measles antibodies were detectable. In contrast to the 
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study of MV in non-immune suppressed ovarian cancer 
patients, shedding of MV vector could be detected in 
bothbloodandthroatswabsamples(Federspiel,ESGCT
2009). Further trials with MV as an oncolytic vector for 
the treatment of multiple myeloma patients are currently 
designed and here Cyclophosphamide will be used as 
the chemotherapeutic agent of choice due to its dem-
onstrated anti-multiple myeloma-activity as well as its 
anti-proliferative effects on immune cells. 
2.5 translation of data from animal models to the clinic
2.5.1 gene therapy animal models using immune 
modulation
It is unclear how well data from different animal models 
will predict the behavior of vectors and immune modu-
lation in a clinical setting and, in retrospect, in many 
cases the clinical relevance of animal models is less than 
anticipated. In the first place this is, obviously, related to 
the host-vector specific issues, such as the presence of 
specific viral receptors and co-receptors on target cells, 
which determine the species-specificity, organ specificity 
and infectivity of the viral vectors and therefore biodis-
tribution, persistence and shedding of the viral vectors. 
For example, a human-derived viral vector may produce 
different results in an animal and vice versa an animal-
derived (pseudotyped) viral vector may result in an 
unpredictable response in human beings. An important 
example of these species-specific effects is the difference 
in efficiencyof transductionofmouse andnon-human
primates, with the AAV8 vector being approximately 2 
logmoreefficaciousinmicethaninmonkeys54. Another 
example is the detection of AAV vector sequences in 
semen of a vector recipient49, an unforeseen, unwanted 
effect, not anticipated by previously studied animal 
models, but later confirmed in a rabbit model50. Here it 
was shown that although AAV vector sequences could 
be detected in semen, these were found in the seminal 
fluid, rather than in the sperm cells50. In the second 
place, this is the direct result of immune system and im-
mune modulation-related issues, such as 1) differences 
in responses to certain immune suppressive agents, eg 
species-specificity of antibodies, or distinct expression 
profiles of specific receptors, eg glucocorticoids55; 2) dif-
ferences in immune suppressive treatment protocols; 3) 
species-related differences in immune responses due to 
presence or absence of pre-existing immunity and cross-
immunity against (human) virus-derived vectors and 
transgenes, which may affect humoral and cell-mediated 
responses, eg up to 80% of the human population pos-
sesses neutralizing antibodies to some AAV serotypes; 4) 
differencesinTcellresponsestoviralcapsidantigens56; 
5) the use of immune compromised animals transplanted 
with human genetically modified cells. For example, 
there are significant differences in immune responses 
against AAV between humans and mice. Although AAV 
inhumanscannotactivateTLRsandinducetypeIIFNS,
itdoesinduceaCTLresponseandclearanceofthevirus.
Incontrast,AAVinfectioninmicecanactivateTLR9and
induce an IFN type I response, but although mice develop 
acytotoxicCD8+T-cellresponse,thesefailtocleartrans-
duced cells56. In the third and most important place, this 
is related to the laboratory animal model intrinsically. 
Most laboratories initiate preclinical testing of viral vec-
tors in specific pathogen free inbred mouse strains. The 
rationale behind these models is clear and encompasses 
the relative predictability and homogeneity of immuno-
logical responses, depending on the immunophenotypical 
characteristics of the inbred strain. These type of animal 
models however, cannot actually be used to predict the 
risk for recombination with wild type viruses in humans, 
nor can they be used to assess the risk of viral transfer 
to secondary or tertiary recipients. The former could 
perhaps be tested by pre-immunizing animals against the 
vector or a similar virus and by infecting animals with 
wild type viruses and measure biodistribution, recom-
bination between viral strains and shedding in excreta, 
such as mouse droppings. The latter could be easily tested 
by transferring viral vectors to one or more animals, and 
measuring shedding and virus production in both treated 
animals and littermates not subjected to gene therapy 
treatment. In addition, some animal models may simply 
not be permissive for propagation of certain viruses, giv-
ing a completely different picture of biodistribution and 
shedding. Furthermore, acquired coexistent infections in 
humans can act as inflammatory adjuvants at the time 
of or shortly after gene transfer. This may enhance the 
host immune response, but is highly unlikely to occur 
‘spontaneously’ in animal models57. In the fourth place, 
the use of otherwise healthy mice as a model for a specific 
human disease may result in differences in anticipated 
immune responses. For example, the pathogenesis of 
HSV in murine and guinea pig models resembles neither 
HSV-related acute lethality or reactivation58. In addition, 
patients, in whom the underlying genetic defect results in 
a null phenotype, may display a robust immune response 
against the foreign transgene, especially if they have not 
received previous protein replacement therapy, whereas 
healthy animals may respond with a mild or negligible 
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response. Or conversely, patients, who have been receiv-
ing prior protein replacement therapy, may have in fact 
developed a tolerance to the transgenic protein and 
display a reduced immune response59. 
All together, a wide spectrum of limitations confines 
the choice of the animal model, and interpretation and 
translation of these data to outbred species, such as hu-
mans, should be approached with due caution. The use 
of non-human primates or other large animals is often 
required to assess specific responses, safety and toxicity. 
Although these models may closely resemble the human 
situation, these studies too should be cautiously designed, 
to allow optimal translation to the human situation and 
unforeseen minor differences may result in unpredictable 
results. For example, differences in dose-responses to glu-
cocorticoids between mice and humans can be attributed 
to differences in the binding of synthetic glucocorticoids60 
and therefore the use of non-human primates as a model 
of human innate immune responses after gene transfer 
is often preferred61. However, comparison of immune 
modulation by glucocorticoids may be less optimal in 
New World monkeys, due to their glucocorticoid resis-
tance and high levels of circulating cortisol62. Another 
more relevant example is the difference observed between 
dose-immune response in preclinical tests in mice and 
monkeys and the Phase I gene therapy trial for ornithine 
transcarbamylase (OTCD)63. The trial was developed as 
a Phase I dose escalation study using a third-generation 
adenoviral vector with safety as the primary endpoint. 
Previous safety tests in rhesus macaques and mice showed 
a substantially improved toxicity profile with the third-
generation vector in comparison with first-generation 
vector64. Furthermore, to assure safety, for the clinical 
trial the maximum dose of the third-generation vector 
was chosen to be 17-fold lower than the dose of first-
generation vector that showed severe toxicity, including 
severe liver damage and clotting disorder, in macaques. 
Simulation of the clinical trial in baboons revealed only 
minor and transient laboratory abnormalities at the high-
est tested vector dose65. However, during the clinical trial, 
17 year old Jesse Gelsinger, who was administered the 
highest dose of the third-generation vector, experienced 
an unexpected and dramatic response with systemic in-
flammation and multi-organ failure, resulting in death57. 
Nevertheless, in studying the effects of immune modula-
tion on gene therapy, under controlled circumstances, 
NHP models can be advantageous, as there is consider-
able experience with the use, safety and toxicity profiles 
of immune suppressive drugs in monkeys; and as drugs 
developed for humans are often active in NHP, due to the 
high degree of conservation of protein domain sequences 
between primates, which is not the case with other mam-
mals.  
In conclusion, even if an appropriate animal model 
is selected for vector testing, differences in dose, mode 
and route of delivery, eg systemic versus directly into a 
particular tissue (intramuscular), organ (intrahepatic) 
or in the vasculature of an organ (hepatic artery), may 
still affect the subsequent immune response and result in 
unpredicted consequences in humans. It is therefore of 
important that new animal models and different readout 
systems are developed to study specific safety risks.
2.5.2 The use of immune deficient preclinical animal 
models
The same safety concerns that could be raised when us-
ing immune modulation during gene therapy are valid 
when using immune deficient preclinical animal models, 
such as nude, athymic or SCID mice. The use of immune 
deficient animal models is commonplace in xenograft 
tumor models. Several oncolytic viruses and viral vec-
tors were tested in different xenograft models. The most 
commonly tested viral vector was replication competent 
oncolytic Ad for the treatment of glioma. Examples for 
the use of replication deficient and replication competent 
viruses in immunedeficient animals aregiven inTable
IID and Table IIE, respectively. An interesting study
was done to compare the effects of different strains of 
immune deficient mice on HSV-1 viral replication in 
tumor tissue66. In the immune competent mouse model 
of oral cancer, HSV-1 produced only limited inhibition of 
tumor growth and loss of the virus coincided with tumor 
regrowth. This was likely the result of innate immunity, 
in particular complement factors, but also humoral fac-
tors, inhibiting HSV-1 replication, as previously observed 
in rats67,68. Although the immune deficient mouse strains, 
ie nod/scid, nu/nu, scid/scid and scid/beige, differed with 
respect to immunefunction(T,B,NKcells,phagocytic
cells) and levels of complement factors, the recovery of 
virus from infected tumors of each strain of mice did 
not show important differences from what was seen in 
the normal immune competent C3H mice with virus 
disappearing rapidly from the tumors66. Although it is 
likely that oncolytic virus replication and biodistribution 
in immune deficient animal models is distinct from in 
immune competent animals, the extent of this difference 
is dependent on the type of immune deficiency, the type 
of virus and the type of malignancy. There are little or 
no data available on the effects of biodistribution and/or 
shedding in these animals.
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2.5.3 Conclusions from preclinical animal models
adenoviral vectors
Adenoviruses induce rapid innate immune responses 
duetoviralbindingtocomplement,TLR9,erythrocytes,
platelets and blood clotting factors (fX) and the adult 
population has a high level of pre-existing immunity ex-
ists against a variety of adenovirus serotypes. The route of 
delivery contributes to the velocity and type of immune 
response as does the expression of foreign viral genes, 
which may even result in direct toxicity. The first gene-
ration vectors are more immunogenic than the second 
generation and the helper-dependent Ad, but even the 
latter are able to induce a durable immune response due 
to the presence of immunogenic capsid surface proteins. 
Whereas the induction of neutralizing antibody forma-
tion prevents readministration, clearance of the viral 
vector from the body ismediated by cytotoxic T-cells.
Current methods to prevent or limit immune responses 
include the use of different (non-human) serotypes, stru-
ctural modifications or PEGylation. However, all these 
methods may equally affect the tropism and efficiency of 
the vector and therefore immune modulation, may be an 
useful alternative.
The following immune modulatory agents or com-
binations thereof were used shortly before or during 
treatment with an adenoviral vector, in most cases Ad2 
or Ad5 (see Table II): blockage of co-stimulation (6
studies), anti-T and/or B-cell antibodies (4 studies),
cyclosporin A (CsA, 3 studies), cyclophosphamide (CY, 
3studies)andcorticosteroids(2studies).Treatmentwith
corticosteroids resulted in an increased level of vector 
copy numbers in the liver after intravenous delivery of 
the vector, but had no effect on the level of transgene 
expression; treatment with human CTLA4Ig, resulted
in the inhibition of formation of neutralizing antibodies 
andanti-AdCD4+andCD8+T-cellsandinamoderately
prolonged transgene expression; cyclosporin A treatment 
had no effect on the formation of neutralizing antibodies, 
but did show in some cases prolonged transgene expres-
sion; cyclophosphamide inhibited activation of CD4+ 
andCD8+T-cells, prolonged transgene expressionand
prevented the formation of neutralizing antibodies. No 
data are available on biodistribution/persistence and 
shedding/transmission. No implicit remarks were made 
on the effect of immune modulation on the number of 
level of infections in animals during or after treatment. 
In vivo, recombination with a wild type Ad may result 
in a replication competent virus resulting in prolonged 
viral replication and dissemination, with the risks for 
such an event decreasing from first generation, to sec-
ond generation and helper-dependent Ad. However, it 
appears that the risks of recombination with wild-type 
adenoviruses after or during immune modulation are not 
considerably larger than in gene therapy studies without 
immune modulation. Furthermore, the risk appears to be 
more related to the type of vector (first generation, sec-
ond generation, helper-dependent) and the production 
procedure (presence of replication competent Ad in the 
vector batch). 
adeno-associated viral vectors
Early infections with the non-pathogenic adeno-associat-
ed viruses results in a low level of pre-existing immunity 
in the community. Although the AAVs lack pathogeno-
associated molecular patterns and are inable to activate 
toll-like receptors, they still display some level of immu-
nogenicity due to activation of pDCs, cross-presentation 
of antigens, and macrophage activation by complement 
C3. The intensity of the immune response is dictated by 
the route of administration, the level of immune activa-
tion (eg as the result of a co-infection with another patho-
gen), the response against the helper virus (Ad, Herpes, 
HPV) and reactions against transgenes and transgene 
products. Clearance and prevention of readministration 
ismediatedbythecytotoxicT-cellresponseandneutral-
izing antibodies. Methods to prevent or limit the immune 
responses include the use of alternative serotypes, pseu-
dopackaging and selection of immune-escape mutants. 
The following immune modulatory agents were used 
in animal studies in combination with AAV-based vectors 
(AAV-1, AAV2, AAV-6 and AAV-8): cyclophosphamide 
(5 studies), blockage of co-stimulation with anti-CD40L 
orCTLA4Ig(2studies),andcombinationsofacalcineu-
rin inhibitor, such asCsAor FK506 (Tacrolimus), and
Mycophenolatemofetil(MMF)withanmTORinhibitor
(sirolimus) and/or an anti-T or anti-B-cell antibody
(rituximab, daclizumab, ATG) in 5 studies (Table II).
Treatment with CY generally prevented the formation
of neutralizing antibodies against the vector and the 
transgenic protein, when administered before the gene 
therapy vector, but when it was used 2 weeks after gene 
therapy; blockage of co-stimulation resulted in decreased 
neutralizing antibody formation, prolonged transgene 
expression, and increased transduction efficiency; the
various combination treatment protocols showed some 
variable effects on prevention of neutralizing antibodies 
and induction of tolerance to the transgene (but not the 
vector),buttheadditionofdaclizumabandATGresulted
in unwanted effects, such as loss of transgene expression 
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duetoinhibitionofregulatoryT-cellsandlymphopenia,
respectively. Specific data on changes in biodistribution/
persistence and shedding/transmission as a result of the 
immune suppression are not currently available. However, 
the risks of immune modulation on the environment due 
to shedding and transmission of AAV-vectors appears 
to be negligible, due to the fact that 1) the AAV vectors 
are replication deficient and require several mutations, as 
well as the presence of a helper virus, to spread, 2) AAV 
is not associated with any disease, and 3) the presence of 
(inducible) immunity in the healthy population. 
retroviral and lentiviral vectors
Rapid capsid turnover prevents effective recognition of 
immunogenic epitopes of lentiviral vectors by activated 
effectorT-cellsandimmuneresponsesagainstLVoccur
almost exclusively in presence of an antigenic transgene69. 
However, immune responses may occur against the LV 
virion (p17 and p24) itself and envelope proteins. Both 
retroviruses (MLV-based) and lentiviruses (HIV-based) 
can induce a moderate innate immune response by APCs 
(DCs)andaT-cellresponse.Thefirstgenerationlentivi-
ral vectors induced moderate immune responses against 
viral proteins, whereas second and third generation 
lentiviral vectors, which contain no viral proteins, pseu-
dotyped with VSV-G can induce the adaptive immune 
reponse due to increased transduction of APCs. Intrave-
nous administration of retroviral vectors in combination 
with blockage of co-stimulationwithCTLA4Igwith or
without anti-CD40Lwas tested in 3 studies (Table II).
In general, this resulted in prevention of anti-transgene 
cytotoxicT-cells,neutralizingantibodies,andinduction
of tolerance to the transgene. In one study an increase 
in RV copy numbers was found in the liver, indicating 
prolonged presence in the circulation. Recombination 
events with wild type retroviruses resulting in replication 
competent RV (RCR) are negligible (see also paragraph 
2.3), whereas recombination with wild type lentiviruses 
can only occur in HIV patients, where it may not affect 
the degree of the disease. It may however lead to prolon-
ged viral replication and dissemination in the patient due 
to the absence of a complement response or anti-HIV 
immunity. Due to the rapid capsid turnover, the immune 
response against LV vectors is predominantly directed 
against the presence of an antigenic transgene product 
and gene therapy for HIV is being developed to increase 
or boost the immune response against HIV antigens. It 
seems very unlikely that in these cases immune supp-
ressive immune modulation would be required, as the 
patients are already immune compromised. Due to the 
rapid capsid turnover, the adaptive immune system is 
not a major contributor in the clearance of LV particles. 
Immune modulation directed at suppressing the adaptive 
immune system may therefore be not a determining fac-
tor in the prolonged persistence of the lentiviral vector. 
Therefore, the risks for the environment are considered 
unchanged.
replication-competent vectors
Wild type Herpes Simplex Virus-1 (HSV-1) and HSV-2 
are highly immunogenic and induce the full activation 
of the innate and adaptive immune system, due to rapid 
complement activation and a TLR2, TLR3 and TLR9-
mediated type I IFN response.CD4+ andCD8+T-cell
responses are directed against both structural and non-
structural antigens and >50% of the population possesses 
neutralizing antibody activity against HSV envelope 
glycoproteins gB, gD, gH-gL. Clearance is mediated by 
complement, neutralizing antibodies, but most impor-
tantly through cytotoxic T-cells. Immune modulation
used in preclinical animal models of HSV-based onco-
lytic gene therapy included dexamethasone, cobra venom 
factor and CY. In these studies, the primary outcome was 
the anti-tumor response. Although immune modulation 
may affect biodistribution and prolong viral replication 
of HSV, there are currently no corroborating data avail-
able. Although the risks for shedding might be increased 
by immune modulation, the high level of immunity in 
the community against the HSV provide protection and 
thepresenceoftheTKgene,allowsafetycontrolthrough
treatment with acyclovir and ganciclovir. Other onco-
lytic viruses such as Reovirus and Vaccinia were tested in 
combination with CY, but only anti-tumor effects were 
monitored.
overview of preclinical animal studies
Table II shows anoverviewof preclinical studies using
a variety of replication deficient (mostly Ad, AAV and 
scarcely RV) and competent viral vectors (Ad, HSV, 
Reo, Vaccinia) in combination with different types and 
combinations of immune modulation. In early child-
hood most people develop antibodies against the most 
common adenoviruses and adeno-associated viruses. 
As a consequence, the use of these types of viral vectors 
is restricted to less common serotypes, especially in the 
case of the first generation vectors, which have been 
shown to induce an early and rapid innate and adap-
tive immune response in both animals and humans. It 
is therefore not surprising that particularly the Ad and 
AAV vectors, and to a lesser extent the HSV and RV-
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based vectors are now being tested in combination with 
different immune suppressing regimens. The immune 
modulatory agents used in the described preclinical gene 
therapy studies are typically used for the treatment of 
cancer or in transplantation patients to prevent organ 
rejection (see Table III). Extended clinical experience
with these types of drugs allows for the development of 
short-termimmunemodulatoryprotocolswithsufficient
immune suppression to allow delivery of the vectors and 
tolerance to the transgene without increasing the risk of 
infections. Immune suppressiva used in gene therapy 
studies include corticosteroids, alkylating agents such as 
cyclophosphamide, calcineurin inhibitors such as cyclo-
sporin and FK506, Mycophenolate Mofetil, antibodies 
againstavarietyofT-and/orB-cellsubsets,andblock-
age of T and/or B-cell co-stimulation.However, direct
translation of these animal studies to the clinics remains 
complicated due to the use of 1) different animal species, 
healthy, immune deficient and/or specific disease models; 
2) differences in delivery (route of administration) and 
dose (low, medium, high, single or multiple dosing) of 
viral vectors; 3) differences in immune responses due to 
the presence or absence of a functional immune system 
or pre-existing (neutralizing) immune response against 
a certain viral vector or transgenic protein; 4) differences 
in responses towards immune modulatory agents due to 
species-dependent effects, doses, routes and modes of 
delivery; and 5) lack of clinically relevant readout sys-
tems, such as effects on shedding, biodistribution, vector 
persistence and recombination after vector delivery.   
Before starting the project, assessing the risk of im-
mune modulation by studying animal models seemed 
feasible, but although quite a few different animal models 
and different types of immune modulation can be found 
in literature, the aims and readout systems of these 
studies, ie feasibility of a particular viral vector for the 
treatment of a specific disease by looking at target tissue 
transduction and (long-term) transgene expression, are 
clearly not sufficient to predict changes in viral vector
persistence and biodistribution in general. There are cur-
rently no data available on the use of immune modulatory 
agents in clinical gene therapy trials, although some trials 
for hemophilia54 and lipoprotein lipase deficiency70,71 are 
currently either in preparation or ongoing. Thus, the 
prediction of risks involved with the use of different viral 
vectors and immune modulation remains unclear and 
is largely determined by the characteristics of the viral 
vectors themselves. In case of a high degree of scientific 
uncertainty a worst case scenario may be applied in the 
environmental risk assessment (see also chapter 3).
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3 environMentaL riSk aSSeSSMent (era)
3.1 factors and variables determining environmental 
risk
In order to make a well substantiated environmental risk 
assessment, it is important to know whether and how 
shedding and transmission of viral vectors will occur. 
In addition, the subsequent effect this might have on the 
environment depends on a number of variables, which 
are depicted in the simplified scheme 1 (depicted below).
The route of administration (ROA) determines 
primary biodistribution of the viral vector, and the host 
immunity determines whether ongoing infection with 
the viral vector will occur and if secondary biodistribu-
tion, or distribution of viral vector after local production 
in the target organ (eg local, within a specific tissue-type 
or tumor) will take place. The probability of shedding 
of viral particles is highest during or shortly after vector 
delivery to the patient (through direct contact with the 
inoculation site), but remains present for a certain period 
of time after the vector has been delivered and persisted 
in the patient’s body. Furthermore, the length of this 
particular period depends on the capacity of the vector to 
replicate. In case shedding occurs during or shortly after 
delivery, this will only result in transfer of unmodified 
viral vector, with a known tropism, virulence and im-
munogenicity. In case shedding occurs after persistence 
of the viral vector in the patient, either shedding of the 
unmodified viral vector may take place, but also, theo-
retically, an altered viral vector may be shed. The latter 
can be divided in two groups: 1) alterations resulting in 
a reversal to a wild-type virus, as observed in viral vec-
tors with a single modified gene, generating a virus with 
a known tropism, virulence and immunogenicity or 2) 
recombination with a related wild-type virus, which may 
occur due to co-infection with an endemically circulating 
virus or due to reactivation of a latent infection and may 
result in a virus with unknown tropism, virulence and 
immunogenicity. Reversal to the wild type virus is for the 
environmental risk assessment of less importance, as in 
this situation the risks are not increased in comparison 
to the normal situation. In practice, the chances of re-
combination, depend on the type of vector (replication 
competent vs deficient), the type of virus (RNA/DNA), 
Scheme 1 factors influencing shedding of viral vectors to the environment. Afteradministrationofmodifiedwildtype(WT)virus,therouteof
administration (ROA) determines biodistribution. The type of vector used, ie replication competent or deficient, determines further infection of 
cellsandpersistenceofthevectorinthehost.LossoftransgenesorcomplementationofviralfunctionsmayresultinreversaltoWTvirus,other
mutations can result in a new potentially dangerous virus. Shedding to the environment may take place during administration to the patient, but 
also after persistence in the patient.
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the time needed to complete a single viral life cycle, 
and whether the virus is lytic or not. Good compliance 
with protective measures during vector administration, 
hospitalization and after discharge from the hospital as 
well as education of laboratory/health care personnel 
and house-hold members can prevent transmission of 
(modified) vector strains.  Alternatively, increased safety 
can be provided by vaccination of bystanders (personnel) 
at risk for example when replication competent Vaccinia 
virus is used or certain types of Adenovirus, eg Ad572. 
Careful follow-up of patients, their house-hold members 
and health care personnel is required as long as infectious 
viral particles can be detected in patient excreta.
Immune modulation can affect these variables at 
several levels by interfering with the host immunity 
(red arrows). This may result in increased viral vector 
persistence and possible changes in biodistribution and 
continuous infection. Suppression of the host immune 
system may also result in an increased sensitivity to 
certain pathogens, in particularly herpes viruses and ad-
enoviruses, and lead to primary infection or reactivation 
of latent viruses. These two effects of immune modula-
tion could result in co-infection and an increased risk for 
recombination (scheme 2). Co-morbidity, which might 
render the patient relatively susceptible to infection, or 
diseases which affect the host immune system and other 
treatments, which affect the immune system directly 
or may interfere with immune modulatory agents, can 
therefore by default also affect the risk for co-infection 
and recombination.
Other elements that may interfere, include spe-
cific vector modifications (Δ: deletions or additions) 
determining tissue tropism, immunogenicity, replicative 
capacity, and function of the viral vector; the type and 
duration of immune modulation used, the presence or 
absence of preexisting immunity (Scheme 3). The effects 
on the environment depend strongly on whether the 
shed virus has a survival advantage, the pathogenicity, 
and physico-chemical properties determining stability of 
the virus outside of the body. Factors affecting the risks 
for transmission include the intensity of the contact, pre-
existing immunity in the general population, education 
and information of health care personnel and household 
members, as well as the physical condition of the latter. 
Monitoring of shedding and environmental testing is 
imperative. 
Scheme 2 influence of immune modulation and co-infection: opportunities to minimize risk. Immune modulation can affect biodistribution 
and persistence of viral vectors, by inhibiting the immune system, but can at the same time also increase the risk for co-infection with a wild type 
virus. Other treatments or comorbidity may interfere with immune modulatory agents or directly affect the immune system by itself. These factors 
allplayaroleintheincreasedriskforrecombinationwithWTvirusesandpossiblywithshedding.
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In case of recombination, the potential environmental 
risks of the newly formed mutant virus are dependent 
on its capacity to survive and procreate, but its direct 
clinical effects are dependent on its virulence. Under
normal circumstances, a virus needs to clear a number 
of hurdles to be able to cause disease, including invasion 
of the host; replication in susceptible cells at the site of 
inoculation; resistance of local defense mechanisms; 
spread from the site of inoculation; replication in target 
tissue; and eventually exit from the host. Upon direct
injection of conditionally replicating viral vectors into 
the blood stream or in a specific tissue, not only many 
of these hurdles are bypassed, but also the inoculation 
dose is multiple folds higher than with natural infections. 
Replication and possible recombination can only occur 
in susceptible cells, depending on the (changed) tropism 
of the viral vector and are more likely to occur when the 
virus is non-lytic and has a slow life cycle. In patients, in 
whom local defense mechanisms may be decreased due 
to illness and/or treatment-related immune suppression 
a certain level of replication of a mutant virus may be 
allowed. In contrast, in otherwise healthy bystanders, 
such as relatives and health personnel, with a functional 
immune system, much depends on how well the newly 
formed virus is able to enter a new host and how/whether 
the host immune defenses will respond appropriately 
to the newly formed virus. With age the level of immu-
nity against the most common viruses increases, such 
as adenoviruses (personal communication with Marco 
Schilham). This implicates that younger subjects are not 
only more likely to allow virus propagation for a longer 
period of time, it also indicates that younger bystanders 
are more likely to be susceptible to new virus infections. 
The virulence of this virus in a healthy population is 
largely dependent on the tropism of the new virus and 
thus depends on the presence of appropriate receptors 
on the cell surface of susceptible cells. In a suboptimal 
environment only partial replication may take place, thus 
resulting in an incomplete form of the virus with either 
severely diminished or no capacity to infect other cells. 
It is conceivable that the cellular environment in which 
the mutant virus is formed may therefore not be able to 
sustain a continued infection. Moreover, whether the life 
cycle of the recombinant virus will be completed (ie. is 
the virus complete and can it independently replicate and 
can it be functionally packaged) and how and when the 
Scheme 3 total of factors and variables determining the environmental risk assessment. Many other factors may influence the risks of recom-
bination and shedding as well, such as specific vector modifications, the type and stability of the virus, the transgene, possible survival advantage, 
preexisting immunity, etc. However, transmission can be prevented in most cases by using preventive physical barriers.
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mutant virus will be eliminated from the circulation are 
determinants of the environmental risk. Examples are 
the formation of incomplete retrovirus variants or the 
recombinantion of wild type Ad with Hd-Ad, resulting in 
genomes too large to package. 
3.2 Background information for the era
When assessing the effects of immune modulation on 
viral persistence, risk for recombination and shedding/
transmission, some issues need to be addressed. Firstly, 
immunogenicity of different vectors requires different 
levels of immune suppression, whereas the mechanisms 
through which the vectors induce immune responses 
dictate the choice for a particular immune suppressive 
agent. Although oncolytic Vaccinia and HSV vectors are 
attenuated, they possess their complete immune evasion 
machinery. Thus, despite the fact that many people are 
immunized against Vaccinia and that more than half of 
the population has antibodies against HSV, this does not 
prevent effective use of these vectors or affect the im-
mune response against these vectors or the transgenes. 
However, pre-existing neutralizing antibodies against 
adenovirus severely affect transduction efficiency of
the replication-defective vectors, but are less important 
for the conditionally-replicating vector ONYX-01573. 
ONYX-015 had a deletion in E1B-55 kDa and E3B, but 
still possesses some of the remaining immune modula-
tory E3 genes74. ONYX-015 induces a rapid humoral anti-
Adimmuneresponse,butsafetyorefficacyoftreatment
with ONYX-015 in cancer patients with and without pre-
existing antibodies was found to be comparable73. Sec-
ondly, the environmental risk is dictated by many factors 
that are not influenced by immune modulation, such as 
age, type of vector (conditionally replicating/replication 
defective), transgene (toxic, antibiotic resistance), etc.
The report “Environmental risk assessment for repli-
cation competent viral vectors in gene therapy trials” as 
published in 2008 by the RIVM75 contains a list of points 
to consider when applying for a licence to use replication 
competent viral vectors in humans. The report can be 
downloaded at http://www.rivm.nl/bibliotheek/rap-
porten/601850001.pdf. The immune modulation envi-
ronmental risk assessment questionnaire is based on this 
existing list. Part A and B discuss general, treatment and 
viral vector related issues and have been modified where 
necessary to be able to assess risks and interactions with 
immune modulation treatment. Part C has been added for 
this report and discusses issues related to immune modu-
lation. A short overview of this new ERA is given at the 
next page and all issues are separately discussed in detail 
below.Toclearifywhycertaintopicsarespecificallyim-
portant for the assessment of risks involved with immune 
modulation, small blocks of background information 
are provided. This will help the user to understand the 
reasons for these particular questions and may be helpful 
for future applications. In the ERA, we chose to use the 
AlipogeneTiparvovec(AMT-011)AAV1-LPLS447X vector 
as an example. The rationale behind this was the recent 
initiation of phase I and phase II/III trial with this vector 
by AMT in Canada70,71, making this the most relevant 
example with respect to clinical applications in the near 
future. Another relevant example could have been the 
currently recruiting phase I trial for Hemophilia B with 
AAV2-hfIX54. However, the checklist can be used for 
all types of vectors, not only AAV, and is also relevant 
for other types of immune modulation, mediated for 
example through the use of stealth technology.  
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Part a: 
general and treatment-related issues
Step 1:  describe the patient population
1a.  How many patients are included in the clinical trial
1b.   What is the age range of the patient population
1c.  Describe the disease (genetic, cancer, etc)
1d. Does the disease affect the immune-responses of the patient
1e.   What are specific in/exclusion criteria
1f.   What are the primary and/or secondary endpoints
Step 2:  viral vector administration
2a.  What is the route of administration (ROA)
2b. What is the way of administration
2c.  What is the dose and timing of administration
2d.  Is the target organ an immune-privileged site
Part B: 
vector-related issues
Step 1:  information about the wild type virus
1a.   Which wild type virus is used as backbone for the vector
1b.  Infectivity of non-replicating cells
1c.  Integration into host genome
1d.  Virulence and pathogenicity
1e.   Host-range (human/animal, broad/restricted)
1f. Tissuetropism
1g.  Biodistribution
1h.  Persistence
1i.  Cell lysis and lateral spreading
1j.  Innate immune response
1k.  Viral clearance
1l.  Horizontal transmission
1m.  Vertical transmission
1n.  Genetic stability
1o.  Availability of anti-viral treatment
1p.  Physical and chemical stability
1q.  Immune evasiveness
era teMPLate for iMMune ModuLation gene theraPy
Part C: 
immunity-related issues
Step 1:  information about host immunity
1a.   Does the patient have a functional immune system
1b.   Does the patient have a condition affecting immunity
1c.   Does the patient have pre-existing or cross-reacting 
 immunity
1d.  Is the patient a carrier of a related virus
Step 2:  information about immune modulation
2a.  What is the type of immune modulation(s) used
2b.   What is the dose and duration of the treatment(s)
2c.   What is the level and duration of immune suppression
2d.   Explain the choice of immune modulation
Step 3:  effect of immune modulation on the risk of infection
3a.   Increased risk for primary infection
3b.   Increased risk for reactivation of latent infection
Step 4:  information about other treatments 
4a.   Which other treatments are used, at what dose and duration
4b.   Do these treatments affect the immune modulatory agents
4c.   Do these treatments affect the patient’s immune system
4d.   Do these treatments influence vector kinetics
Step 5:  effect immune modulation on vector distribution and 
 persistence
5a.   What are the relevant animal/clinical studies
5b.   Does immune modulation after vector biodistribution
5c.   How are biodistribution and persistence  measured
5d.   How long is biodistribution/persistence measured
Step 6:  effect of immune modulation on recombination
6a.   What are the relevant studies
6b.   How are recombination or reassortment affected
Step 7: effect of immune modulation on risk for shedding 
 and transmission
7a.  What are the relevant (pre)clinical studies?
Step 3:  information about other treatments applied to the   
 patient population
2a. Treatmentsdirectlyaffectingtheimmunesystem
2b. Treatmentsaffectingpharmacokineticsofviralvectors
2c. Treatmentsaffectingpharmacokineticsofimmune
modulatory agents
Step 4:  information about the patient’s environment
4a. Hospitalization-related information
4b.  Housing-related information
4c.  Out-house activities 
4d.  Animal contacts (occupational or recreational)
Step 5:  information about protective measures used to prevent   
 transmission
5a. Tohealthcarepersonnel
5b. Tohouseholdmembers
5c. How long will these measures be continued
5d.   How is compliance with the measures assessed
Step 2:  information about the viral vector
2a.  Is the vector replication competent
2b.   Can the vector infect non-replicating cells
2c.   Can the vector integrate into the host genome
2d.   Information about deletions of viral sequences
2e.   Information about inserted transgenes or sequences
2f.   Replication of the viral vector in normal cells
2g.   Immune evasiveness of the viral vector
2h.  Availability of preclinical models
2i.   Information about tropism, targeting and expression
2j.   Information about biodistribution after injection
2k. Information about persistence after in vivo administration
2l.   Information about mutation rates and recombination in vivo 
2m.  Information about possible toxicity 
2n.  Environmental shedding
2o.  Horizontal transmission
2p.  Safety back-up
Step 3:  information about production of the vector
3a.  Which producer cell lines are used
3b.   Which viral functions are provided by the cell lines
3c.   Which quality control measures are used
3d.   Which criteria are used to reject a batch
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Part a:  generaL and treatMent-reLated 
iSSueS
Step 1: Describe the patient population
1a.  How many patients are included in the clinical trial?
1b.  What is the age range of the patient population?
Background 
In the first few years of life, the immune system is still 
naïve and highly sensitive to new infections. In addi-
tion, the high virus load in the excreta of these children 
increases the risk of infection of members of the same 
household (siblings) as well as their peers. Also elderly 
are particularly susceptible to infections, which may 
affect their responses towards a viral vector (see be-
low). Of the viruses used as vectors, particular interest 
should be given to HSV and VACV. Wild-type HSV-1 
infection in pre-immune children (neonates) and im-
mune incompetent patients can result in HSV enceph-
alitis76. Although HSV-vector induced encephalitis has 
never been reported in humans, in animal models it 
was shown that high doses of first generation oncolytic 
HSV vectors could induce significant morbidity and 
mortality77. Also sensitivity to VACV is particularly 
high in preimmune children below the age of 1 year78-
80 and immunocompromised patients and infection 
can lead to progressive vaccinia, postvaccinial central 
nervous system disease, and eczema vaccinatum. 
Before the age of 5 children are prone to Ad infections 
and develop a long-lasting cross-reacting immunity. 
Although the youngest, pre-immune children and the 
elderly are at increased risk for infections, in many tri-
als they are the two target groups for gene therapy: the 
youngest to treat genetic diseases, the eldest to treat 
neoplastic growth. Age is an important risk factor for 
patient-related infectious risks.
Possible effects immune modulation 
Age can affect the choice, dose and regimen of im-
mune modulation, with for children the preference for 
specific immune modulatory agents over systemic and 
cytotoxic immune suppressives and for elderly the pos-
sibility of interaction with other medication. Increased 
risks for infections, observed in certain age groups, 
may be aggrevated due to use of immune modulation 
and allow for an increased risk of co-infection and 
recombination.
1c.  Describe the disease (genetic, cancer, etc)
1d.   Does the disease itself affect the immune responses 
of the patient?
1e.  What are in/exclusion criteria
1f.   What are the primary and/or secondary endpoints 
of the study?
Background 
The route of administration strongly affects the bio-
distribution and evoked host immune reponse. Ex 
vivo viral gene transduction is not likely to induce a 
host response against the vector itself, but the route of 
administration of transduced cells may nevertheless 
affect the immune response against the transgene. In 
vivo administration of viral vectors is bound to induce 
an immune response, but route of administration 
may affect the intensity and velocity of the induced 
immune response. Immune modulation can be used 
to decrease the immune host response against both the 
viral vector and/or the transgene. Immune modula-
tion in combination with ex vivo gene transfer could 
be used to induce tolerance for the therapeutic gene.
Step 2: How is the viral vector administered?
2a.   What is the route of administration (ROA)? 
(systemic: sc, ip, iv, ia; or local: intratumoral, intral-
esional, intrathecal, intrapulmonary.) 
2b.   What is the way of administration? (injection, in-
haler/spray, other)
2c.   What is the dose (pfu, vp, ip) and timing of adminis-
tration (single dose, multiple doses, time in between 
treatments)?
Background 
A single dose may not require the use of immune 
modulatory agents, whereas multiple doses for opti-
mal effect may require accessory immune suppressive 
treatment, even if injected in immunoprivileged sites81. 
A large viral load is a potent stimulus for pattern 
recognition receptor (PRR) signaling, and receptors 
suchasTLR7areactivatedbyexposuretoengineered
viral genomes82. A large viral load can also satisfy the 
system and induce significant toxicity83, eg binding of 
Ad vector to platelets after intravenous administration 
can result in induction of thrombocytopenia. Multiple 
dosing or high dose treatments to achieve sufficient
therapeutic effect may require multiple doses of/pro-
tracted immune modulation therapy, with increased 
risks for infections, recombination, etc.
2d.   Is the target organ an immune-privileged site or not
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Background 
Certain compartments of the body, such as the brain84, 
eye, placenta and testes85, are either naturally tolerant 
or experience attenuated and delayed immunologic re-
sponses to newly introduced foreign antigens86. These 
anatomical sites are said to be immune privileged and 
a certain level of tolerance is maintained through mul-
tiple mechanisms, including the blood-brain barrier87, 
the blood-testis barrier and limited blood supply to 
the cornea or lack of MHC class I and II expression. 
This immune privilege is however not absolute but 
relative in comparison to other tissues and increasing 
doses of immunogenic antigens, such as viral vectors, 
will result in an increased inflammatory response and 
elimination of the foreign gene83. Direct injection 
of increasing doses of Ad-LacZ from 106 up to 108 
infectious units into the mouse striatum resulted in 
increased transgene expression, reaching a plateau at 
vector doses of 108 i.u. and minimal cytotoxicity, but 
doses exceeding this level resulted in cytotoxicity due 
to upregulation of IFN-type 1 regulated genes and 
chemokines88 leading to acute inflammatory-induced 
cell death and loss of transgene expression83. Similarly, 
doses of 102 to 106 transducing units of SIN-LV-GFP 
in the brain resulted only in a minimal increase in 
inflammatory markers69. Systemic immunization of 
animals with Ad89, but not LV69, or with the transgene 
canresultinanCD4+andCD8+T-cell89 and B-cell90 
mediated adaptive immune responses and loss of 
transgene expression in the immunoprivileged site. In 
addition, a preexisting immune response against Ad is 
insufficienttoblockvectortransductionandtransgene
expression from FG or HDAd vectors injected in brain 
of immunized animals91-94.Transient,innateimmune
responses may occur when AAV vectors are injected 
into the brain parenchyma95 and, as with other viral 
vectors, are likely dose-dependent, with low doses 
in the order of 2-4x108 particles inducing little or no 
detectable immune responses81,96, and high doses of 
4x1010 particles or multiple doses inducing significant 
transient intrastriatal inflammation95. Maintenance of 
immune privilege is not an easy task, and is influenced 
by age84. Immune modulation is indicated if a preexist-
ing immune response exists against either the vector or 
the transgeneandaffects the transductionefficiency.
For replication deficient vectors short-term immune 
modulationcouldsuffice,asviralcapsidproteinsare
only presented shortly during initial processing of the   
virions; for replication competent vectors, induction 
of tolerance or prolonged immune suppression is re-
quired. In immune privileged sites, the use of immune 
modulation is most likely only required upon multiple 
injections, or when high vector doses are needed to 
obtain a clinical response.  
Possible effects of immune modulation 
Immune modulation is likely to affect biodistribution 
and persistence of  replication deficient or replication 
competent vectors when administered systemically, 
but upon local injection in an immune privileged site, 
such as the brain, short-term immune modulation 
may allow optimal transduction without negative 
effects on biodistribution and shedding, thus shifting 
thebalancetowardsincreasedefficiency.Nevertheless,
it should be noted that small molecules may diffuse 
through the brain and may not only activate local in-
nate immune responses, but also an adaptive immune 
response,leadingtolossofefficacy.
Step 3: Information about other treatments applied to the 
patient population
Required information
Information is required concerning all treatments, 
other than gene therapy, that are provided shortly 
before and during the gene therapy procedure and re-
covery period, such as chemo- or radiotherapy, growth 
factors, (re)vaccination, angiogenesis inhibitors, other 
agents affecting the immune system or biodistribution 
and persistence of the viral vector, etc.
 
3a. Treatmentsdirectlyaffectingtheimmunesystem
3b.Treatments affecting pharmacokinetics of viral 
vectors
3c. Treatments affectingpharmacokineticsof immune
modulatory agents
3d.  Other
Step 4: Information about the patient’s environment
Possible effects immune modulation
The environment itself can influence the risk of shed-
ding to the environment by affecting the contact-zone, 
the intensity and duration of contact, etc. 
4a.  Hospitalization-related information
4b.   Housing-related information, including household 
information, nursing-home
4c.   Out-house activities, such as profession, military, 
kindergarten/schools, sportsclubs, etc
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4d.  Animal contacts (occupational or recreational) 
Possible effects immune modulation 
The total of effects of immune modulation determines 
the risk for recombination or shedding, but whether 
transmission will take place between a patient and its 
environment is not directly dependent on the immune 
modulation, but on the intensity of the contact and the 
compliance of the patient and its environment to apply 
the appropriate precautionary measures.
Step 5: Which protective measures are utilized to prevent 
transmission?
5a. Tohealthcarepersonnel
5b. Tohouseholdmembers
5c.   How long will these measures be continued, eg 
before, during and after therapy
5d.  How is compliance with the measures assessed
Possible effects immune modulation 
Depending on the type and duration of immune 
modulation used, the usage of protective measures 
may have to be prolonged.  
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Part B: veCtor-reLated iSSueS
Step 1: Information about the wild type virus
Background 
The characteristics of the wt virus determine largely 
the risks encountered with the vectors and provide 
information about the mechanisms employed by the 
vectors to infect, spread, shed and recombine. The 
characteristics of the wt viruses used as backbones 
for vectors that are used in combination with immune 
modulation are summarized in Table IV.
Required information 
This section should include all relevant scientific 
information about the wild type virus and/or modified 
(lab)strains on which the viral vector is based.
1a.   Which wild type virus is used as a backbone for the 
vector
1b. Infectivityofnon-replicatingcells(TableIV)
1c. Integrationintohostgenome(TableIV)
1d. Virulenceandpathogenicity(TableIV)
1e.   Host-range: Human/Animal, Broad/Restricted 
(TableIV)
Background 
Viruses, which occur naturally in non-human species 
and are non-pathogenic for humans seem a logical 
choice to use as viral vectors. However, if modified 
replication-competent vectors become pathogenic due 
to (a series of) recombination and mutation and en-
counter an immunological naïve population, there is 
a risk for a possible epidemic97. From a safety perspec-
tive, an oncolytic replicating vector should therefore 
be derived from viruses, which are naturally endemic 
among the human population. The use of dangerous 
human pathogens is inadvisable, due to the risk of 
reversion to wild-type or recombination with wild-
type into an even more virulent strain, with a possibly 
different tropism. Therefore, the best approach to 
develop a replication-competent vector would be the 
use of a highly prevalent but only weakly pathogenic 
human virus, such as Ad. Reversion to a wild-type 
phenotype would then not result in a serious risk for 
the patient and upon inadvertent release in the human 
population, the mutant virus would be encountered by 
(cross-reacting) neutralizing antibodies, and disease 
burden would be low. However, the possibility that 
recombination or mutation could give rise to a more 
virulent variant of the virus remains an important is-
sue, and the risk is largely determined by the tissue tro-
pism, the structural modifications and the promoter 
used in the vector, as well as the transgene involved97. 
Modifications restricting the tropism of the vector, in 
comparison to the wild-type virus, would not pose a 
serious risk, whereas the choice of the transgene may 
have important implications (see below). 
Possible effects of immune modulation 
During early life people develop neutralizing an-
tibodies against the most common adenoviruses 
and adenoassociated viruses. To prevent an instant
immune response, viral vectors can be pseudotyped 
or alternative, less common or animal serotypes can 
be used. Immune modulation is only indicated if a 
significant immune response is anticipated, eg if the 
dose of the vector is high, if an immune response exists 
against the transgene, or if multiple doses of  vector 
are administered. Immune modulation may allow 
for increased persistence and altered bio-distribution 
of the viral vectors and possible prolonged shedding 
of viral vectors which are not recognized by the gen-
eral population. The risk for the general population 
upon transmission depends on the immunogenic-
ity of the viral vector and possible cross-reactiv-
ity, and the functionof the transgene (seeTableV).
1f. Tissuetropism(TableVI)
1g.  Biodistribution
Background 
Primary biodistribution is strongly dependend on the 
route of administration (local/systemic) and whether 
the target tissue is an immune privileged site or not. Sec-
ondary biodistribution depends on the host immunity 
and whether the vector is replication competent or not. 
1h.  Persistence
1i.Celllysisandlateralspreading(TableIV)
Background 
The time available for recombination is shorter for virus-
es that spread by killing and lysing the cells in compari-
son to viruses that spread through cell-to-cell contact. 
1j. Innateimmuneresponse(TableIV)andindetail
discussed in appendix A.
1k. Viralclearance(TableIV)andindetaildiscussedin
appendix A.
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 201032 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Possible effects of immune modulation 
Recombination can only occur during the life cycle 
of the virus. Replication-competent viruses allow for 
recombination with wild-type viruses during each life 
cycle. Immune modulation may decrease the host im-
mune response against the viral vector and allow for 
longer viral persistence and changes in biodistribution. 
Both may increase the risk for recombination with wild 
type viruses and risks associated with shedding of the 
viral vector.   
2b.  Can the vector infect non-replicating cells?
Background 
Some wild type viruses, such as HSV, may remain 
latent in non-replicating cells, eg in neurons.
Possible effects of immune modulation
Immune suppression may result in reactivation of 
latent viruses, in particularly herpes viruses and recom-
bination with HSV-based vectors could occur under 
these circumstances. 
2c.  Can the vector integrate into the host genome?
Required information 
Provide relevant information on the location of the 
integrations (preferential sites, genes, chromosomes) 
and possible results thereof.
Background 
The two major issues related to viral integration are 
insertional mutagenesis, which may occur when a virus 
integrates in a somatic cell, and germline transmission. 
All dsDNA viruses and retroviruses, which synthesize 
DNA during replication, have the potential to be onco-
genic through insertional mutagenesis.
Adenoviral vectors
After infection of cells Ad rarely integrates into the 
genome: infection with wild-type Ad of permissive cells 
leads to lytic infection, but integrations may occur in 
non-permissive cells (e.g., hamster cells infected with 
Ad12)99,100, or under non-permissive circumstances 
(e.g., specific temperatures with Ad5)101. Although 
transformation of cells after infection with adenovi-
ruses has been observed in culture systems102, adeno-
viruses appear not to cause tumors in vivo in humans 
duringthenaturalcourseofinfection.Transformation
of mammalian cells can be achieved with DNA plas-
mids carrying no more than the Ad E1 region103, and 
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1l.   Horizontal transmission: Specific characteristics 
of wt viruses, affecting transmissibility are sum-
marizedinTableVII
1m.  Vertical transmission 
1n. Geneticstability/Recombination(TableIV)
1o. Availabilityofanti-viraltreatment(TableIV)
1p. Physicalandchemicalstability(TableIV)
1q. Immuneevasiveness(TableIV)
Background 
The intensity of the immune response depends largely 
on virus’s capability to hide itself from the immune sys-
tem, the socalled immune evasion mechanisms. Repli-
cation-competent oncolytic vectors often possess all or 
most of the viral evasion equipment, but in replication 
defective vectors many of the genes that viruses use to 
evade the immune response are removed to increase 
safety and/or to allow the insertions of larger genes. 
For example, in the helper-dependent Ad vectors, 
all viral genes have been removed, except the ITRs
and the packaging signal and these vectors may 
cause an even more robust immune response in 
reaction to the viral vector than to the wild-type 
virus. Other factors affecting evasiveness include, 
shielding and variability in antigenic structure. Viral 
evasion mechanisms are discussed in Appendix A. 
Step 2: Information about the viral vector
Required information 
All relevant scientific information about the viral vec-
tor should be addressed here. 
2a. Is the vector replication-competent? 
Background
As with live-attenuated vaccines (see Appendix C), 
replicating viral vectors may raise serious safety 
concerns with respect to pathogenicity, mutation 
rate/risk and risk of recombination, risk for spread 
of a mutated pathogenic vector and risk for germline 
transmission98. If pathogenic mutations occur in the 
replication competent vectors, this could potentially 
lead to serious epidemics in susceptible populations, 
particularly under conditions which favor trans-
mission (see above). Where the first generation 
replicating vectors had deletions in a single gene, 
the second generation replicating vectors contain 
multiple deletions, rendering the viruses safer and 
with a decreased risk to reverse to a wild-type variant.
2b.  Can the vector infect non-replicating cells?
2c.  Can the vector integrate into the host genome?
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although for transformation of rodent cells E1A or 
E1A and E1B-19K suffice, it is much more efficient
in presence of the E1B-55K protein103-105. In contrast, 
for the transformation of human cells the full Ad E1 
region is required106,107. The oncogenic phenotype of Ad 
serotypes is determined by the E1A108,109 gene, which 
modifies the function of key regulatory proteins such 
as retinoblastoma (Rb) and the chromatin remodeling 
protein p400, an inducer of the cellular oncoprotein 
Myc110,111, but is deleted in most adenoviral vectors. 
The role of E1B-55K in tumorigenesis is however less 
clear. It was shown that the protein binds and inhibits 
p53 and has an anti-apoptotic function112,113. The E1-
substituted and helper-dependent Ad vectors show 
integration efficiencies of respectively 10-3 to 10-5 per
cell.Thehigher integration efficiencies of thehelper-
dependent vector can be attributed to the lack of viral 
genomic sequences or to the lack of leaky expression 
of viral genes, which may inhibit normal cellular 
machinery, unlike those in the E1-deleted vector. 
Analysis of host cell chromosomes revealed that most 
genomes contained extra Ad vector fragments and that 
although gene expression from the integrated vector 
was relatively stable, integrated vectors may be subject 
to further rearrangements and altered gene expres-
sion114. However, the replication-deficient vectors are 
deleted for E1, and most of the conditionally replicat-
ing adenoviruses, such as ONYX-015, are deleted for 
E1B-55K. It was suggested that the helper-dependent 
adenoviral vectors might have a higher risk for inser-
tional mutagenesis, due to the vast amount of genomic 
stuffer DNA which might facilitate integration through 
homologous or homology-mediated mechanisms. In 
contrast, like E1-deleted vectors, integration occurred 
at randoms sites, mainly by insertion of a monomer 
with close to no loss of sequences at either vector end115.
Adeno-associated virus-based vectors
Although the genome of single stranded AAVs can 
stably integrate into host-cell DNA, the naturally oc-
curring AAVs are not associated with oncogenesis. 
However, rAAV vectors lose their ability for site-
specific integration due to deletion of the rep gene and 
may integrate randomly116,117.Twostudiesdocumented
insertional mutagenesis in neonatal rodents as a result 
of integration of rAAV vectors118-120. Whether the risks 
for insertional mutagenesis can be translated to a clini-
cal setting remains to be seen and depends on a number 
of factors. Thusfar only few reports of tumorigenesis in 
neonatal rodents have surfaced and none in other ani-
mal species, but other factors, such as the vector dose 
required to transduce sufficient cells123, the route of 
delivery and the immune response toward transduced 
cells49 may affect the outcome in humans and make it 
difficult topredict theactual risks. Inaddition to the
risks of tumorigenesis, also the risks for true germline 
transmission appear low48,49. Patients with hemophilia 
B treated with rAAV-fIX showed short-lived expression 
of therapeutic fIX levels after injection in muscle124,125 
or direct into the hepatic artery49, as a result of the 
induced host immune response. However, after injec-
tion into the hepatic artery, for up to 12 weeks vector 
sequences were detected in semen, even in the lowest 
dose treatment group and clearance was more quickly 
by younger than older patients49. Fractionation of the 
semen demonstrated the presence of vector DNA in 
the seminal fluid and no evidence was found of vector 
sequences in motile sperm49. This is in agreement with 
data showing that AAV2 does not transduce spermato-
gonia directly126,127. In addition, data from intravenous 
AAV2 and AAV8 vector transfer to vasectomized 
rabbits demonstrated that the presence of vector 
sequences in seminal fluid50. Thus, no true germline 
transmission could be found, but shedding in seminal 
fluid was found to be transient in all animals and 
clearance was found to be dose- and time-dependent, 
but serotype-independent50. Therefore, it was recom-
mended that subjects use barrier contraception until 
the semen becomes negative for vector sequences49. 
Herpes virus-based vectors
EBV has been directly linked to the occurrence of 
Burkitt’s lymphoma, but although there are some reports 
associating HSV-2 with cervical cancer, evidence of a 
direct link with HSV is circumstantial and often a sec-
ond infection with either HPV or Chlamydia is present. 
HSV generally does not integrate, but exists episomally, 
making the risks for insertional mutagenesis very low. 
HHV6, was recently shown to be unique among Herpes 
virusesinthatitefficientlyintegratesintotelomeresof
chromosomes during latency, rather than forming epi-
somes and that the integrated viral genome is capable 
of producing infectious virions128. Other DNA viruses 
such as HPV and the hepatitis viruses HBV and HCV 
are associated with oncogenesis as well, but as they are 
not commonly used as gene therapy vectors, the discus-
sion of these viruses is beyond the scope of this project.
Retroviral vectors
Germline infections of ancestors millions of years ago 
have resulted in the presence of human endogenous 
retrovirus (HERV) sequences, which make up 8% of 
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the human genome129. Some of the HERV members 
have undergone repeated outbursts of replication, 
resulting in more than 60 proviral copies and over 
2500solitaryLTRs129,130, and the proviral elements of 
HERV-K not only still retain their open reading frames 
for all viral genes131, but the various loci of HERV-K 
elements can code for all structural, regulatory and 
enzymatic viral proteins130. In addition, at least 50% 
ofhuman-specificHERV-KLTRsservein vivo as ac-
tive promoters for nearby genes132.  The four known 
humanexogenousretrovirusesareHTLV-1,HTLV-2,
HIV-1andHIV-2.TheHTLV-1Taxproteincancause
adult T-cell leukemia due to activation of cellular
proliferation in 1-2% of infected patients, often after a 
latency of up to 50 years129. In animals, oncogenic ret-
roviruses,suchasMLV,MMTVandFeLV,cantrans-
form normal cells by 3 mechanisms, i.e. by picking up 
cellular oncogenes and subsequent co-infection with 
a wild type helper virus for replication, by insertional 
mutagenesis resulting in destruction or disruption of 
tumor suppressor genes, or by downstream activation 
of nearby proliferation supporting cellular genes129. 
Retroviral vectors based on MLV display preferen-
tial integration in transcription start sites and regula-
tory gene regions133. These integrations were shown to 
result in the activation of cellular proto-oncogenes, 
(LMO2, MDS-EVI1, CYCLIND2, or BMI1) and 
caused the development of leukemia in 5/19 patients 
from two X-SCID trials134,135 and a growth advantage 
for gene-transduced cells resulting in the occurrence 
of dominant clones in a trial for X-CGD136. 
Although many AIDS patients develop malignan-
cies during their illness, HIV-1 has not been linked 
directly to cancer, even though all HIV-infected cells 
carry randomly integrated proviruses. Lentiviral vec-
tors integrate preferentially in transcribed genes, rather 
than in transcription start sites and regulatory gene 
regions and are therefore considered less genotoxic 
than the gammaretroviral vectors133. Furthermore, it 
was shown that the genotoxic potential of retroviral 
vectors is strongly modulated by vector design, in 
particular the vector’s enhancer-promoter elements133 
andtheLTRs137.Thenewself-inactivating(SIN)LTRs
were shown to significantly enhance the safety of both 
LVsandRVsandalterationsoftheLTRshadagreater
effect on safety than the retroviral insertion pattern137. 
Vaccinia-based vectors
Members of the family of Poxviruses are not associated 
with malignancy, but may give rise to benign tumors. 
Vaccinia virus is a ds DNA enveloped lytic DNA virus, 
but in contrast to other DNA viruses, its life cycle takes 
place exclusively in the cytoplasm of the infected cells.
Possible effects immune modulation 
Immune modulation may increase the amount of 
infectious particles that integrate and thereby increase 
the risk for insertional mutagenesis in the treated pa-
tient. However, only in cases of germline transmission 
and insertional mutagenesis after horizontal transmis-
sion to thirds would this be considered an increased 
risk for the environment. 
2d. Information about deletions of viral sequences 
I  Deletions of genes to render viruses replication 
deficient
II   Deletions of genes important for immune evasion
III  Deletions of other viral sequences
2e. Information about inserted transgenes or sequences
Background 
Transgenes can be categorized according to cel-
lular gene and function. A workable classification 
therefore would be into genes encoding structural 
proteins, eg actin or myosin; enzymatic proteins: se-
rum proteases, phosphatases etc; metabolic enzymes: 
required for amino acid metabolism or nucleotide 
synthesis; proteins required for cell growth and house 
keeping; proteins required for cell cycle and cell divi-
sion; proteins used in DNA replication; membrane 
proteins: ion channels, G-coupled protein receptors, 
transporters, etc; proteins enhancing cytotoxic or 
lytic activity, eg fusogenic membrane proteins138; 
tracking genes such as GFP, luciferases and photo-
reactivegenes; selectiongenes, egMGMT;antibiotic
resistance genes, such as neomycin (G418); suicide 
genes, such as TK/ganciclovir139; prodrug-activating 
genes, eg 5-Fluorocytosine/cytosine deaminase139,140, 
P-450/ Cyclophosphamide141,142; active subunit genes 
for toxins, eg botulinum toxin, Shiga, and Shiga-like 
toxins; regulatory genes, transcription factors; growth 
factors, cytokines, chemokines; immune modulatory 
molecules, egCTLA4Ig, B7-1; oncogenes,mutations
intumorsuppressorgenes.SeeTableV.
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I Toxicity
II   Survival advantage, eg cytokine, growth factor, 
receptor
III   Survival disadvantage, eg antigen,  
replication inhibitor 
IV  Antibiotic resistance, eg selection gene
V  Requires activation, eg tumor suppressor 
VI  Other, eg deficiency, suicide, marker 
Possible effects immune modulation 
Of these categories, the genes coding for toxins or 
cytotoxicity enhancing molecules and the genes 
that may result in survival advantage, eg oncogenes 
or mutations in tumor suppressor genes, antibiotic 
resistance genes and to a lesser extent the regulatory 
genes are genes that might carry a possible risk for 
theenvironment.Transferof thesegenesasa result
of shedding into the normal population may be 
increased by immune modulation indirectly (by 
increasing risk for shedding).
2f.  Replication of the viral vector in normal cells
2g.  Immune evasiveness
Background 
Whether or not the immunomodulation is used de-
pends on the remaining viral evasion mechanisms of 
the vector after modifications, as well as on the new 
shielding techniques applied. No matter how well the 
viral evasion mechanisms function, the viral vector 
inoculation dose is far larger than any number of viral 
particles encountered as the result of a natural infec-
tion. In addition, here the route of administration and 
the target organ or tissue is highly important in the de-
termination of whether or not some form of immune 
modulation should be used. The goal of immune  
modulation is to allow the vector to reach its target 
tissue, when its own viral evasion mechanisms are 
insufficient.
Viral evasion mechanisms present in the vector
I  Viral evasion mechanisms
II   Structural modifications (shielding or stealth 
mechanisms) affecting antigenic variability of the 
vectors
2h.  Availability of preclinical models
2i.   Information about the tropism, targeting and re-
stricted expression of vectors
Background
The natural tropism of a virus can be restricted if broad 
to increase safety or enhanced if limited to target more 
tissues. Vectors have been modified to preferentially 
target and replicate in specific cells, eg tumor cells or a 
specific cell type, to minimize the effects on other cells 
ortissuesandincreasetheefficiencyofgenetransfer97. 
The role of targeting becomes more important when 
gene therapy is delivered systemically than upon local 
(tumor/tissue) injection and issues that need to be 
addressed when applying systemic approaches include 
the immune response, single or multiple administra-
tions, and the stability and pharmacokinetics of the 
complex when injected in the peripheral circulation97. 
For more information, see also: Engineering targeted 
viral vectors for gene therapy by Waehler et al143. 
I Transductionaltargeting:Surfacetargeting&Cap-
sid modifications
Background
•Serotype switching144,145 (eg Ad, AAV), selection of 
specific variants (AAV)146-148 
•Pseudotyping:mayalter surface receptorsandhost
range/cell tropism (VSV-G/GALV, ecotropic/ am-
photropic), immunogenicity of the vector (VSV-G) 
and immune escape (AAV)149
•Engineering of viral envelope, eg designed capsid
domains150
•Alteredwayofadsorption/penetration:changedcell
attachment (CAR-binding mutants), entry and cell-
to-cell spread, different surface antigens/receptors/
fusogenic peptides, proteins or antibodies (indirect 
targeting) or genetic targeting by introduction of 
specific sequences, eg RGD151,152
•Coatingofviral surfacewithpolymers:PEGylation
(affects strongly persistence of virus in circulation 
and biodistribution to distinct organs153
II Transcriptional targeting: Genome modifications
for targeted replication
Background
•Tissue/cell-specificpromoters(note:oftentoospecif-
ic, target only a subgroup of cells in a tumor, choose 
tumor-specific promoters or radiation-activated 
promoters)154
•Targetedreplicationofoncolyticvirusincancercells
(eg p53)154
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•Targetedreplicationintumorsthroughlocalactiva-
tion7 (eg MMP)155
•Targeted transcription by promoter elements that
become activated in chemotherapy resistant tumor 
cells156, radiation inducible elements157, hypoxia-
response enhancer elements158, or Cre/loxP97,159 
III Targetedreplicationbypost-transcriptionalregula-
tion of replication of expression
Background
Transgeneexpressioncanbedetargetedbyexpression
of endogenous tissue-specific miRNAs160,161
2j.  Information about biodistribution after systemic 
injection, local injection in a non-immuneprivileged 
site, local injection in an immune privileged site.
Background 
Biodistribution is strongly dependent on the route of 
administration (see above) and on whether the vector is 
replication competent or not. Replication of oncolytic 
vectors can result in a local or distant distribution of 
infectious virus. From a safety perspective, treatment of 
large tumor masses with local injection and replication 
of oncolytic virus would be ideal. However, intratu-
moral injection therapy is limited to needle-accessible 
disease sites, whereas intravenous administration 
allows the potential for viral infection of even non-
injectable disease sites and treatment of metastases.
Replication-competent vectors
Without replication, ONYX-015 is cleared from 
the circulation within 24 h in animal models and in 
patients after iv administration. DNA titers in plasma 
declined with a half-life of about 20 min over the first 2 
hrs following dosing, after which a plateau was reached 
for 2-6 hrs, followed by a steady increase in viral DNA, 
indicating replication73. Viral infection of metastatic 
tumor sites and shedding into the circulation was 
observed for several weeks in high-dose patients and 
viral pharmacokinetics were not altered by neutral-
izing antibody formation73. Vaccinia virus is highly 
stabile in the circulation and intratumoral or systemic 
injections of Vaccinia virus leads to dissemination to 
distant tumor sides.
Replication-defective vectors
Biodistribution is here mainly dependent on the route 
of administration, level of pre-existing host immunity 
and the total dose of infused vector.
Possible effects immune modulation 
Immune modulation may prolong the existence of 
both replication competent and defective viral vector 
in systemic circulation or in local tissues. This may re-
sult in a broader biodistribution pattern and increased 
off-target transduction, in particularly the liver, and 
increase the risks of co-infection and recombination.
2k.   Information about persistence after in vivo admini-
stration
2l.   Information about mutation and recombination 
after in vivo administration
Background 
Mutation and recombination are events that occur 
more often in RNA viruses than in DNA viruses due 
to the absence of proofreading mechanisms. Other 
factors of influence on the rate of mutations/recombi-
nations involve the viral strain, the transgene position 
and level of expression and the host cell. Selection 
agents, eg ganciclovir and acyclovir, may also put 
strain on the viruses to increase mutation rate. A high 
vector inoculation dose will increase the likelihood of 
co-infection of a cell with a related wt virus, since more 
cells are infected.
 
I  Is the vector replication competent or replication 
deficient?
II  What is the incidence of mutation and recombina-
tion of the parental virus?
III  What is the incidence of mutation and recombina-
tion of the vector in vitro/in vivo
IV  Information on complementation or missing 
functions in the vector by the wt virus
V  Other treatments that may influence recombina-
tion/mutation (eg ganciclovir)
Possible effects immune modulation 
Immune modulation may increase the number of 
particles available to infect target cells, increase the 
vector persistence and thus the time for interac-
tion with wt virus and may affect the viral life cycle 
and biodistribution. Immune modulation can also  
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 37
Environmental Risk Assessment (ERA)
potentially increase the risk for a new primary infec-
tion with wt virus or may result in reactivation and 
active replication of wt latent viruses, increasing the 
risk for co-infection. Replication-defective vectors are 
used in most cases to deliver a transgene to a target 
tissue, but since the vector cannot replicate, the vector 
particle dose has to be relatively high to obtain good 
transduction efficiency. Immune modulation may
berequired to increase initial transductionefficiency
and induce tolerance against the transgene. The time 
needed to bridge with immune modulation may be 
protracted, but with relatively little effects on recombi-
nation. Replication-competent vectors are mostly used 
in treatment of tumors and a relatively low vector dose 
canbesufficienttoallowlocalandtumorcell-sensitive
replication. Immune modulation may be given for a 
short period of time only, since vectors are actively 
replicating, may still have a considerable effect on 
recombination.
2m.   Information about possible toxicity (as a result of 
either the vector itself or the encoding transgenes)
2n.  Environmental shedding
Background 
Presence of viral sequences in tissues or specific organs 
may increase the risk for environmental shedding. 
Body fluids can be a source of (replicating) viral vec-
tor and inadvertent exposure to blood, urine, seminal 
fluids (AAV)49 or needlestick accidents may result in 
transmission of vector. In the wild, rodents are associ-
ated with outbreaks of exanthematic lesions caused by 
Vaccinia virus in humans and dairy cattle and have 
been shown to serve as a virus reservoir162,163. It was 
shown that for 20 days after wt Vaccinia exposure, 
infectious particles could be detected in feces, whereas 
viral DNA could be detected for up to 60 days163. Ex-
posure of healthy mice to excreta of Vaccinia infected 
mice resulted in horizontal transmission164. Thus, 
shedding and long-lasting stability of Vaccinia virus 
in murine feces requires careful handling of Vaccinia 
infected laboratory animals and their excreta should 
be considered a potential source of transmission. In 
addition, it is highly recommended that all labora-
tory personnel working with VACV be vaccinated79. 
Direct contact with VACV vector injection sites was 
shown to result in transmission to secondary and even 
tertiary recipients52,165.
I Respiratory
II Body fluids
III Feces
IV Direct contact
Possible effects immune modulation 
Immune modulation can prolong the half-life of viral 
vectors in circulation and change biodistribution. As a 
result, shedding may be observed for a longer period of 
time and from multiple different excreta.
2o.  Horizontal transmission
2p.  Safety back-up
Background 
Does the vector system contain a suicide gene (natural 
or engineered) or can adverse events be terminated by 
the use of anti-viral agents.
I Is a suicide gene present?
II  Are the vectors sensitive to anti-viral agents? (See 
alsoTableIV)
Step 3: Information about production of the vector
Required information 
An overview of the production process, ie the origin 
of the producer cell lines, the genetic components of 
these cell lines, required to complement virus produc-
tion, quality control measures and criteria used to 
reject a batch) are required.
3a.  Which producer cell lines are used?
3b.  Which viral functions are provided by the cell lines?
3c.  Which quality control measures are used?
3d.  Which criteria are used to reject a batch?
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Part C: iMMunity-reLated iSSueS
It must be kept in mind that although discussed 
separately, many of these factors are interconnected and 
influence each other, such as age and the development of 
immunity. 
Step 1: What is the level of host immunity?
Required information 
All relevant medical information about the patient, 
affecting the host immune system, such as genetic fac-
tors and patient medical history pointing or suggesting 
a compromised immune system.
1a. Does the patient have a functional immune system: Is 
the patient immune-competent or (relatively) immune-
deficient. If the patient is immune impaired, what is the 
extent of the immune deficiency?
Background 
A malfunctioning or absent immune system cannot 
defend the host against the invading organism and 
even a harmless or attenuated virus can result a patho-
genic response, a disseminated infection, with possible 
lethal outcome and spreading to the environment. If 
the functional immune sstem is (relatively) impaired, 
this could potentially influence the viral life cycle, the 
virulence of the vector, the biodistribution, persistence 
and shedding. This may affect in particular the choice 
for a replication competent or replication deficient 
virus. Whether immune modulation will be used in 
patients with an already defective immune system 
depends on the depth and duration of the immune 
deficiency. It was shown that for an effective secondary 
anti-VACV response, the antibody response is obliga-
tory, whereas the CTL response is non-essential166. 
However,mostotherviralantigensareT-dependent,
which means that for an optimal B-cells response 
interactionwithTcellsisrequired15. 
I impaired innate immune system
II  impaired adaptive/cellular immune system 
I primary immune deficiency (PID) 
II  secondary immune deficiency (AIDS) 
III   induced transient immune suppression 
(chemo/radiotherapy)
Possible effects immunomodulation 
The risk for adverse events (infections, spreading, 
recombination, increased virulence) can be increased 
in patients with a defective immune system, irrespec-
tive of the cause, although the sensitivity for specific 
types of infections may differ. Immune modulation 
can affect the outcome of patients with an otherwise 
functional immune system and result in prolonged 
presence of vector. 
1b.  Does the patient have a pre-existing condi-
tion (co-morbidity) affecting immunity, such as a 
mental or physical disability or for example diabetes? 
I  Due to the presence of any or more of the factors in 
TableVIII
II  Due to increased risk of exposure to a specific virus 
(eg hospital personnel, laboratory personnel)167
1c.  Does the patient have proven pre-existing or cross-
reacting immunity (presence of antibodies) against the 
viral vector or is it expected that the patient may have 
pre-existing or cross-reacting immunity against the viral 
vector?
Background 
The functional immune system will interact with any 
viral vector, but the velocity and the magnitude of the 
responsedictatetheclinicalefficacyofthetreatment:
A primary immune response against the vector will 
be relatively slow. If the transgene is recognized as a 
neoantigen, and has been administered to the patient 
before, eg factor VIII or enzyme replacement therapy, 
an adaptive immune response against the protein will 
result in a CTL-mediatedresponseand formationof
neutralizingantibodiesthroughaCD4+T-cellfacili-
tated mechanism168. The development of neutralizing 
antibodies, which bind to the surface of viral particles, 
prevents viral binding to cellular receptors required 
for cell infection.
The non-neutralizing antibodies bind to viral par-
ticles, fixing the complement pathway and are less im-
portant here. The secondary response due to preexist-
ing immunity against the viral vector or the transgene 
can result in a rapid onset and clearance of the vector 
and foreignprotein, resulting in lowclinical efficacy
and may cause considerable side effects, expecially 
when the response against the vector becomes unbal-
anced. Although neutralizing antibodies or memory 
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T-cell responses can also make readministration
impossible, the neutralizing activity may also prevent 
spread of replicating virus, adding to safety: in im-
munocompetent animals, preexisting immunity to the 
vectordidnotaffectvectorantitumorefficacyfollow-
ing intratumor injection of the vector, but it markedly 
reduced spillover of the vector to the liver and lungs169 
and decreased toxicity of the treatment170. Oncolytic 
virus may locally replicate and infect tumor cells, but 
spread and replication in less permissive tissues may 
be relatively contained. The presence of absence of pre-
existing immunity is more important when multiple 
viral vector doses are required (eg cancer treatment).
I  previous infection with the wt virus or a closely 
related virus
II  previous vaccination with the wt virus or closely 
related virus 
III  previous treatment with this viral vector or a similar 
vector
IV  previous contact with the transgene, eg enzyme 
replacement therapy 
V  confirmed presence of neutralizing or cross-reacting 
antibodies (make sure the test is not inadequate due 
to low assay sensitivity)
Possible effects immune modulation
If the answer to any of the above is Yes, it is likely 
that the half-life of the vector upon injection will be 
decreasedandthereforetheefficacyofthetreatment.
Re-evaluation will be necessary and the treatment pro-
tocol may have to be adapted accordingly, eg increased 
vector dose, different serotype of vector or immune 
modulation may be indicated. Each of these choices 
will affect the environmental risk and re-evaluation 
has to start from the beginning. Immune suppression 
targeting specifically pre-existing immunity includes 
cyclophosphamide (CY), targeting B-cells and CD4+ 
T-cellsandCyclosporinA(CsA).Althoughtransgene
expression is usually somewhat prolonged, there ap-
pears to be no effect of CsA on neutralizing antibody 
levels.CYincreasesanti-tumorefficacy(independent
of the presence of NAb), likely by decreasing not only 
the anti-vector response (and thus may increase the 
vector response) but may also by boosting the host 
anti-tumor immunity169. Preexisting immunity can 
prevent spread from oncolytic virus and although 
CY treatment decreases NAb, it does not affect the 
NAb-effect on containing spread and replication of 
oncolytic virus to other organs, suggesting some level 
of NAb can be protective. 
1d.  Is the patient a known or suspected carrier of a virus, 
similar or closely related to the viral strain, used for the 
vector (presence of viral nucleic acids)?
I  Does the patient have a history of infection(s) with 
wt virus used as viral vector?
II  Does the patient have a current infection or inflam-
mation?
Background
Acquired coexistent pathologies, eg infections, can act 
as inflammatory adjuvants at the time of gene transfer57. 
This can have two opposite effects: the overstimulated 
innate responses activated by a concurrent infection 
may result in a more pronounced host immune re-
sponse against the vector, or can result in more severe 
(lethal) side effects. In addition, injection of viral HSV 
vectors may reactivate or recombine with endogenous 
latent HSV, and similarly Ad vectors with endogenous 
latent wt Ad. Even more, previous encounters with the 
same wt virus that is used as a vector may result in an 
accelerated and enhanced immune response against 
thevector,decreasing theefficiency (seepre-existing
immunity. If the subject is a carrier of latent wt virus, 
closely related to the intended vector, treatment with 
the vector may result in reactivation from latency (eg 
HSV, AAV, Ad), recombination, mutation or reversal 
to wild-type status. Current infections or inflamma-
tory processes should be treated and resolved before 
proceeding, after which the risks can be re-evaluated. 
An exception to this may be the treatment of HIV car-
riers with lentiviral vectors, where ongoing HIV infec-
tion is a requirement for the treatment per se, however, 
other opportunistic infections should be treated and 
cleared before gene therapy.
Possible effects immune modulation 
Immune modulation may increase the risk for reac-
tivation of latent wt viruses and recombination with 
vector-type virus, it may affect spreading, biodistribu-
tion and shedding. Immune modulation may increase 
the severity of ongoing infections or inflammatory 
processes and give rise to serious side effects in the 
patient. However, the latter is not relevant for the 
environmental risk assessment.
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Step 2: What type of immune modulation is used?
Required information 
All relevant information concerning dose, duration 
of treatment, and its relation to the depth of immune 
suppression,inparticularT-cellimmunity.
Background 
As discussed extensively in appendix B, there are many 
types of immune modulation, each targeting different 
systems with more or less specificity. The rationale 
behind the use of immune modulation in gene therapy 
isclear(increasedvectorefficiency),butitshouldout-
weigh the possible risks, such as an increased risk for 
other infections, the likelihood of recombination, 
effects on the viral life cycle, and the prolonged per-
sistence of vector in the body and spreading through 
the circulation (biodistribution) and shedding. In 
addition, often immune suppressive treatments are 
administered for primary tumor-treatment and not 
with the intention to prolong vector existence, but this 
may nevertheless have the same effect.
2a.   What is the type of immune modulation(s) used?
Stratify according to 4 risk categories:
I  Systemic immune suppression with drugs resulting 
in total myeloablation, severe myelosuppression 
orT-celldepletion(inparticularATGorAlemtu-
zumab)
II  Specific targeted immune modulation with agents 
blocking co-stimulation
III Steroids
IV Other
Possible effects of immune modulation 
Systemic immune suppression affects multiple routes 
of immunity, and may in some cases even lead to bone 
marrow suppression, whereas specific immune sup-
pression, even if delivered systemically, affects a single 
factor. Even more, specific immune suppression, for 
examplewithCTLA4Ig,candecreasetheimmunere-
sponse towards the vector, without increasing the risk 
for infection. Long-lasting immune suppression can 
significantly increase the risk for infection, whereas 
transient immune suppression may allow the vector to 
infect the cells, but not increase the risk for infection. 
The effect of the different immune modulatory agents 
and their effect on infection risk are summarized in 
TableIII.
2b.   What is the dose (single or multiple) and duration of
the treatment(s)?
2c.  What is the anticipated (intended) level and dura-
tion of immune suppression achieved with this type of 
immune modulation? Ie, is the immune suppression 
intended to be transient or long-term.
2d.   What is the rationale behind the choice of immune
modulation?
I  Based on induced immune response against the vector
II Based on animal studies
III Other
Step 3: What is the effect of this particular immune 
modulation regimen on the patient’s risk of infection?
Required information 
All relevant data indicating increased risk of infection 
in relation with the depth and duration of the type of 
immune modulation used (For further information, 
checkTableIII)?
Background 
Increased infection risk, may increase the chances 
of two related viruses (ie a wt virus and the vector) 
to interact with each other. The risk of infection is 
determined by a number of variables, some of which 
are treatable (eg predisposing diseases or particular 
treatments), whereas others cannot be influenced (eg 
age). Based on experience with immune compromised 
patients and human vaccinations, the infection risk in 
general appears to be considerably higher in specific 
groups of people. These groups have been summarized 
inTableVIII.Inaddition,someoccupationalexposure
can result in an increased risk for specific infections.
3a.   Is the immune modulation used associated with an
increased risk for primary infection?
3b.   Is the immune modulation used associated with
reactivation of latent viral infection? 
Possible effects immune modulation 
Immune modulation can affect the risks for multiple 
(simultaneous) infections, especially in groups of pa-
tients who already display an increased risk of infection.
Step 4: Is the patient subject to other treatments that may 
affect the immune modulation facilitated gene therapy 
treatment?
Environmental Risk Assessment (ERA)
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Required information 
This involves all relevant information about additional 
treatments which may interfere with the functioning, 
the biokinetics and halflife of the immune modulatory 
agents, directly affect the immune system itself, either 
as an intended effect or as a known side-effect, or other 
systems indirectly affecting the immune system, as well 
as treatments that may influence the biodistribution, 
persistence, viral life cycle, recombination and shed-
ding of the viral vector.
4a.  Which treatments are (possibly) used, at what dose 
and duration?
4b.  Do these treatments in any way affect the function-
ing, biokinetics and half-life of the immune modulatory 
agents?
4c.  Do these treatments affect in any way the patient’s 
immune system?
4d.  Do these treatments influence the viral vector, by 
interfering with biodistribution, persistence, viral life 
cycle, recombination and shedding?
Step 5: Does the immune modulation in any way affect viral 
vector biodistribution and persistence?
Required information 
Provide any scientific information (and references to) 
concerning relevant animal or clinical studies where 
this type of immune modulation is used in combina-
tion with gene therapeutic applications. What are the 
relevant (pre)clinical studies and why are the relevant 
here: which organs are involved and how long can 
vector be measured and by which techniques, eg. Semi-
qPCR,RT-PCR,nestedPCR,Taqman,PCR/Southern;
tracking genes, eg EGFP, luciferase, LacZ; Histology; 
FISH; ELISA; transgenic protein/gene expression; cell 
culture, etc.
5a.  What are the relevant animal/clinical studies?
5b.  How is biodistribution of the vector affected by im-
mune modulation?
5c.  How was biodistribution and persistence of the vec-
tor measured?
5d. How long were biodistribution and persistence 
measured and up till what time were samples found to 
contain evidence of viral presence?
Step 6: Does immune modulation affect the likelihood of 
recombination or reassortment of the viral vector?
Required information 
Provide scientific information (and references), if 
available, on recombination events in in vitro and in 
vivo animal studies.
6a.  What are the relevant studies?
6b.  How are recombination or reassortment affected?
Step 7: Does immune modulation affect the risk for shedding 
and transmission of the viral vector?
Required information 
Provide relevant scientific data (and references) on 
shedding from animal and clinical studies. Which 
sites were sampled (eg injection site, respiratory tract, 
excreta (urine, stool, semen), bandages, patient’s 
(hospital and home) environment, which methods 
were used to obtain the samples (blood, serum, swab, 
etc) and to confirm shedding (PCR, cell culture, etc) 
and how sensitive are these tests. At which time point 
was shedding measured and up till what time and how 
often.
7a.  What are the relevant pre(clinical) studies?
I How was shedding measured? 
II From which sides was shedding measured 
III  How often and how long was shedding measured? 
IV  How was secondary/tertiary transmission mea-
sured? 
V  Were any negative effects of secondary/tertiary 
transmission documented?
This ERA consists of three parts, as discussed above: Part 
A: General and treatment-related issues; part B: Vector-
related issues; and part C: Immunity-related issues. A 
fourth part D is not provided here, but would ideally con-
tain all aspects as discussed above and allow an integral 
evaluation of the risks, according to directive 2001/18 
(effects on human health, medical practice, animal 
health, veterinary practice, population dynamics) and the 
assessment of the overall environmental risk. However, 
all relevant information needed for such an individual 
risk evaluation is provided in different parts of this report 
and background reading can be found in the appendices. 
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3.3 era SaMPLe CLiniCaL triaL
example of a fictional era with the aav1-LPLS447X 
vector. 
Part a: generaL and treatMent-reLated 
iSSueS 
Step 1: Describe the patient population
1a.   How many patients are included in the clinical trial?
Estimated enrollment 8.
1b.  What is the age range of the patient population?
Over 18 years
1c.   Describe the disease (genetic, cancer, etc). 
 Lipoprotein lipase (LPL) is the principle enzyme involved 
in the clearance of triglycerides from plasma. Severe LPL 
deficiency is a disorder affecting approximately 5000-
10000 individuals in the Western world. The prevalence of 
familial LPL deficiency is approximately one in 1,000,000 
in the general population. These patients present with 
colicky pain, eruptive xanthomas, growth retardation 
and recurrent acute pancreatitis, resulting intensive 
care admissions, diabetes or death. Approximately 25% 
of affected children develop symptoms before age one 
year and the majority develops symptoms before age 
ten years. There is currently no specific therapy available 
other than severe reduction of dietary fat, to 20 grams/
day or less, which is impossible to comply with in the 
long term. Lipoprotein lipase (LPL) is the key enzyme in 
the metabolism of triglyceride-rich lipoproteins and is 
mainly produced in fat tissue, skeletal and heart muscle. 
Enzymatic activity of LPL mediates hydrolysis of triglyc-
erides in chylomicrons and very low density lipoproteins 
(VLDL), resulting in the production of free fatty acids 
for either energy-expenditure or –storage. Consequently, 
these triglyceride-rich lipoproteins are rapidly cleared af-
ter every meal and the triglyceride levels in the circulation 
are reduced. LPL deficiency is an autosomal recessive in-
herited condition caused by homozygosity or compound 
heterozygosity for mutations in the LPL gene.
1d.   Does the disease itself affect the immune responses
of the patient?
No
1e.  What are in/exclusion criteria
Inclusion criteria:
•BeingdiagnosedwithLPLDdefinedas:
•Confirmed homozygosity or compound heterozygos-
ity for the mutations in the LPL gene, resulting in LPL 
deficiency
  -  Having a post heparin plasma LPL activity of < 20% 
of normal or a well defined mutation for which it is 
documented that the LPL mass and activity are within 
the limits described above
  - Having a history of pancreatitis
-Having fluctuating TG concentrations with median
fastingplasmaTGconcentrations>10mmol/L
•Beingingoodgeneralphysicalhealthwithintheopin-
ion of the investigator:
  -  No other clinically significant and relevant abnormali-
ties in the medical history, which could interfere with 
the participation to the study
  -  No clinically significant abnormalities at the physical 
examination, which could interfere with participation 
to the study
  -  No clinically significant abnormalities at the routine 
laboratory evaluation performed prior to the trial
•Womenofnon-childbearingpotentialorwithanega-
tive pregnancy test
•Nonbreastfeedingwomen
•Women using appropriate contraceptive (if relevant)
and their partner using barrier contraception 2 weeks 
before starting immunosuppressive therapy
•Menpracticingbarrierbirthcontrolandtheirpartner
using appropriate contraception.
•Willingtofullycomplywithallstudyproceduresandre-
quirements of the trial such as restrictions to a low-fat diet.
Exclusion criteria:
•Havingachronicinflammatorymuscledisease
•Any current or relevant previous history of serious,
severe of unstable physical of psychiatric illness, any 
medical disorder that may make the subject unlikely to 
fully complete the study, or any condition that presents 
undue risk from the study medication or procedures 
based on the investigator’s opinion (eg. malignant 
neoplasia)
•Activeinfectiousdiseaseofanynature,includingclini-
cally active viral infections
•Havingoneofthefollowingoutcomesfromtheblood
screening tests after appropriate correction due to the 
presence of chylomicronemia:
   - Platelet count < 100 x 109/L 
   - Hemoglobin < 6.2 mmol/L
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   -  Liver function disturbances (bilirubin > 1.5 x normal, 
ALT>2xupperlimitofnormal)
-CPK>2xULN
   -  Cockcroft-Gault estimated creatinine clearance < 50 
cc/min
-PTandPPToutsidenormal rangeornotdetermin-
able unless judged as acceptable for the subjects by the 
investigator
   -  Having a positive test for HIV, Hepatitis B, Hepatitis 
C or being positive for tuberculosis
•Obesitydefinedasabodymassindex(BMI)>30kg/m2
•Having a recent history of alcohol or drug abuse, eg
barbiturates, cannabinoids and amphetamins, and the 
subject is positive in a urine screen for drugs of abuse
•Usinganti-coagulants
•Participation inanotherclinical trialorreceiptofany
other investigational drug within 30 days of screening 
or planning to participate in another clinical trial dur-
ing the course of the study, except observational studies
•Subjectswhichcannotbetreatedwithimmunosuppres-
sive medication or steroids
•Knowntobeallergictoanyconstituentofthetherapy
(including immune suppressors) or having a condition 
that prohibits the use of therapy
•ReceivedprevioustreatmentwithAAV1-LPLorother
gene therapy investigational product
•Requiring a post-heparin plasma LPL activity test
for diagnostic confirmation and having a history of 
heparin-induced thrombocytopenia or other heparin-
related complications
1f.   What are the primary and/or secondary endpoints
of the study?
 The primary endpoint is a reduction in median fasting 
plasma TG concentrations at week 12 of levels < 10
mmol/LorareductioninTGlevelsof>40%.Secondary
endpoints include reductions in chylomicrons and/or the 
chylomicron/TGratioat12weeks,thebiologicalexpres-
sion of the LPLS447X transgene product, the safety profile, 
a reduction in the incidence of pancreatitis and shedding 
of viral the vector at week 14.
Step 2: How is the viral vector administered?
2a.   What is the route of administration (ROA)?
 (systemic: sc, ip, iv, ia; or local: intratumoral, intralesional, 
intrathecal, intrapulmonary.) 
Intramuscular delivery in the upperlegs
2b.  What is the way of administration? (injection, in-
haler/spray, other)
A single series of multiple injections (40-60) of 500 μL 
each, was previously shown to be well tolerated in a clini-
cal trial (Stroes et al. 2008).
2c.   What is the dose (pfu, vp, ip) and timing of admini
tration (single dose, multiple doses, time in between 
treatments)?
 1x1012 genome copies per kg body weight. A previous 
study (Stroes et al. 2008) showed that higher doses 
showed better results in terms of clearance of fasting 
plasma trigliceride levels. 
2d.  Is the target organ an immune-privileged site or 
non-immune privileged site?
Non-immune privileged site
Step 3: Information about other treatments applied to the 
patient population
3a. Treatmentsdirectlyaffectingtheimmunesystem
None
3b. Treatments affecting pharmacokinetics of viral 
vectors
None
3c.  Treatmentsaffectingpharmacokineticsofimmune
modulatory agents
None
3d.   Other
None
Step 4: Information about the patient’s environment
4a.   Hospitalization-related information
Patients are nursed in a controlled environment where 
a dedicated facility appropriate for gene therapy pro-
cedures is available, with limited monitored access for 
experienced and fully trained personnel, according to 
legal regulations.
4b.   Housing-related information, including household
information, nursing-home
This section is patient specific and should be evaluated on a 
case by case basis. Here no particular circumstances apply. 
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4c.  Out-house activities, such as profession, military, 
kindergarten/schools, sportsclubs, etc
This section is patient specific and should be evaluated 
on a case by case basis. Here no particular circumstances 
apply.
4d.   Animal contacts (occupational or recreational)
This section is patient specific and should be evaluated 
on a case by case basis. Here no particular circumstances 
apply.
Step 5: Which protective measures are utilized to prevent 
transmission?
5a. Tohealthcarepersonnel
 Infection precautions recommended for adenoviruses 
should be maintained, because transmission of AAV may 
be similar to that of adenovirus and is most probably 
via the respiratory or gastrointestinal tract. In addition, 
prevention of adenovirus, herpes virus, or vaccinia virus 
infections may be useful, because propagation of AAV 
is dependent on coinfection with these helper viruses. 
Infection control of adenovirus is difficult. Adenovirus
can persist for up to 30 days on surfaces and are not 
eliminated by standard detergents, alcohol or chlorhexi-
dinegluconate.Handwashingmaythereforenotsuffice.
However, the use of sodium hypochlorite (10% bleach) 
is effective in killing the virus (Evans and Lesnaw, 2002). 
Contact with bandages and the site of injection should 
be minimimized to prevent transmission. Droplet and 
contact precautions, including personal protective equip-
ment and hypochlorite in case of spilling, are required 
during and shortly after administration and during 
hospital admission standard precautions and the use of 
personal protective equipment (surgical gloves, mask) 
will be maintained. Equipment from the patient’s room 
will be discarded, if appropriate and waste will be dis-
posed of as regulated medical waste. 
5b. Tohouseholdmembers
5c.  How long will these measures be continued, eg 
before, during and after therapy
 Airborne and Contact Precautions will remain in effect 
until two consecutive assays for the appropriate body site 
or fluids are negative for the vector.
5d.  How is compliance with the measures assessed
Hospital personnel, patients and family members will all 
receive appropriate instructions. 
Part B: veCtor-reLated iSSueS
Step 1: Information about the wild type virus
1a.  Which wild type virus is used as a backbone for the 
vector.
The adeno-associated viruses (AAV) are small, non-
pathogenic, single-stranded DNA viruses and naturally 
replication-defective. The most commonly used rAAV 
vector for gene therapy is based on AAV-2. However, 
due to the high level of immunity against AAV-2 also 
the use of other AAV serotypes is explored, including 
AAV-1. The choice of AAV serotype is strongly deter-
mined by their tropism. The natural tropism of AAV-1 
for muscle tissue, CNS and liver tissue and the decreased 
immunogenicity of this serotype, make this serotype 
ideal to serve as a viral vector to target muscle. Here, a 
recombinant AAV, produced in a baculovirus sytem is 
used, pseudotyped with AAV-1 capsids and containing 
AAV-2 inverted terminal repeats.
1b.   Infectivity of non-replicating cells
AAV can infect both replicating and non-replicating 
cells.
1c.   Integration into host genome
In the absence of helper virus, AAV-2 can become latent 
and integrate site-specifically into chromosome 19q13.4. 
This specificity of integration is determined by the pres-
enceoftheITRsandtherepgene.
1d.   Virulence and pathogenicity
AAV is a non-pathogenic virus and although infection 
with wild type AAV may occur, this is not associated 
with human disease. Approximately 85% of adults have 
antibody against AAV and seroconversion usually occurs 
in childhood. The route of infection is presumed to be, 
like adenoviruses, respiratory or gastro-intestinal.
1e.   Host-range: Human/Animal, Broad/Restricted
AAVs can be found in humans, non-human primates 
and a broad range of other animals.
1f. Tissuetropism
The tissue tropism of AAV is broad and includes muscle, 
CNS and liver, but depends on the serotype and expression 
of receptors and co-receptors. For example, AAV-2 gains 
entry into target cells through binding to heparan sulfate 
proteoglycan and one or more co-receptors including 
anb1 and anb5 integrins, FGF-R1, HGF-R and the lam-
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inin receptor and targets kidney, liver, muscle, lung and 
CNS tissue. AAV-1 tropism is restricted to muscle, CNS 
and liver tissue and uses sialic adic as its primary receptor.
1g.  Biodistribution
Biodistribution data of AAV1 in mouse models showed 
short-term vector leakage from intramuscular injection 
sites into the circulation, followed by liver-mediated 
clearance. AAV1 pseudotyped AAV2 vaccine vectors 
showed that after intramuscular injection in rabbits bio-
distribution and persistence depended on the vector dose 
and were most common at the injection site and highly 
perfused tissues, eg liver, iliac lymph nodes, spleen and 
testes, but not in sperm. One liver sample tested positive 
for integration, all other samples persisted as unintegrated 
episomal concatemers (Schnepp et al. 2006). 
1h.   Persistence
Most AAV serotypes persist episomally and can remain 
present in non-dividing cells for extended periods of 
time. AAV2 can integrate in the genome and is usually 
found as a provirus integrated into chromosome 19 of 
the host cell genome, where it remains latent until helper 
viruses supply missing proteins and genes, required for 
successful replication. 
1i.  Cell lysis and lateral spreading
 Naturally occurring AAV serotypes, in particularly AAV-
2, can become widely disseminated following primary 
infection in children (Chen et al. 2005). The most prob-
able route of infection is through the respiratory system, 
after which primary infection occurs in association with 
a helper virus, most commonly adenovirus. Replication 
with the help of adenovirus, results in the formation of 
new AAV particles, which may spread through the oro-
pharynx or bloodstream to distant sites. Even widespread 
dissemination is not associated with any clinical disease 
or pathology (Chen et al. 2005).
1j.   Innate immune response
AAV is able to evade innate host immune surveillance, 
due to lack of pathogen associated molecular patterns 
(PAMPs), preventing the activation of Toll-like recep-
tors (TLRs).Thehost responseagainstwild-typeAAVs
is therefore at least partially determined by coinfection 
with a helper virus, which induces the innate immune 
response and facilitates the immune response against 
AAV. Other parameters that determine the host immune 
response against AAV are pre-existing immunity, route 
of administration, inoculation dose, serotype and its 
ability to infect APCs.  
1k.   Viral clearance
AAV clearance is predominantly cytotoxic lymphocyte 
mediated. 
1l.   Horizontal transmission
TransmissionofrAAVismostlikelytobesimilartothat
of adenoviral vectors and may occur through droplets 
from the respiratory tract or body fluids, such as stool 
and urine.  
1m.   Vertical transmission 
Vertical transmission of AAV has not been observed in 
any preclinical or clinical study. Although vector genome 
from different AAV serotypes, eg AAV-1, AAV-2 and 
AAV-8 could be transiently detected at low levels in the 
gonads or semen after administration to several animal 
species, including mice (Rip et al. 2005; Jakob et al. 2005), 
rabbits (Favoro et al. 2009) and non-human primates 
(Toromanoffet al. 2008), this did not result in germ-line 
transmission (Van Amersfoort et al. 2007; 2008) and the 
overall risk was considered very low. Importantly, the ap-
pearance of vector genome copies in semen was shown to 
occur in a dose-dependent and time-dependent fashion 
(Schuettrumpf et al. 2006). Similarly, in two phase I/II 
clinical studies for lipoprotein lipase deficiency with an 
AAV-1 pseudotyped vector (Nierman et al. 2007) and 
with an AAV-2 vector for hemophilia (Manno et al. 
2006) vector sequences were detected in semen. In the 
latter, however, vector appearance and clearance from 
semen was found to be not dose or time-dependent, but 
rather depended on the age of the patients, with younger 
men displaying earlier clearance than older men. In rab-
bits, clearance of vector sequences from the motile sperm 
fraction was more rapid than from total semen, and there 
was no evidence of transduction of early spermatogonia 
(Schuettrumpf et al. 2006). Semen fractionation in hu-
mans demonstrated the absence of vector sequences in 
motile sperm (Manno et al. 2006).   
1n.   Genetic stability/Recombination
No data are available on the genetic stability or recombi-
nation of naturally occurring AAV.
1o.   Availability of anti-viral treatment
Currently not available.
1p.   Physical and chemical stability
AAV has is stable against heat and pH changes and has 
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a relative solvent resistance. It is not resistant to various 
solutions containing 10% bleach.
1q.  Immune evasiveness
AAV lacks PAMPs, as a result of which they cannot acti-
vatetheTLRs.AlthoughAAV-2caninfectDCsthrough
binding of Heparan Sulfate Proteoglycan (HSPG), a 
post-entry block inhibits successful transgene product 
expression and upregulation of co-stimulatory molecules 
and MHC classes I and II. As a result, AAVs are not able 
to induce maturation of human DCs and production of 
type I IFNs.
Step 2: Information about the viral vector
2a.   Is the vector replication-competent? 
 Previous vector production was performed using plasmid 
transfectionoftheHEK293cellline.Upscalingofthevec-
tor production required modification of the production 
system. For the current AAV1-LPLS447X vector, insect cells 
are infected in suspension culture with three separate 
recombinant baculoviruses containing the essential genes 
(P5 for Bac.VD88, Bac.VD84 and Bac.VD43 encoding 
rep, cap and LPLS447X) for AAV vector production, thus 
eliminating the transfection process (Twisk et al. 2007; 
Gaudet et al.2008).Thevectorsarepurifiedusingaffinity
chromatography. All essential viral genes are provided by 
the baculoviruses, as are the helper functions of Ad. The 
resulting AAV-LPL vector is replication deficient. For 
more information, see also part B, step 3.
2b.   Can the vector infect non-replicating cells?
Yes.
2c.   Can the vector integrate into the host genome?
The vector remains usually present as an episomal con-
catemer, but it cannot be excluded that the vector may 
integrate at a very low level in the host genome. 
2d.   Information about deletions of viral sequences
I  Deletions of genes to render viruses replication 
deficient
II  Deletions of genes important for immune evasion
III   Deletions of other viral sequences
AAV requires the help of helper viruses, such as Herpes 
Virus, Adenovirus or Vaccinia for succesful replication. 
In absence of these viruses, AAV is replication deficient. 
AAV contains 2 genes, rep and cap, which encode poly-
peptides necessary for replication and encapsidation. 
Removal of all internal viral coding sequences of the 
wild-type virus and replacement by a therapeutic gene 
renders the recombinant AAV completely replication 
deficient. Here, expression of the LPL variant LPLS447X is 
under control of the inverted terminal repeat sequences 
of AAV-2, whereas the capsid proteins are provided by 
AAV-1. The choice for AAV-1 capsid proteins is twofold, 
1) it is less immunogenic than AAV-2; and 2) it has in-
creasedspecificityandefficacyoftransductionofmuscle
cells.
2e.   Information about inserted transgenes or sequences
I Toxicity
II  Survival advantage, eg cytokine, growth factor, re-
ceptor
III   Survival disadvantage, eg antigen, replication inhi-
bitor 
IV Antibiotic resistance, eg selection gene
V Requires activation, eg tumor suppressor
VI   Other, eg deficiency, suicide, marker 
 Lipoprotein lipase (LPL) plays a central role in human 
lipid homeostasis and energy metabolism. The main 
function of this enzyme is the 1) hydrolysis of plasma 
triglycerides(TGs)and2)clearanceofatherogenicrem-
nant lipoproteins from the circulation  (Rip et al. 2006). 
The protein is mainly expressed in skeletal and heart 
muscle and adipose tissue. Loss of the LPL gene or loss-
of-function mutations result in hyperlipoproteinemia. 
The S447X polymorphism is found in ~20% of the general 
population and results in the production of a truncated 
protein. The LPLS447X transgene is based on the finding 
that this LPL variant, with a gain-of-function mutation, 
is associated with beneficial effects on lipid homeostasis 
and atheroprotection (Wittrup et al. 1999) and associated 
with protection against cardiovascular disease. Overex-
pression of the LPL variant is not associated with any 
known toxicity, but expression of the gene in the normal 
population appears to be associated with a decreased risk 
for cardiovascular disease. The transgene is transferred 
to patients with severe LPL deficiency (category VI) and 
does not result in any known survival advantage or disad-
vantage of transduced cells. It does not confer antibiotic 
resistanceorrequireactivation.Transferof theLPLS447X 
variant to LPL-/- mice resulted in more effective rescue 
in terms of longevity and lipoprotein metabolism, com-
pared with the transfer of wild-type human LPL (Ross et 
al. 2005).
2f.   Replication of the viral vector in normal cells
 The AAV1-LPLS447X vector is locally injected through 
multiple injections in the skeletal muscle, where the LPL 
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protein becomes active. The LPL protein is expressed lo-
cally and transported to the capillary endothelium where 
it binds to chylomicrons and VLDL. Since the vector it-
self is replication deficient, it will not replicate in any cell 
without the help of a wild-type AAV and the presence of 
a helper virus to complement missing proteins and genes.
2g.   Immune evasiveness
I  Viral evasion mechanisms present in the vector
II  (Structural modifications, shielding or stealth 
mechanisms) affecting antigenic variability of the 
vectors
AAV-1 is naturally innate immune evasive as it does not 
transduce and activate antigen presenting cells, due to 
lack of pathogen-associated molecular patterns (PAMPs. 
However, adaptive immune responses may occur towards 
immunogenic epitopes of the capsid or the transgene 
product. Whereas the capsid is solely delivered as a 
protein from an exogenous, non-self renewing source, 
the transgene product is endogenously produced in the 
host in a renewable manner (Vandenberghe and Wilson, 
2007).
2h.  Availability of preclinical models
LPL-/- cat (Ross et al. 2006) and mouse models (Rip et 
al. 2005) are available. It was shown in the LPL-/-  mouse 
model that a single intramuscular administration of 
adeno-associated virus (AAV) serotype 1 vector, encod-
ing the human LPLS447X variant, resulted in complete, 
long-term normalization of dyslipidemia in LPL-/- mice 
(Rip et al. 2005) and that in cats injection at two sites, 
greatly limiting the amount of transduced muscle, was 
sufficienttocompletelycorrectthedyslipidemia(Rosset 
al. 2006). 
2i. Information about the tropism, targeting and re-
stricted expression of vectors
I Transductionaltargeting:Surfacetargeting&Cap-
sid modifications
II Transcriptional targeting: Genome modifications
for targeted replication 
III Targetedreplicationbypost-transcriptionalregula-
tion of replication of expression
The AAV-LPLS447X vector is pseudotyped with AAV-1 
capsidproteins andcontains the ITRofAAV-2. Itwas
shown in a mouse study that transduction of muscle 
is superior by AAV-1 compared to AAV-2 and that 
immune responses against AAV-1 after intramuscular 
injections are less pronounced than with AAV-2 (Arruda 
et al. 2004). Local diffusion of vector in muscle was found 
to be limited and although vector sequences could be 
transiently detected in all body fluids measured, expres-
sion of the transgene was found to be restricted to muscle 
tissue (Rip et al. 2005). Whole blood samples tested posi-
tive for viral DNA until day 28, but viral DNA in plasma 
was rapidly cleared (<3–4 days). On day 7, vector DNA 
was detected mainly in the injected muscles, spleen, liver, 
inguinal lymph nodes, marrow and gonads. Levels of 
vector DNA in the various organs and tissues declined 
with time and were dependent on the vector dose. On 
day 28 and day 90, vector DNA was detected only in the 
injection sites, liver and inguinal lymph nodes and viral 
DNA levels in gonads were just above background levels 
(Rip et al. 2005).
2j.  Information about biodistribution after systemic 
injection, local injection in a non-immune privileged site, 
local injection in an immune-privileged site.
In LPL-/- mice, shortly after intramuscular administra-
tion of AAV1-LPLS447X, vector DNA was detected in 
muscle, but there was also considerable leakage into the 
circulation, liver and gonads. AAV DNA sequence also 
accumulated in lymph nodes close to the injection site, 
indicating drainage via the lymphatic system (Rip et al. 
2005). Expression of the LPL protein was only detected 
in the injected muscles, but not in liver, heart or adipose 
tissue (Ross et al. 2004). In a non-human primate model, 
it was shown that up to 34 months after im injection, 
rAAV-1 vector copy numbers were high at the site of 
injection with little diffusion throughout the muscle, re-
sultinginclustersoflocallytransducedcells(Toromanoff
et al. 2008). It was shown by using a replication assay with 
a sensitivity of 5x102 infectious particles/mL of serum, 
that the number of infectious AAV-1 particles in serum 
was highest at 6 hours after im delivery and completely 
negative within 7 days of injection; using a PCR with a 
sensitivity of 350 vg/mL of serum, rAAV-1 particles could 
be detected for up to 1 month in serum; using Southern 
blotting of PCR amplicons, the detection limit was low-
ered to ~3x10-5 copy/diploid genome and positive samples 
were found in liver, draining and distant lymphnodes, the 
gonads, spleen, kidney and PB-mononuclear cells up to 
34monthsafter injection (Toromanoffet al. 2008). No 
immune response was observed against rAAV-1.
In a phase I/II clinical trial with AAV1-LPLS447X it was 
found that after local intramuscular delivery of 1x1011 or 
3x1011 gc/kg vector sequences could be detected at high 
levels in muscle biopsies, but also at low levels in all body 
fluids tested, including serum, saliva and urine (Nierman 
et al. 2007). 
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2k.  Information about persistence after in vivo adminis-
tration
 In LPL-/- mice, persistence of AAV1 vector DNA was 
limited to the injected muscle and draining lymph nodes, 
and spread to reproductive organs was limited. Plasma 
clearance was rapid (within days), resulting in accumula-
tion of vector in filtering organs, particularly the liver. 
Short-term clearance of the vector by the liver is likely 
followed by efficient degradation, for example, by liver
Kupffer cells, because levels of vector DNA sequence in 
liver decline rapidly as well. In agreement with the rapid 
clearance from the circulation, spread of AAV1-LPLS447X 
to distant organs such as liver did not result in transgene 
expression. Vector DNA was detected in both male 
and female gonads, but the levels declined over time to 
undetectable (low dose) or low (high dose) levels after 3 
months (Rip et al. 2005). In LPL-/- cats, vector sequences 
were detected in testes en epididymides at 8-10 weeks 
after intramuscular AAV1-LPLS447X delivery. However, 
the corresponding motile sperm fraction contained little 
(<10 copies) to no vector DNA sequence (Ross et al. 
2006).
In the phase I/II clinical trial with AAV1-LPLS447X 
vector clearance from the serum occurred at a rate of 1 
to 2 logs per week and urine was free of vector sequences 
as early as one week after administration. Very low levels 
of maximally 25-28 vector copies/mg DNA could be 
detected in semen (Nierman et al. 2007).  
2l.  Information about mutation and recombination 
after in vivo administration
I   Is the vector replication competent or replication 
deficient?
II   What is the incidence of mutation and recombina-
tion of the parental virus?
III  What is the incidence of mutation and recombina-
tion of the vector in vitro/in vivo
IV  Information on complementation or missing func-
tions in the vector by the wt virus
V  Other treatments that may influence recombina-
tion/mutation 
 The vector is replication deficient and the likelihood of 
recombination is low, because it would require both co-
infection with a wild-type AAV (to supply missing rep 
and cap genes) and a helper virus to complete the viral 
life cycle. There are no data available on the incidence of 
mutation and recombination of the parental virus. Even if 
such an unlikely event would occur and replication com-
petent AAV vector would result in ongoing infection, this 
would clinically most likely result in a gastroenteritis or 
upper respiratory tract infection, although the total effect 
and in particularly possible toxicity depends largely on 
the transgene (see below). 
2m.  Information about possible toxicity (as a result of 
either the vector itself or the encoding transgenes)
 AAV-1 was shown to be well tolerated in male and female 
C57Bl/6 mice (Rip et al. 2005). No deaths or significant 
changes in overall health or food intake were found, 
except for a reduced body weight gain in the high dose 
treatment group (-30% at the high dose of 1013 gc/kg). 
Marked overexpression of LPL in skeletal muscle has 
also been shown to result in reduced body weight gain 
in transgenic mice (Levak-Frank et al. 1995) and rab-
bits (Koike et al. 2004). No significant hematological 
or biochemical abnormalities were observed (Rip et al. 
2005). Microscopically, a transient lymphoid hyperpla-
sia was found in the spleen of animals in the high dose 
treatment group at days 7 and 28; a grade 1 myositis was 
found in all animals, both control and low-dose (1x1011 
gc/kg) treated, at day 7 as a result of the intramuscular 
injections, but histology was normalized by day 28 in 
all groups, except the high dose treatment group, which 
were found to display a grade 2 myositis at day 90 (Rip 
et al. 2005).Treatmentof femaleCD1micewithdoses
up to 1013 gc/kg at 4 weeks prior to mating, resulted in 
increasing concentrations of vector DNA in maternal 
tissues, but not in any of the fetuses and fetal death or 
abnormalities were not observed (Van Amersfoort et al. 
2007; 2008). In addition, treatment of pregnant mice with 
AAV-LPLS447X demonstrated the presence of vector DNA 
in the maternal, but not the fetal site of the placenta and 
absence of germline transmission (Van Amersfoort et al. 
2007; 2008). Intramuscular treatment of LPL-/- mice with 
vector did not result in an increase in creatine phospho-
kinase (CPK), a marker of muscle injury, or local signs 
of toxicity due to the injection, the AAV vector or LPL 
expression (Ross et al. 2004). In the LPL-/- cat model, 
CPK levels did increase in response to AAV-LPLS447X, 
with peak levels at week 3-4 and normalization of CPK 
to baseline levels at week 8 (Ross et al.2006).Treatment
with Cyclophosphamide could not prevent the increase 
in CPK levels, but in cats that did not generate an im-
mune response, CPK levels were generally lower (Ross et 
al. 2006). In previous clinical trials, except for a minor 
discomfort during injection, there were no signs of 
hepato- or nephrotoxicity after injection and later during 
follow-up (Stroes et al. 2008). Muscle function tests and 
fat content were unaffected by AAV-LPLS447X and only 
1 patient developed a transient increase in serum CPK 
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levels at 4 weeks postinjection, coinciding with a loss of 
transgene expression and suggestive ofT-cellmediated
destruction of transduced muscle cells (Stroes et al. 2008; 
Mingozzi et al. 2009).  
2n.   Environmental shedding 
There is a substantial amount of literature available sug-
gesting that shedding of rAAV is dependent on the dose 
and route of administration, and that vector DNA can be 
detected for a number of weeks in serum, and early times 
i.e. day 1 post administration, in saliva, serum, urine and 
semen (Favre et al. 2001; Manno et al. 2006; Provost et al. 
2005). Ideally, if positive DNA signals are observed, the 
samples should be followed up for infectious virus quan-
tification. The data derived from non-clinical shedding 
studies and from early phase clinical studies can then be 
used to assess the likelihood of transmission and to justify 
the extent of viral shedding evaluation in subsequent tri-
als. Since shedding of AAV, if any, is expected to come 
from respiratory secretions, stool, urine and semen, and 
therefore these sources will be monitored. However, after 
intramuscular injection, the highest risk of shedding is 
during initial injection and risks are expected to be very 
low thereafter (see above). 
2o.   Horizontal transmission 
Horizontal transmission is highly unlikely to occur with 
the proposed safety precautions (see ERA, part A, step 
4). In case of inadvertent transmission, immunity against 
AAV will rapidly clear the vector and no serious toxicity 
is expected from either the vector or the transgene (Rip 
et al. 2005). 
2p.  Safety back-up
I  Is a suicide gene present?
II Are the vectors sensitive to anti-viral agents? 
There is no suicide gene present in the vector construct 
and there are currently no treatment options for persons 
inadvertantly exposed to the vector. 
Step 3: Information about production of the vector
3a.  Which producer cell line(s) are used?
3b.   Which viral functions are provided by the cell lines?
3c.  Which quality control measures are used?
3d.   Which criteria are used to reject a batch?
 
rAAV for use in gene therapy was previously produced 
in mammalian cell culture systems by providing DNA 
plasmids that contain the therapeutic gene flanked by 
theITRsofAAVreplication,genesforAAVreplication
and genes for virion or structural proteins. In addition, 
a plasmid containing adenoviral genes was provided to 
enhance the expression of the AAV genes and improve 
vector yield (Grimm et al. 2008). Nevertheless, in most 
mammalian cell culture systems, the number of AAV 
particles generated per cell is ~104 viral particles (Clark 
et al. 2002), whereas for a clinical study >1015 particles of 
rAAV may be required. Large scale production of clini-
calgraderAAVvectorhasprovendifficulttoachievein
mammalian cell culture systems, but have been proven 
feasible in the baculovirus insect cell system (Meghrous 
et al. 2005). Thus, to overcome production problems, the 
current replication incompetent rAAV-LPLS447X vector 
isproducedinabaculovirussystem(Urabeet al. 2002). 
Baculovirus is produced using the Bac-to-Bac baculovirus 
expression system (Invitrogen). rBac-Cap is amplified by 
infecting 2x106 Sf9 (Spodoptera Frugiperda) cells and the 
supernatant containing the virus is recovered after 3 days. 
rAAV batches are produced using three recombinant 
baculoviruses (Urabe et al. 2002): the first baculovirus 
contains the construct for the LPLS447X transgene, the 
second baculovirus harbors the AAV replication genes, 
Rep 78 and Rep 52, the third baculovirus harbors the 
AAVl capsid sequence. In comparison to the mammalian 
system, the rAAV construct produced in the baculovirus 
insect system has a significantly higher amount of VPl 
compared to the amount of VP2 in the capsid, result-
ing in virus particles with improved infectivity. AAV 
particles are purified by affinity-purification, using an
immobilized monoclonal antibody against an AAV 
capsid protein. In view of the safety of viral vectors it is 
desirable to construct a viral vector unable to propagate 
after initial introduction into a cell. An AAV replicating 
inamammaliancelltypicallyhastwoITRsequences.By
using a chimeric ITR, ie a single ITR suffices forAAV
propagation of a circular vector, increased safety is pro-
vided(US2003148506).
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Part C: iMMunity-reLated iSSueS
Step 1: What is the level of host immunity?
1a.  Do(es) the patient(s) have a functional immune 
system: Is the patient immune-competent or (relatively) 
immune-deficient. If the patient is immune impaired, 
what is the extent of the immune deficiency?
I impaired innate immune system
II impaired adaptive/cellular immune system 
 •primaryimmunedeficiency(PID)
 •secondaryimmunedeficiency(AIDS)
 •induced transient immune suppression (chemo/
radiotherapy)
 All patients are adults over 18 years of age and with a 
normal and functional immune system.
1b.  Do(es) the patient(s) have a pre-existing condition 
(co-morbidity) affecting immunity, such as a mental or 
physical disability or for example diabetes?
I Due to the presence of any or more of risk factors
II Due to increased risk of exposure to a specific virus
Patients with a pre-existing condition other than LPL 
deficiency, affecting the general health and/or immune 
status are excluded from the trial. Some patients may 
have drug-controlled diabetes.
1c.  Do(es) the patient(s) have proven pre-existing or 
cross-reacting immunity (presence of antibodies) against 
the viral vector or is it expected that the patient may have 
pre-existing or cross-reacting immunity against the viral 
vector?
I   previous infection with the wt virus or a closely 
related virus
II  previous vaccination with the wt virus or closely 
related virus 
III  previous treatment with this viral vector or a similar 
vector
IV   previous contact with the transgene, eg enzyme 
replacement therapy
V  confirmed presence of neutralizing or cross-reacting 
antibodies 
In a recent study of the prevalence of IgG and neutral-
izing factors to AAV types 1, 2, 5, 6, 8 and 9 in the hu-
man population, it was shown that natural exposure to 
AAV resulted in the production of antibodies from all 
four IgG subclasses, with a predominant IgG1 response 
and very low IgG2, 3 and 4 responses. Prevalences of 
anti-AAV1 and 2 total IgG were highest (67and 72%, 
respectively) and followed by those of anti-AAV5 
(40%), 6 (46%), 8 (38%), and 9 (47%) (Sylvie et al. 2010). 
There are currently no vaccinition programs against 
AAV and previous treatment with a gene therapy vec-
tors is a factor to exclude patients from this trial. There 
is currently no enzyme replacement therapy available for 
the treament of LPL deficiency and in a recent clinical 
trial with AAV-LPLS447X, 4 out of 8 subjects developed 
T-cellresponsestocapsidproteinsandIgG3anti-AAV-
antibodies with a dose-dependent kinetics of appearance, 
butnoneofthesubjectsdevelopedB-orT-cellresponses
to the LPL transgene product (Mingozzi et al. 2009).
1d. Is the patient a known or suspected carrier of a virus, 
similar or closely related to the viral strain, used for the 
vector (presence of viral nucleic acids)?
I   Does the patient have a history of infection(s) with 
wt virus used as viral vector?
II   Does the patient have a current infection or inflam-
mation?
 Patients with active infections, such as with adenoviral, 
herpes simplex virus or vaccinia, are excluded from the 
trial as these viruses are known helper viruses to AAV. 
Selecting AAV naïve subjects is currently not possible due 
to lack of (sensitivity of) available assays and also most 
humans are already exposed to wild-type AAV before the 
age 5 (Mingozzi and High, 2007; Sylvie et al. 2010). Prior 
to inclusion in the study, patients will be screened for the 
presence of pre-existing neutralizing anti-AAV-1 capsid 
antibodies. 
Step 2: What type of immune modulation is used?
2a. What is the type of immune modulation(s) used? 
Stratify according to 4 risk categories:
I  Systemic immune suppression with drugs 
resulting in total myeloablation, severe myelo- 
suppressionorT-celldepletion(inparticularATG
or Alemtuzumab)
II   Specific targeted immune modulation with agents 
blocking co-stimulation
III  Steroids
IV  Other
 Combination treatment with Mycophenolate Mofetil, 
Cyclosporine A and methylprednisolone (category I)
2b.  What is the dose (single or multiple) and duration of 
the treatment(s) (and in between treatments)?
Patients will be treated with Mycophenolate Mofetil per 
os at 2 g/day from day -3 till week 12; Cyclosporine A per 
os at 3 mg/kg/day from day -3 till week 12 (both risk cat-
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egory I); and methylprednisolone, as a single intravenous 
bolusof1mg/kgbodyweight(riskcategoryIII).Together
this protocol induces a systemic immune suppression 
that can be regarded moderately severe-severe.  
2c.  What is the anticipated (intended) level and dura-
tion of immune suppression achieved with this type of 
immune modulation? Ie, is the immune suppression 
intended to be transient or long-term.
These regimens are initially based on regimens used in 
the suppression of immune responses during kidney 
transplantation, but have been tested in several animal 
models as well. In clinical kidney transplantation the tra-
ditional or ‘‘conventional’’ immunosuppressive protocol 
generally consists of a calcineurin inhibitor (Cyclosporine 
AorTacrolimus),anantimetaboliteasadjunctive(Aza-
thioprine or MMF), and prednisone (Yabu and Vicenti, 
2009). Cyclosporine A (CsA) specifically and reversibly 
inhibitsproliferationofT-lymphocytes,butdoesnotaf-
fect hematopoiesis or disrupt the function of phagocytic 
cells of the innate immune system. In kidney transplant 
studies, these regimens were shown to offer an excellent 
long-term safety profile. A reasonable starting point for 
thedesignofaregimentoblocktheCD8+T-cellresponse
to AAV capsid is therefore to use regimens used in organ 
transplantation. However, whereas the goal in organ 
transplantationistoblockT-cellresponsestothousands
of antigens on the donated organ, in AAV-mediated 
genetransfer,thegoalistoblocktheT-cellresponseto
the vector capsid, a single antigen that is only transiently 
present and is not actively expressed.
2d.   What is the rationale behind the choice of immune 
modulation?
I  Based on induced immune response against the vec-
tor
II Based on animal studies
III Other
 In both mouse and cat models, induction of an immune 
response was observed after intramuscular injection and 
asaresultefficacyofgenetherapywastransient,because
of an anti-hLPL neutralizing antibody immune response 
blunting LPL expression. In the cat model, the level and 
durationofefficacyweresignificantlyimprovedwithcy-
clophosphamide immunosuppression (Ross et al. 2006). 
LPL-/- cats on a commercial cat-food diet were treated 
with increasing doses of AAV-LPLS447X up to 1x1012 gc/kg 
im and treated with 100-200 mg/m2/wk Cyclophospha-
mide po. Immune suppression with cyclophosphamide 
improved short-term efficacy after administration of a
high vector dose, and prevented formation of anti-LPL 
antibodies in 2 out of 3 cats treated with the lowest vector 
dose (1x1011 gc/kg) (Ross et al. 2006). In other studies us-
ing intramuscular delivery of AAV vectors for the treat-
ment of hemophilia B in dogs, it was shown that immune 
suppression with Cyclophosphamide started before but 
not after AAV1-fIX delivery could prevent the formation 
of anti-fIX antibodies (Arruda et al. 2004). 
Step 3: What is the effect of this particular immune 
modulation regimen on the patient’s risk of infection?
3a.  Is the immune modulation used associated with an 
increased risk for primary infection?
With the conventional kidney transplant immune sup-
pression protocols (Yabu and Vicenti, 2009), consisting 
of a CNI (cyclosporine or tacrolimus), an antimetabolite 
(azathioprine or MMF), and prednisone, which is the 
basis of the immune suppression suggested in this clini-
cal trial, susceptibility for and reactivation of different 
viral infections are following a certain time pattern. Both 
CsA and MMF are associated with an increased risk for 
Herpes infection, in particular CMV. Short term treat-
ment with methylprednisolon is not clearly associated 
with any type of infection, but it may increase the risk 
for primary infections, when combined with CsA and 
MMF. The effects of this type of immune modulation are 
notlong-lasting,suchaswithATG,andarapidrecovery
of immune competence is expected after withdrawal of 
the treatment. As with monitoring of organ transplant 
recipients, prevention of viral infections is necessary and 
upon signs of viral infection, immune suppressive agents 
will be lowered or stopped.
3b.  Is the immune modulation used associated with 
reactivation of latent viral infection? 
During the first 1-2 months, patients with a history of 
HSV may have a reactivation, followed by infection (2-4 
months) with other herpes viruses such as CMV, EBV, 
VZV, HHV8, Parvovirus B19 and measles. Community-
acquired infections such as influenza, RSV, and adenovi-
rus may appear at any time (Kotton and Fishman, 2005). 
Here, the intended use of CsA and MMF is up to 12 
weeksaftergenetransfer.Thismaybesufficienttoallow
tolerance to the transgene, while preventing long term 
infectious complications. 
Step 4: Is the patient subject to other treatments that may 
affect the immune modulation facilitated gene therapy 
treatment?
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4a.  Which treatments are (possibly) used, at what dose 
and duration?
4b.  Do these treatments in any way affect the function-
ing, biokinetics and half-life of the immune modulatory 
agents?
4c.  Do these treatments affect in any way the patient’s 
immune system?
4d.  Do these treatments influence the viral vector, by 
interfering with biodistribution, persistence, viral life 
cycle, recombination and shedding?
The patients are not subject to any other treatment proto-
cols other than a fat-restricted diet. 
Step 5: Does the immune modulation in any way affect viral 
vector biodistribution and persistence?
5a.   What are the relevant animal/clinical studies?
See question 5b.
5b.  How is biodistribution of the vector affected by im-
mune modulation?
Cyclophosphamide had been shown previously to delay 
the onset of the antibody responses to AAV-1-mediated 
transgene expression of factor IX in a dog model of he-
mophilia B (Arruda et al. 2004). In a LPL-/- cat model, 
the effects of different doses of cyclophosphamide rang-
ing from 100-200 mg/m2 per week were tested on the 
immune response against AAV-LPLS447X and were shown 
to significantly improve both the level and duration of 
efficacy(Rosset al. 2006). AAV-LPLS447X gene therapy in 
cats demonstrated prolonged resolution of visible plasma 
lipemiaanda96%reductionofplasmaTGslastingover
8 weeks when combined with immunosuppressive treat-
ment. However, after cessation of the immune suppres-
sive treatment at 8 weeks of treatment, an anti-human 
LPL immune response occurred, resulting in loss of 
efficacyandan increase inplasmaCPK levels. In addi-
tion, after local im injection of the AAV vector and im-
mune suppressive treatment, expression and activity of 
the LPL protein was found only in treated muscles and 
not in untreated muscle biopsies or liver samples (Ross 
et al. 2006), indicating that rAAV1-mediated LPLS447X 
expression remains localized within the injected muscle 
tissue as reported previously in non-immune suppressed 
animals (Ross et al. 2004). In a non-human primate 
model of hemophilia B, the effects of combinations of 
other immune suppressive agents on the formation of 
anti-AAV2/8 antibodies and transgene expression of fIX 
were tested (Mingozzi et al. 2007). Regimens as used in 
renal transplant patients, including an antimetabolite, 
suchasMycofenolateMofetil(MMF)andanmTORin-
hibitor, such as sirolimus, have been shown to have a long 
term safety profile and were used to prevent an immune 
response against AAV and human fIX in rhesus monkeys 
(Mingozzi et al. 2007). Monkeys received 25mg/kg MMF 
twice daily po from 1 week before gene therapy to 10 
weeks thereafter and Sirolimus, which is often used in the 
clinics in patients unable to take Cyclosporin treatment, 
at a dose of 4 mg/kg/d po from day +1 to day +7 and 
2 mg/kg/d thereafter up to 10 weeks after gene therapy. 
Such a regimen of transient immune suppression did not 
substantiallyaltereithertransductionefficiencyorvector
biodistribution of AAV-2-mediated liver-directed gene 
therapy (Mingozzi et al. 2007). Previous studies in non-
human primates treated with AAV-8-fIX demonstrated 
that a regimen composed of MMF and tacrolimus (FK-
506)doesnot affect the liver transduction efficiencyor
biodistribution of the vector (Jiang et al. 2006).
5c.  How was biodistribution and persistence of the vec-
tor measured?
 In the non-human primate model, as described above, 
using an immune suppression regimen consisting of 
MMF and sirolimus, biodistribution and vector per-
sistence were measured using real-time quantitative 
PCR to determine vector copy number in liver tissue 
at 8 weeks and of various other tissues (spleen, testis, 
kidney, thymus, heart, skeletal muscle, diaphragm, 
lung, inguinal lymphnodes and different liver lobes) at 
40 weeks. No substantial differences were detected in 
vector biodistribution after direct injection into hepatic 
artery of AAV2-fIX vector (Mingozzi et al. 2007). In the 
LPL-/- cat study using AAV1-LPLS447X im, treatment 
with Cyclophosphamide did not result in changes in the 
biodistribution of LPL activity or protein expression as 
measured with an ELISA (Ross et al. 2006). Other models 
using AAV2-cfIX in canine hemophilia missense and 
nonsense models in combination with Cyclophospha-
mide only looked at formation of antibodies against the 
transgene and the vector (Herzog et al. 2001; 2002) and 
not at biodistribution or vector persistence. The study of 
AAV-8-fIX in non-human primates, transiently treated 
with MMF and FK-506, used realtime QPCR at 6 months 
after intrahepatic vector injection to assess gDNAs from 
various tissues, including heart, kidney, liver, testis, lung, 
spleen and thymus (Jiang et al. 2006). The limit of detec-
tion was 8x10-5 vector copies/diploid genome.
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5d.  How long were biodistribution and persistence 
measured and up till what time were samples found to 
contain evidence of viral presence?
This strongly depended on the type of study, as described 
above at 5b and 5c.
Step 6: Does immune modulation affect the likelihood of 
recombination or reassortment of the viral vector?
6a.  What are the relevant studies?
None.
6b.  How are recombination or reassortment affected?
Immune modulation does not appear to affect the 
likelihood of recombination or reassortment of the 
AAV1-LPLS447X vector. The risks for recombination or 
reassortment of AAV-1 are very low under study condi-
tions where no immune suppression is used and although 
only limited data are available on the use of immune 
modulation therapy to prevent an immune response 
against an AAV vector or transgene, thus far no data 
have been published that indicate an increased risk for 
recombination or reassortment in cases where immune 
modulation is used.
Step 7: Does immune modulation affect the risk for shedding 
and transmission of the viral vector?
7a.  What are the relevant pre(clinical) studies?
I   How was shedding measured?
 From which sides is shedding measured?
II   How often and how long was shedding measured? 
At which time points is shedding measured and up 
till what time.
III   How is secondary/tertiary transmission measured? 
Which method is used.
IV   Were any negative effects of secondary/tertiary 
transmission documented?
 A phase I/II clinical trial of AAV-LPL (1 or 3x1011 gc/kg) 
assessed the excretion and shedding of a previous  AAV-
LPL vector batch, which was produced in HEK293 cells 
and injected im (Nierman et al. 2007). With a sensitive 
quantitative PCR, vector sequences could be transiently 
detected in serum, saliva, urine, semen, and muscle biop-
sies. The highest vector concentrations were detected in 
theserum,witharapidclearanceby1–2logs/week.Urine
was free of vector sequences 1 week after treatment in the 
first dose cohort. Very low levels (at maximum 25–58 
copies/mg DNA) were detected in the semen for short pe-
riods of time, making the risk for germline transmission 
extremely low. Persistent presence of high levels of vector 
sequences was only detected in injected muscle and leak-
age of vector from the injection site was limited (Nierman 
et al. 2007). No clinical data are presently available on 
shedding during AAV-LPL treatment in combination 
with immune suppression and only limited animal studies 
in healthy animals or disease models have been per-
formed, as described above, using similar types of vectors, 
but different types of immune modulation. Nevertheless, 
it is expected that the effects of immune modulation will 
be minimal since 1) the AAV vectors do not replicate; 
2) the vectors are continually diluted from the point of 
administration to potential sites of shedding; 3) shedding 
is limited by cell barriers even if the immune system is 
relatively suppressed. 
    Vector shedding can be measured by using Q-PCR 
techniques or bioassays, such as the replication or infec-
tivity assay, and although Q-PCR is more sensitive, the 
infectivity assay is more informative about the possible 
implications of viral shedding. The Q-PCR should be 
designed with a set of primers able to distinguish between 
the mutated gene and the transgene as well as differentiate 
the vector from wild type AAV. There are no data avail-
able on secondary or tertiary transmission, but even in 
case of shedding and transmission, the AAV vector does 
not propagate outside of cells and as discussed before, the 
risks for recombination or reassortment of AAV vectors 
are very low and require the presence of a wild-type AAV 
and a helper virus; wild type AAV itself is not known to 
be pathogenic and the transgene is not associated with 
any negative effects in the normal population.
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A possible remark from the governmental institutions ad-
dressing this fictional trial could have been the following:
The immune suppressive effects of CsA in animal models 
to prevent an immune reaction against gene therapy 
vectors is minimal to low, see Table II. Furthermore,
this regimen was chosen based on previous experience 
with the use during clinical kidney transplantation. In a 
review paper on the topic by Yabu and Vicenti in 2009, 
however, it was stated that “compared with cyclosporine, 
tacrolimus has been shown to have a more favorable effect 
on hypertension and lipid profiles and is often preferred 
over cyclosporine in recipients with difficult-to-control hy-
pertension or severe dyslipidemia”. In addition, one of the 
known side effects of CsA is pancreatitis and hyperlipid-
emia and additional use of methylprednisolon is known 
to increase blood levels of CsA (Farmacotherapeutisch 
Kompas 2010, http://www.fk.cvz.nl). In particular in a 
patient population with hyperlipidemia and an increased 
risk of lethal pancreatitis, this choice of immune sup-
pressive regimen may need a better substantiation. For 
example, if other immune suppressive regimens are not 
possible due to other reasons, these should be mentioned 
in the applications. A rational treatment choice could 
havebeenthesubstitutionofCsAforTacrolimusoran
altogether different type of immune suppression, such as 
Cyclophosphamide, which was effective in most animal 
models and has also been tested in preclinical trials of 
AAV-LPL.
3.4  era sample animal study
This section consists of an example of a fictional ERA with 
a replication-deficient adenoviral vector, which is used 
in animal studies using immune suppressed or immune 
deficient animals. Only part C of the ERA, concerning 
immunity-related issues, is discussed here. The example 
is based on the use of an immune competent hemophilia 
B mouse model, using a second generation E1/E2a/E3-
deleted hAd5 vector with a CMV enhancer/promoter and 
a therapeutic transgene (hfIX) and immune modulation 
with cyclophosphamide. The vector is produced in the 
293 helper cell line, which harbors no sequence overlap 
with the vector, preventing homologous recombination 
and formation of replication competent Ad (RCA). 
Although it is possible that a revertant E1 Ad (REA) or 
that helper-dependent E1-positive particles (HDEP) are 
formed, the additional absence of E2a prevents the for-
mation of replication compentent virus. As homologous 
recombination with wild-type Ad could occur after in 
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vivo gene therapy, resulting in replication-competent 
virus, all animals should be free of wild-type Ad.
Adenoviruses are infectious for human beings and 
often cause mild respiratory illness, eye infections or gas-
troenteritis. Although hAd5 only causes mild respiratory 
infections in healthy humans, it may cause fatal kidney or 
lung infections in immune compromised patients. As rare 
cases of severe disease may occur, its use as a genetic vec-
tor requires the use of adequate containment equipment 
and practices. Biosafety containment level 2 for animal 
facilities using micro-organisms (DM-II) is appropriate 
for standard use of many adenoviral constructs in rats or 
mice(CGM/000330-01)andareconsideredsufficientto
prevent transmission of aerosol Ad particles in which case 
some additional measures are taken (i.e. use of filtertop 
cages, wearing gloves during procedures, work in safety 
cabinet class II in case cage is opened with a contami-
nated filtertop).  Particular care should be given to vectors 
containing genes that make products that may be similar 
to products made by the deleted adenovirus genes, even 
though this does not affect the DM-II containment level: 
both replication-deficient and replication-competent 
adenoviral vectors are contained at this level. 
Twoscenariosareenvisagedbywhichimmunemodu-
lation may influence the risk assessment in contained use 
applications: 1) the presence of an immune modulatory 
transgene might change pathogenicity or virulence of the 
vector in comparison to the wild-type virus (may affect 
containment level); 2) the use of a replication-competent 
or deficient virus in an immune suppressed or immune 
compromised animal could prolong the halflife of the 
vector, vector distribution and viral shedding and hence, 
the risk assessment for instance in case experiments need 
to be carried out at lower containment level. The latter is 
discussed in this preclinical ERA example. 
Part C: iMMunity-reLated iSSueS
Step 1: Information about host immunity
1a.  Does the animal model have a functional immune 
system
Yes. The animal model used here is the hemophilia B 
C57Bl6/J/129 mouse, which has a large deletion of fIX 
and is fully immune competent. 
1b.  Does the animal model have a condition affecting 
immunity
No.  
1c.  Does the animal model have pre-existing or cross-
reacting immunity
No.
1d.  Are the animals carriers of a related virus
No. All animals are housed under strict conditions as 
prescribed by the Federation of European Laboratory 
Animal Science Associations (FELASA). This ensures the 
absence of murine adenoviruses in the mice and requires 
regular screening. Even if the animals would be carriers 
of a murine Ad, the risks of recombination between the 
used hAd5-FIX vector and the wt murine Ad would be 
very low, due to the minimal sequence homology between 
murine and human Ad. 
Step 2: Information about immune modulation
2a.  What is the type of immune modulation(s) used
Cyclophosphamide (cytoxan, CY) 
2b.  What is the dose and duration of the treatment(s)
CY is administered in 200 ml saline at doses of 20 or 50 
mg/kg by intraperitoneal (IP) injection at the day of vec-
tor administration (day 0) and biweekly thereafter up to 
week 6.
2c.  What is the level and duration of immune suppres-
sion
See 2b.
2d.  Explain the choice of immune modulation
 CY is a commonly used immune suppressant, known to 
inhibitB-cellsandCD4+andCD8+T-cellsandhasbeen
used for this reason in multiple animal models (Dai et al. 
1995, Jooss et al. 1996, Fields et al. 2001).
Step 3: Effect of immune modulation on the risk of infection
3a.  Increased risk for primary infection
The animals might be more susceptible to primary infec-
tions due to the immune suppressive treatment, but since 
the animals are kept in filtertop cages at DM-II level and 
handled under strictly controlled FELASA conditions, the 
risk for primary infections is considered negligible. These 
conditions have previously been sufficient to sustain
animals receiving lethal doses of radiation and immune 
deficient mice without the complications of infections. If 
the animals require transfer from their cages to a lower 
level of containment (D-I area), for example for imag-
ing procedures, additional precautions need to be taken 
to prevent infection. General precautions are taken to 
prevent transfer of possible infectious viral particles from 
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the animals to the researchers and vice versa, to prevent 
primary infection of mice by laboratory personnel and 
contamination of the laboratory and imaging device. Ad-
ditional measures may include the use of sterile transport 
filtertop cages for the mice, and masks, gloves and labora-
tory glasses for researchers, and sedation of animals. The 
imaging area is cleaned with 1% SDS and 70% ethanol, to 
kill wt virus particles before use and again after animal 
imaging to prevent transfer of possible viable infectious 
vector particles.
3b.  Increased risk for reactivation of latent infection
All animals are specific-pathogen free (SPF) animals and 
are born and kept under controlled conditions (FELASA). 
The risks for reactivation of latent infections is therefore 
considered negligible.
Step 4: Information about other treatments 
4a.  Which other treatments are used, at what dose and 
duration
Mice will receive ciprofloxacin in their drinking water to 
prevent bacterial infections.
4b.  Do these treatments affect the immune modulatory 
agents
Yes. It was shown in rats (Xie et al. 2003) and humans 
(Afsharian et al. 2005) that ciprofloxacin alters the 
pharmacokinetics of CY. CY is a prodrug, which re-
quires hepatic biotransformation and cytochrome P450 
to exert its cytotoxic effect. Ciprofloxacin (Cipro) is a 
fluoroquinolone agent, which has gained widespread use 
in the treatment of a broad range of infections, but has 
been shown to inhibit Cytochrome P450 enzymes. It was 
shown that Cipro affects CY metabolism, when used at 
high doses, but not at lower doses. Therefore, in this study 
two different doses of CY, ie 20 mg/mg and 50 mg/kg will 
be tested.
4c.  Do these treatments affect the animal’s immune 
system
A rare side effect of Cipro is that in some cases Cipro 
may result in pancytopenia and bone marrow depression 
(0.01-0.1%) in human beings. However, in our experi-
ence, Cipro has never been associated with any form of 
cytopenia in mice.
4d.  Do these treatments influence vector kinetics
No. Cipro affects DNA synthesis by inhibition of bacte-
rial DNA-gyrase. This is not expected to influence vector 
kinetics. In addition, drugs affecting the cytochrome 
P450 system are not known to affect vector kinetics. 
However, systemic Ad5 administration has been shown 
in a rat model to negatively affect at least two cytochrome 
P450 enzymes (Callahan et al. 2005) and therefore may 
affect CY levels. 
 
Step 5: Effect immune modulation on vector distribution 
and persistence
5a.  What are the relevant animal/clinical studies
Comparable animal studies were done in normal mice 
treated with different types of immune suppressive drugs, 
including a study using CY and Cyclosporin A (CsA) with 
an 1x109 pfu Ad5-CMV-hfIX vector im (Dai et al. 1995). 
They showed that CsA alone had no effect while CY with 
or without CsA allowed prolonged transgene expres-
sion. A second study was done in normal mice injected 
with 5x108 pfu Ad5-CMV-lacZ iv. Here CY prolonged 
transgene expression (Jooss et al. 1996). A third study 
was done in hemophilia B mice. Here 1x1011 vg of AAV-
CMV-mfIX were injected iv. Different immune sup-
pressive drugs, including CY, FK506, CsA, anti-CD40L 
and CTLA4-Ig were used (Fields et al. 2001). Here, it 
was shown that anti-CD40L has no effect on transgene 
expression, FK506 resulted in short-term partial correc-
tion of the phenotype, FK506 was affective as long as the 
drug was administered, CsA resulted in renal toxicity and 
death of animals and CY resulted in long-term systemic 
expression of fIX (Fields et al. 2001).  
5b.  Does immune modulation after vector biodistribu-
tion
There are no data available yet, but the purpose of this 
study is to see if immune modulation with CY will affect 
vector biodistribution and vector persistence, as well as 
prolonged systemic transgene expression.
5c.  How are biodistribution and persistence measured
 By using real-time quantitative PCR to determine vector 
copy number in liver tissue at 8 weeks and of various 
other tissues (spleen, testis, kidney, thymus, heart, skel-
etal muscle, diaphragm, lung, inguinal lymphnodes and 
different liver lobes) at 6 months and 12 months.
5d.  How long is biodistribution/persistence measured
See 5c.
Step 6: Effect of immune modulation on recombination
6a.  What are the relevant studies
 There is no relevant study and the effect of immune 
modulation on recombination is currently unknown, but
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 will be a secondary readout in this study. 
6b.  How are recombination or reassortment affected
 There are no available data. Recombination and forma-
tion of replication competent Ad (RCA) in this system 
can occur during the production process by homologous 
recombination and complementation of missing func-
tions (E1) or after in vivo administration after recombi-
nation with wt Ad. The use of a second generation hAd5 
with multiple deletions makes recombination during 
production highly unlikely, and the presence of RCA in 
the virus batches is an exclusion factor for the use of that 
virus batch. In vivo immune modulation however, does 
not affect vector production. Prolonged presence of hAd5 
infectious virus particles due to the use of CY may increase 
the risk for recombination. However, animals used in this 
study are free of murine Ad and even in case of infection 
with murine Ad, the risk of recombination between a wt 
murine Ad and hAd5 is low due to minimal sequence 
homology. Thus, a recombination event resulting in the 
formation of RCA appears highly unlikely, even in case of 
prolonged immune suppression. The most likely scenario 
resulting in RCA would be co-infection of the mice by a 
wt human Ad derived from research or laboratory per-
sonnel. The proposed housing and working conditions 
(DM-II) and barrier safety measures, however, should 
minimize, if not completely prevent, these risks.     
Step 7: Effect of immune modulation on risk for shedding 
and transmission
7a.  What are the relevant pre(clinical) studies
One of the endpoints in this study will be whether iv 
administration of hAd5-hFIX and treatment with CY will 
result in (increased) shedding and possible transmission. 
For this reason, plasma, anal swaps, and mouse droppings 
will be tested for shedding of the viral vector.  
Conclusions
Little is known about biodistribution, recombination and 
shedding of viral vectors in immune compromised or im-
mune suppressed animals. It is anticipated that immune 
modulation or lack of an optimal immune system will 
allow for longer persistence of infectious viral particles in 
the animals. Studies as the one proposed above should be 
able to help answering these gaps in current knowledge. 
In this fictional preclinical ERA, we propose the use of a 
second generation E1/E2a/E3 deleted adenoviral vector 
based on human serotype 5 in a murine immune com-
petent animal model of hemophilia using short term Cy-
clophosphamide to prevent an immune response against 
the viral vector and/or transgene. Although in this model 
prolonged presence of the vector is anticipated, possibly 
affecting biodistribution and shedding, it seems highly 
unlikely that with the currently required DM-II housing 
and safety procedures, infective RCA will occur due to 
sequence differences between murine and human Ad. 
Transferoftheanimalsafterin vivo gene therapy with a 
replication-deficient hAd5 to D-I areas, for example for 
imaging purposes (eg MRI or bioluminescence) may be 
possible under certain restricted conditions (e.g. as de-
scribed under step 3a). Other studies using hAd5 in in vivo 
models as described in COGEM advices CGM/031031-06 
(hAd5 in pigs) and CGM/021216-03 (Ad in apes), but 
without the use of immune modulation, require the use 
of a specific test to demonstrate absence of shedding of 
infectious viral particles in serum, urine and faeces and/
or RCA for at least 24 hours (pigs) and 7 days after gene 
therapy (apes). Pigs can be further housed under D-I con-
ditions 3 days after in vivo gene therapy (CGM/031031-
06), whereas apes can be housed under D-1 conditions 7 
days after in vivo gene therapy when absence of shedding 
in feces has been confirmed with a validated PCR test 
for 7 consecutive days (CGM020513-03, CGM/021216-
03). These requests are based on the relatively low level 
of sequence homology between porcine and human Ad 
(5-20%) and the high level of homology between simian 
and human Ad, as well as the fact that apes are possible 
carriers of wt human Ad and susceptible to primary hAd 
infections. In the case of immune modulation in the mu-
rine model, absence of shedding for 3 consecutive days 
with specific tests (eg validated PCR) in addition to the 
use of personal barrier restrictions (mouth masks, gloves, 
laboratory glasses) and cleaning measures (1% SDS and 
70% ethanol) of used surface areas outside of the DM-II 
containment areas would result in a negligible increase in 
environmental risk. 
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4 ConCLuSionS and reCoMMendationS
4.1 introduction
Host immune responses play a major role in the clear-
ance from viral infections from the body.  The induction 
of these immune responses are now being used to our 
advantage in the treatment and specific recognition of 
certain cancers, whereas for the treatment of monogenet-
ic diseases, the same (acquired) host immune responses 
play a crucial role as a determinant of long-term expres-
sion and couldhamper clinical efficacy.This studywas
initiated by the Netherlands National Institute for Public 
Health and the Environment (RIVM) to assess the pos-
sible environmental risks associated with the use of im-
mune modulation in combination with gene therapy and 
the resulting report contains an overview of existing data. 
This chapter will give general conclusions and recom-
mendations for the current policies in The Netherlands. 
4.2 general conclusions
This project has been very timely: Just recently the first 
and very relevant review papers and a book on this topic 
of have been published (Arruda, Favaro and Finn – Strat-
egies to modulate immune response: a new frontier for 
gene therapy, Mol Ther 2009; Nayak and Herzog – Im-
mune responses to viral vectors, Gene Ther 2010 and 
Gene Therapy Immunology, Wiley-Blackwell 2009, 
edited by R. Herzog). From these publications as well as 
this report, it becomes clear that similar as in the trans-
plantion field, the gene therapy field is learning how to 
circumvent, manipulate or suppress unwanted immune 
responses. New developments include vector engineering 
such as capsid engineering, miRNA-regulated expression 
cassettes; optimization of delivery techniques, adminis-
tration to immune-privileged sites, taking advantage of 
organ-specific immune responses171. In addition, experi-
ence from the organ transplant field can be used as a first 
reference to use immune suppression in gene transfer 
protocols (reviewed in Appendix B). Still, the specific 
immune suppressive treatment (combination of drugs, 
period of time) needed for gene therapy purposes will 
be depending on the vector, disease, target tissue and the 
therapeutic outcome.
Please note that more extensive and in depth infor-
mation, including separate conclusions on the different 
subtopics can be found in appendices below: immuno-
genicity of currently used viral vectors (Appendix A); all 
relevant non-gene therapy, clinical studies from related 
fields, including (stem cell) transplantation to assess the 
risk of co-infections with wild type viruses (Appendix B); 
vaccination studies with live attenuated viruses to assess 
the risks for shedding and transmission (Appendix C); 
and all preclinical gene therapy studies using any type of 
immunemodulation (Table II). Furthermore, practical
suggestions on extension of current ERA forms have been 
provided in chapter 3, as well as samples for a clinical and 
animal study. Performing this exercise makes one realise 
once again the emerging importance of documentation 
and accessibility of clinical data to other/relevant parties, 
not only for the ERA but also for the benefit of individual 
patients.
4.2.1 indications for immune modulation
Immune modulation in a clinical gene therapy setting 
may occur for multiple reasons:
I To balance the immune response against the vec-
tor, transgene and transgenic protein to achieve a 
maximal therapeutic effect and tolerance against the 
exogenous antigen. This requires a relative modest, 
short-term immune modulation, which changes 
thebalancebetweeneffectorT-cellsandregulatory
T-cells in favor of the latter.Viral vectorsmay be
replication deficient or and replication competent 
and carry a therapeutic transgene.
II Totreatamalignancy.Thisrequirestheuseofcom-
binations of cytotoxic agents, which may directly 
affect innate and adaptive immunity, but usually 
maintains some level of pre-existing immunity. On-
colytic viral vectors specifically target and replicate 
in malignant cells and are used with or without a 
transgene, which may require local activation.
III Tocreatespaceinthebonemarrowforengraftment
of gene-corrected hematopoietic cells. Myeloabla-
tive treatment is used, resulting in the long-term 
absence of a functional adaptive immune system 
and possible loss of pre-existing immunity to com-
monviruses.Transductionsofcellsaredonein vitro 
rather than in vivo.
4.2.2 risks of immune modulation
The most common risk of immune suppression is the 
increased susceptibility to opportunistic infections or 
reactivation of latent infections. The type of viral infec-
tion that occurs, depends on the specific combinations 
of immune suppression applied (seeTable III) and the
duration (and depth) of the treatment. In general, it is 
expected that this will render no difficulties in view of
the risk assessment related to viral recombination events, 
since these will not occur between the virus species ob-
served and viral vector applied. 
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Conclusions and recommendations 
Conclusions in general relating to risk assessment of 
immune modulation in clinical gene therapy studies: (1) 
choice of immune modulation during (pre)treatment is 
most relevant for the risk assessment relating to the indi-
vidual patient; (2) modification of the viral vector system 
resulting in immune escape could be most relevant for 
risk assessment of the environment. 
4.2.3 relevance regulatory affairs
Finally, this project is also very timely since the first 
clinical trial has now been started (in Canada for LPL) 
andthesecondisabouttostart(inUSAforHemophilia).
The first clinical gene therapy study including immune 
modulation in The Netherlands can be expected in the 
upcoming year(s). Adaptation and further implementa-
tion of findings obtained in this study in regulatory 
processing will therefore be availabe in time and delays 
can be prevented.
4.3 recommendations
Preclinical animal studies and readout systems
•Applicationformsanimalexperimentsextensionwith
explicit questions on anticipating (environmental) 
risk assesment and obtaining relevant data
Clinical studies & Immune modulation
•Newareaofexpertisewithfurthereveremergingneed
of documentation and accessibility of data available 
to other parties
 Precautionary measures 
•Overviewofeducationandtrainingofhospitalper-
sonnel involved during application of gene therapy 
and effects of precautionary measures used to prevent 
shedding and transmission
Regulatory aspects and risk assessment
•Proposal of extended version of current ERA for
preclinical studies
•ProposalofextendedversioncurrentERAforclinical
studies
•Proposalfutureproject
4.3.1 Preclinical animal studies and readout systems
Application forms animal experiments extension with 
explicit questions on anticipating (environmental) risk 
assesment and obtaining relevant data. 
As emphasized in the summary above and throughout 
the report, the effects of or the risks associated with im-
mune modulation during gene therapy cannot be easily 
translated from the current animal studies to the clinic. 
The immune functions of the animal models used and 
their responses to viral vectors and immune modulation 
do not per se reflect the situation in patients. It is recom-
mended that gene therapy animal models using immune 
modulation,inadditiontotransductionefficiencyofthe
target tissue, transgene expression or anti-tumor effect 
also measure secondary outcomes such as changes in bio-
distribution and persistence, which are more relevant for 
prediction of clinical and environmental risks. Awareness 
of the researchers to include these kind of more clinically 
relevant readouts in addition to their primary readouts 
could be increased by additional questions in the applica-
tion forms for animal experimental studies, addressed by 
the animal experimental committee (DEC). This could 
result in a better implementation of the principles of 
the three R’s, ie replacement, reduction and refinement, 
as introduced by Russell and Burch in the nineteen fif-
ties172. By making a small adjustment/addition to ongoing 
animal studies, the distribution and presence of viral 
vectors and genomes in different organs could be easily 
fully documented after necropsy, without increasing the 
number of animals needed and without increasing the 
discomfort of the animals themselves, but with an enor-
mous gain of knowledge about vector persistence and 
distribution and a more clear picture of possible clinically 
relevant risks. In addition, preclinical studies in animal 
models measuring transfer of vector strain virus might 
be of additional value here and an animal study, which 
would include the highest possible immune suppres-
sion in combination with a replication competent viral 
vector would be a reflection of the ultimate “worst case 
scenario” and could probably best predict the possible 
risks, including recombination, shedding and transmis-
sion. However, these types of studies are unlikely to be 
initiated by separate research groups and might require 
the specific request from governemental policy institutes. 
Nevertheless, the importance of these studies is clear and 
may result in a much better understanding of how to 
translate shedding and transmission data from preclini-
cal gene therapy and vaccination studies in animals to the 
human situation. 
4.3.2 Clinical studies & immune modulation
New area of expertise with further ever emerging need of 
documentation and accessibility of data available to other 
parties.
Importantly, the choice of a particular immune suppres-
sive regimen in the clinic is currently based on clinical 
experience available from organ transplantation proto-
cols, rather than whether this protocol would be truly 
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advantageous for this particular patient population and 
this specific viral vector system. The considerations which 
may play a role in the choice of immune modulation for 
long-term immune suppressive treatment to prevent 
organ rejection may be quite different from the ones in 
gene therapy, where short-term, low dose immune sup-
pressionmaysuffice.Thechoiceofimmunemodulation
therefore, should be strongly substantiated by either data 
from animal studies, other clinical studies, if available. 
In fact the use of immune modulation in patient popula-
tions, in which immune modulation has not been used 
or indicated before, should be a new area of expertise. As 
the immune suppression is relatively mild and intended 
for short-term use, patient responses, the risk of infec-
tious complications and side-effects may be different. 
Unintendedorinsufficientresponsescouldbemonitored
and a transparent, accessible databank for other re-
searchers with patient results, eg shedding, transmission, 
education, etc after treatment with gene therapy with or 
without immune modulation could be maintained. 
4.3.3 Precautionary measures 
Overview of education and training of hospital personnel 
involved during application of gene therapy and effects 
of precautionary measures used to prevent shedding and 
transmission.  
From a safety point of view, the most important issue is 
which precautionary measures are taken by the personnel 
and bystanders, during the processing of the vectors, the 
transduction and handling procedures, the transport to 
the patient and during final administration. The risks 
of shedding and transmission are not negligible during 
these procedures and more likely higher than after bio-
distribution and persistence in a patient, even when this 
patient is treated with immune modulation. Independent 
of whether shedding may occur during administration or 
later after persistence in the patient, prevention of trans-
mission should be an important focus. In the vaccination 
studies is was shown that despite education of bystanders 
a certain level of vaccine strain transmission was not un-
common (Appendix C). In addition, not only shedding 
and transmission was measured but also survival of the 
vaccine strains outside the vaccinee and in the surround-
ings of the vaccinee were measured. Although there 
are general recommendations on how to act in case of 
spilling or during administration of various viral vectors, 
there is no literature available, which describes whether 
these recommendations are followed and whether or 
not they are effectively used. A database of clinical gene 
therapy protocols and shedding/transmission data is 
warranted. In addition, training and education programs 
for laboratory and hospital personnel, as well as for house 
hold members and other care takers may result in an 
increased awareness and a decreased risk of inadvertent 
transmission. 
4.3.4 regulatory aspects and risk assessment
• Proposal of extended version current ERA for clinical 
studies
We propose an extended version of a previously pro-
posed ERA for clinical studies75, which can be used 
when starting a clinical gene therapy trial with immune 
modulation and can also be relevant in making decisions 
for screening and monitoring patients and their environ-
ment, including health-care personnel and house hold 
members, during the trial. The (extension of the) ERA 
consists of three parts, focusing on the patients involved, 
vector characteristics and effects of immune modulation 
(chapter 3.3 ERA sample clinical trial). 
• Proposal of extended version of current ERA for precli-
nical studies
We propose an extention of the current ERA for pre-
clinical studies. This can be helpful when assessing risks 
in contained use applications (chapter 3.4 ERA sample 
animal study). 
• Proposal future project 
Highest risks remain during preparation and moment of 
administration of vector underlining the importance of 
knowledge, training and education. We propose a special 
project to assess the risks of vector shedding and trans-
mission before, during and shortly after administration. 
This project should include data on which precautionary 
measures are used in clininal gene therapy trials with 
different viral vectors; should assess actual compliance 
with these measures; should contain information on how 
education of hospital personnel and family members 
are instructed to prevent transmission, and should if 
possible contain recommendations to improve all of the 
above. We also propose the establishment of an open and 
interactive database for monitoring the clinical aspects of 
gene therapy trials with or without immune modulation 
and access to standardized protocols on how to prepare 
patients for gene therapy trials to increase safety and al-
low more rapid adaptation of these protocols in response 
to new clinical findings. New or unexpected findings are 
now often only presented in medical literature and the 
time between important observations and publication is 
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protracted. Also negative findings, difficult to publish, 
could be discussed here.
4.4 future expectations and developments
Further developments in the field of immune modulation 
in gene therapy will be in the area of vector modifications 
and should be closely monitored. From first generation to 
second generation and last generation vectors, a decrease 
in immunogenicity has been pursued and often achieved 
through relatively easy modifications, such as the use of 
different serotypes and a decrease in expression of viral 
genes. Futher reduction of immunogenicity is expected 
for the newest generations of vectors, which make use of 
stealth technology, restricted/regulated expression (mic-
roRNAandTet-Ontetracyclineregulatablesystems)and
induction of tolerance. These and other new strategies to 
prevent immune responses for long-term gene therapy 
will eventually make the concomitant use of immune 
modulation less essential. Nevertheless, the use of immu-
ne modulation is likely to remain an important treatment 
strategy for diseases that require multiple gene therapy 
procedures. However, despite these exiting new deve-
lopments todays gene therapy regimens still require the 
use of short-term, low-level immune modulation. Some 
decades of experience with immune suppressive agents in 
transplantation medicine has lead to the development of 
specific treatment regimens using different combinations 
of drugs. These have been shown to decrease dose-related 
side effects, while maximizing immune suppressive 
effects. Preclinical animal models using these types of 
regimens have been used with variable degrees of success 
and new clinical studies in gene therapy trials will have to 
show, which regimens should be preferred. The relative 
low frequency of these types of trials require open access 
to clinical data and an extensive sharing and exchanging 
of information for the benefit of the patients and for an 
optimal assessment of potential environmental risks. 
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aPPendiX a iMMune reSPonSe againSt 
veCtorS
Antigen presenting cells (APCs), such as macrophages 
(MF) and dendritic cells (DC), recognize pathogen-
associated molecular patterns (PAMPs) with pattern 
recognition receptors (PRR), such as membrane-
boundToll-likereceptors(TLRs)andintracytoplasmic
RNA helicases (RIG-1, Mda-5). Recognition of viral 
RNA or DNA sequences triggers downstream signal-
ing pathways, leading to induction of type I interferons 
(IFNa and b).
PPr localization  pattern     
                                                   
TLR3 endosomal, dsRNA,polyI:C
 cell surface 
TLR7/8 endosomal ssRNA,RNAhomologs
TLR9 endosomal CpG-DNA,CpG-ODN
RIG-1/Mda-5 intracyto- viral RNA
 plasmic
The innate immunesystem is phylogenetically conserved 
and present in almost all multicellular organisms173. The 
functional components of the innate system are com-
prised of neutrophils, the mononuclear phagocytic cells 
such as blood monocytes and tissue macrophages, and 
natural killer cells as the main source of soluble factors, 
including complement, antimicrobial agents and inflam-
matory cytokines. Professional antigen-presenting cells, 
such as macrophages (MΦ) and dendritic cells (DCs) 
are present in various tissues throughout the body in 
an immature state174. Immature DCs patrol the tissues 
and sample their environment by pinocytosis of soluble 
material or phagocytosis of particles. It is the first line 
of defense upon entry of pathogens into the body and 
it recognizes conserved microbial structures, known as 
pathogen-associated molecular patterns (PAMPs) with 
germline coded pattern recognition receptors (PRR)175. 
The Toll-like receptors (TLRs) are membrane-bound
PRRs and recognize a broad spectrum of microbial 
components, including viral vectors. RNA helicases are 
cytoplasmic sensors of viral infections and detect RNA. 
RecognitionofviralRNAorDNAsequencesbyTLRsand
RNA helicases triggers the activation of signaling path-
ways and induction of transcription of type I interferons 
(IFN-a and IFN-b), which are the principal mediators of 
the innate immune response to viruses, as well as other 
pro-inflammatory chemokines and cytokines which 
activate the adaptive immune response. TLR7/8 (pres-
ent inmouse/man, respectively) and TLR9 are present
inendosomesandrecognizeviralnucleicacids.TRL7/8
recognize ssRNA and ribonucleic acid homologs, such as 
R-848(resquimod),gardiquimodandimiquimod;TLR9
is present in endosomes and activated by CpG DNA 
motifs and CpG-oligodeoxynucleotides (ODNs); TLR3
can be expressed at the cell surface or within endosomes, 
depending on the cell type, and is activated by dsRNA, 
which is formed during viral replication in host cells, and 
dsRNA analogs, such as polyI:C.   
UponendocytosisofaproteinbyAPCs,thepeptid-
antigens are presented by MHC class II molecules to anti-
gen-specificCD4+Tcells.Whenforeign(viral)proteins
are present in the cytoplasm of a cell after transduction, 
the protein is digested into smaller antigenic peptides. 
The proteasome has a maintenance function here and 
controls degradation of different proteins present in the 
cytoplasm. Viral proteins are marked for degradation by 
covalent linking to multiple small polypeptides, named 
ubiquitins. After ubiquitination, the proteins unfold, the 
ubiquitin molecules are removed and the proteins are 
degraded by the proteasome. The peptides are then trans-
ported to the ER via transporter associated with antigen 
processing(TAP1and2)proteins,wheretheyassociate
withtheMHCclassImolecules.TheTAPproteinspres-
ent in theER regulate theATP-dependent transportof
the peptides from the cytosol to the lumen of the ER and 
are covalently linked to newly synthesized MHC class I 
moleculesviathelinkerproteintapasin.Uponentryofa
peptideintotheERbyTAP,itbindstoaspecificgroove
in the class I molecules. This complex is then released 
from tapasin and free to leave the ER to be transported 
via the Golgi system to the cell surface. The a-chain/
b2-microglobulin dimers, not linked to peptides, are very 
unstableandcannotbeefficiently transported fromthe
ER. In contrast, the peptid-bound MHC class I complex 
is structurally stable and will be transported to the cell 
membrane, where the peptides are presented and recog-
nizedbypeptide-specificCD8+CTLs.Thiscell-mediated
immune response plays an important role in the elimina-
tion of viruses from the body. 
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iMMune reSPonSe againSt viruSeS, viraL 
veCtorS and tranSgeneS
The intensity and type of host immune response 
depends on the viral vector, the transduced cell or 
tissue type, the level of transgene expression, the im-
munogenicity and localization of the transgene and the 
immunologic competence of the host.
Viruses use host mechanisms to multiply. Cytopathic vi-
ruses multiply quickly and have to rapidly spread to other 
organisms before they cause cell death of the infected cell 
or before they are cleared by the immune system. Per-
sistent viruses, such as herpes viruses, can exist latently 
for longer periods of time in infected cells and display 
minimal expression of viral genes, with the exception of 
genes absolutely indispensible for virus survival. These 
viruses can reactivate at any given moment and reinitiate 
production of virus particles176,177. However, as a general 
rule, the defense mechanisms of the host determine for 
both types of viruses the time period during which the 
virus can actively reproduce. Viruses with the ability to 
either prolong this period or evade immune recognition 
have increased probabilities of transmission and survival. 
Dealing with the anti-vector innate immune responses 
remains one of the major bottlenecks of gene therapy. 
Prudent strategies to limit the innate immune response 
include ex vivo gene transfer or in vivo delivery of a 
minimal number of viral particles. Strategies to limit the 
adaptive immune response against the vector and the 
transgene product use a two sided approach, in which 
simultaneously the immunogenicity of the vector cq 
transgene product is minimized by vector modifications 
(targeting and shielding) and/or restricted expression 
and the host immune system is suppressed with immune 
modulatory agents. 
adenoviruses
Adenoviruses (Ad) are icosahedral, non-enveloped dou-
ble-stranded DNA viruses with 35-40 kb genomes114,174. 
There are currently 54 serotypes classified into seven 
groups (A-G) based on sequence homology and their 
ability to agglutinate red blood cells178-180. Adenoviruses 
can infect a wide variety of both dividing and quiescent 
cells, but only rarely integrate in the host genome114; they 
are easily purified to high titers of up to 1012 to 1013 vec-
tor particles per mL; they can accommodate 5-8 kb (first 
generation Ad vectors), 10-13 kb (second generation Ad 
vectors) to 36-37 kb (gutted vectors) non-viral transgenic 
material178; and the serotypes most commonly used for 
therapeutic purposes, i.e. species C Ad2 and Ad5 are 
well characterized. Most Ad virusus, species B excluded, 
make use of CAR as their primary docking receptor to 
infect cells177. Disadvantages of Ad include the presence 
of preexisting immunity in the majority of humans, low 
transduction of important gene therapy target cells due 
to low expression of CAR and innate toxicity upon in-
travascular administration as a result of complement ac-
tivation, cytokine release and vascular damage, resulting 
in a systemic, possibly lethal, inflammatory response179. 
Cross-reacting antibodies against Ad are directed against 
the hexons present in the protein capsid and contain the 
generic antigenic component common to all mammalian 
Ad176. Serotype-specific sites on the hexons are respon-
sible for induction of neutralizing antibodies. Adenoviral 
vectors based on different serotypes make use of their 
specific virus attachment receptors, which affects both 
vector tropism, and downstream signaling pathways, 
resultingindistincthostimmuneresponses(TableIX).
Modification of the virus has resulted in different types 
of adenoviral-based vectors developed in recent years, 
resulting in the development of first generation (E1A and 
E1B deleted with or without partial deletions of the E3 
genes), second generation with additional modifications 
in E2A, E2B, E3 and/or E4 regions, and helper-dependent 
(HD), high-capacity (HC) “gutted” or “gutless” vectors, 
stripped of all viral gene products181,182.Toallowefficient
packaging of the latter into the Ad capsid, a genome size 
between 27.7kb and 38 kb is required and can be obtained 
by including “stuffer” DNA sequences in the E3 region of 
the helper virus183,184. Another advantage of the “stuffer” 
DNA is that although it does not prevent homologous 
recombination, it does result in recombinant genomes 
unpackageable because of their large size, exceeding 
the packaging capacity of the Ad virion32. The oncolytic 
conditionally replicating adenoviral vectors (CRAd) were 
developed to target tumor cells, however, without target-
ing, oncolytic CRAd can only infect CAR-expressing 
tumorsandefficacyoftransducingothercancersislow185. 
A variety of molecular targeting and shielding strategies 
(see appendix B) have therefore been applied to develop 
CAR-independent oncolytic Ads, such as tumor-specific 
promoters (TSP)upstreamof theE1Agene for specific
expression in target cells or deletion of viral functions, 
dispensible in neoplastic cells, eg oncolytic Ad5-based 
vector ONYX-015 (dl1520) was created by the deletion 
of E1B-55K186 and results in a vector that can replicate 
in p53-defective cells, but a 100-fold less in normal cells 
expressing functional p53186. Similarly, Oncorine H101 
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contains a deletion of E1B-55K and has been used as an 
oncolytic vector to treat nasopharyngeal cancers, glioma, 
pancreatic and ovarian cancers4,187. Gendicine, or Ad-p53, 
contains the p53 transgene in place of the viral E1 region 
under a Rous sarcoma virus promoter and has recently 
been approved for clinical use in China for the treatment 
of head- and neck squamous cell cancer in combination 
with radiotherapy187,188, but has also been tested in a wide 
range of other solid tumors, such as lung cancer, liver 
cancer and cancerous ascites188. 
Immune response against adenovirus and adenoviral 
vectors
Adenoviruses have been shown to precipitate immune 
responses throughTLR-dependent (pDC) andTLR-in-
dependent mechanisms (Kuppfer cells)189. These immune 
responsesagainstAdarerapidandpreventefficientre-
administration of the vector. Induction of cytokines, such 
asIL-6andTNF-a, appearing in response to Ad infection, 
ismediatedthroughTLR9,anendosomallylocatedTLR
shown to recognize CpG DNA. Human cell lines express-
ingTLR9,althoughpermissivetobothCAR-andCD46-
interacting Ad serotypes, display preferential activation 
of TLR9 by CD46-interacting serotypes190, presumably 
due to their tendency to reside longer in the late endo-
somal compartments than CAR-interacting serotypes191. 
The route of Ad entry may substantially contribute to 
thetypeofinnateimmuneresponseinitiatedbytheTLR
pathways. In addition, genomic Ad DNA was shown to 
be able to induce of IL-6 and TNF-a181. The cytokines 
and chemokines most important for the anti-adenoviral 
immune response are IFNa and b, IL-1, IL-6, IL-8, IL-
12 and TNFa in humans and KC and MIP-2 in mice. 
Ad virions initiate rapid host transcriptome responses 
independent of Ad transcription, DNA replication and/
or protein expression. Although empty capsids appear 
capable of inducing immune responses, this may not be 
thecaseforallcelltypes.InductionofTypeIIFNsbythe
Chimpanzee AdC68 is independent of viral transcription 
and replication and substantially inhibits vector-derived 
transgene expression97. Innate immune signaling against 
Adsisdependentonendosomaltraffickingand/orrup-
ture184,185. 
In spite of the E1 deletion, the first generation vec-
tors are “leaky” and viral genes are expressed at a low 
level in transduced cells, resulting in direct toxicity and 
immunogenicity of the viral gene products192. Deletion 
of E3 is not always advantageous, as expression of E3 
genes can diminish anti-vector immune responses and 
increase persistence of transgene expression191. In situa-
tions,where short-termgene expression is sufficient to
achieve a therapeutic effect, first generation vectors are 
attractivechoices.ActivationofcytotoxicTcells(CTLs)
in response to newly synthesized viral antigens and trans-
gene product leads to destruction of vector-transduced 
cells and loss of transgene expression182. The major ef-
fectors in elimination of transduced cells are the MHC 
classIrestrictedCD8+CTLs,whereastheCD4+Tcells
by secretion of IFN-γ sensitizes virus-infected cells to 
CTLs through upregulation ofMHC class I expression
and allow the development of a fully competent CTL
response and contribute to the formation of neutral-
izing antibodies193,194. Second generation Ad vectors were 
developed to decrease activation of cellular and humoral 
immune responses192. The fact that high-capacity helper-
dependent Ad vectors, devoid of any viral genes, induce 
remarkably similar immune responses as conventional 
Ad, including a prominent IFN type I response within 
6 hours after administration and upregulation of IFN-
responsive genes, suggests that capsid structures, rather 
thanleakyviralgeneexpression,aresufficienttoinduce
an innate immune response195. However, the period of 
time during which the immune system can recognize 
cells infected with the HDAd vector is very limited and 
only takes place when antigens derived from HDAd 
capsid proteins are transiently presented on MHC class I 
molecules during the disassembly of the injected vector. 
Once the input virion proteins have been metabolized, 
the HDAd transduced cells become invisible to anti-Ad 
specificT-cells196. 
Human adenoviral viral vector serotype 5 (Ad5) is 
presently the primary viral vector used in gene therapy 
trials. However, binding of the Ad5 fiber to CAR results 
in the activation of ERK1/2 and JNK MAPK kinases 
and subsequent upregulation of transcription of pro-
inflammatory genes, such as IL-8, GRO-a, GRO-g, 
RANTESandIFNg-inducible protein (IP-10). Activation 
of complement by Ad5 results in opsonization by macro-
phages and Kuppfer cells and in the release of inflamma-
tory cytokine and chemokine production and is required 
for the induction of neutralizing antibodies197,198. Neu-
tralizing antibodes against anti-Ad reaches its peak 7-14 
days post-virus treatment, whereas the anti-transgene 
responses peaks somewhat later around days 23-28197.
Many pathways work together during the inititia-
tion of the acute anti-Ad immune response and require 
attentiona: inhibiting one of these, will diminish the im-
muneresponse,butisnotlikelytobesufficienttoprovide
complete protection against Ad-immunity. Binding of 
the Ad-vectors to complement, PRRs, erythrocytes199, 
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platelets200 and blood clotting factors, eg factor X201 and 
scavenging of Ad by macrophages and Kuppfer cells202, 
have been implicated in facilitation of the innate immune 
response. 
adeno-associated virus
The adeno-associated viruses (AAV) are non-pathogenic, 
single-stranded DNA viruses and naturally replication-
defective, ie they depend on co-infection of an unrelated 
helper virus for productive infection. Several viruses such 
as adenovirus, herpes virus, but also vaccinia and hu-
man papilloma viruses can provide the helper activities 
required for AAV growth203. Currently, twelve human 
AAV serotypes are known and more than a hundred 
have been isolated from non-human primates. AAV-
based vectors are becoming increasingly popular due to 
its non-pathogenicity and relative low immunogenicity, 
as well as its heat stability and resistance to solvents and 
to changes in pH and temperature204. Recombinant 
AAV vectors consist of merely 300 nucleotides from the 
original viral sequence in the form of non-transcribed 
ITRs,whichisamajorstepforwardinensuringitssafety
for human clinical applications by reducing the risk of 
recombination with wild-type virus. The rAAV vectors 
can be used to target a wide range of different host and 
cell types due to their broad tropism and their capacity 
to transduce both dividing and non-dividing cells, while 
their lack of viral coding sequences reduces the risks of 
eliciting an important cellular immune response and thus 
prolongs expression of transgenes in vivo. The latter is a 
major requirement for gene therapy of some inherited 
genetic diseases. 
The most commonly used rAAV vector for gene 
therapy is based on AAV-2. In the absence of helper vi-
rus, AAV serotype 2 can become latent and integrate site-
specifically into chromosome 19q13.4205. This specificity 
ofintegrationisdeterminedbythepresenceoftheITRs
and the rep gene. However, recombinant vectors lose this 
specificity due to deletion of the rep gene and integrate 
randomly116. AAV-2 gains entry into target cells through 
binding to heparan sulfate proteoglycan (HSPG)193 and 
one or more co-receptors including anb1 and anb5 in-
tegrins, FGF-R1, HGF-R and the laminin receptor (see 
TableX).
AAV-based vectors
In rAAVs used for gene therapy, the ORFs are removed 
and replaced by the transgene and regulatory elements 
flankedby the ITRs.Thevectors arepropagated in cell
lines that provide the AAV genes in trans and provide 
helper virus functions through the E1, E2, E4 and virus-
associated RNA of adenovirus203. Drawbacks of  the single 
stranded (ss) AAV vectors include a restricted packaging 
size (4.7 kb)194, limiting the applications of rAAV to 
relatively small gene diseases, and in case of rAAV-2 
based vectors, inefficient transduction of certain clini-
cally important tissues, such as liver and muscle, and the 
existence of anti-AAV-2 neutralizing antibodies206. In 
addition, inefficient intracellular viral processing207 and 
second-strand synthesis208, which have been identified 
as rate-limiting factors in AAV gene expression, could 
be optimized. Several novel techniques, such as trans-
splicing AAV vectors, are being developed to increase 
the genome capacity for AAV and enhance gene expres-
sion209. This approach entails the co-administration of 
two independent trans-splicing rAAV vectors encoding 
complementary segments of a large therapeutic transgene 
cassette and intron donor and acceptor signals and allows 
delivery of therapeutic genes up to 9 kb in size. However, 
the trans-splicingvectorsarelessefficientthantherAAV
vectors. An alternative approach is the development of 
self-complimentary AAV vectors, which circumvent the 
delay in transgene production expression associated with 
the conversion from ss to ds DNA, and shows superior 
transduction of certain cell types, but have a packaging 
capacity limited to half of that of the traditional ss AAV 
vectors.
Immune responses against AAV and AAV-vectors
The host response against wild-type AAVs is likely 
partially determined by the helper virus, which induces 
the innate immune response and facilitates the immune 
response against AAV, but is also strongly dependend 
on the level activation of the immune system. Other 
parameters include pre-existing immunity, the route of 
administration, the kinetics of expression, the dose, the 
serotype, the host species, in case of vectors the immuno-
genicity of the transgene and importantly, the ability to 
transduce or infect antigen-presenting cells210. Since AAV 
vectors themselves appear to lack PAMPs, they cannot 
activateTLRs211. Although AAV2, in contrast to AAVs 
from other clades, can infect DCs directly through bind-
ing of HSPG212, an unidentified post-entry block inhibits 
successful transgene product expression and upregula-
tion of co-stimulatory molecules and MHC classes I and 
II213,214. As a result, AAVs are not able to induce matura-
tion of human DCs and production of type I IFNs215. In 
contrast, in mice, type I IFN responses can be induced 
by AAV through activation of mouse plasmacytoid DCs 
(pDCs)viaTLR9-MyD88andarecrucialfortheactiva-
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tionoftheCD8+T-cellresponse216. However, AAVs can 
induce capsid and transgene product-specific immune 
responses, including neutralizing antibodies217,218. One 
reason that AAV2 vectors induce an immune responses 
is that they uncoat relatively slowly allowing for a pro-
longed period of time during which processed AAV2 
capsid peptides are presented in the context of MHC 
classItoantiviralT-cells219-221. Pseudotyping the particles 
with capsids from AAV6 or AAV8, which in contrast to 
AAV2 do not persist as encapsidated molecules219, or the 
use of AAV5 vectors, which uncoat more rapidly than 
AAV2 capsids196, results in better transduction and de-
creased inflammation. Short-term immune modulation 
during the uncoating of AAV2 could therefore be helpful 
in preventing presentation of capsid epitopes by MHC 
class I molecules and the duration of the immune sup-
pression would thus be directly linked to the half-life of 
the viral capsid proteins196. Other mechanisms involved 
in the clearance and induction of immune responses 
against AAV include inhibition of AAV replication by 
APOBEC3A (hA3A)222, cross-presentation of antigens211 
and macrophage activation by complement223. AAV 
capsid binding to C3 complement proteins enhances 
AAV uptake into macrophages and macrophage acti-
vation and, indeed, intravenous treatment of DBA/2 
mice with AAVlacZ resulted in a rapid, but short-lived 
inductionofTNF-a,RANTES, IP-10,MIP-1b, MCP-1, 
and MIP-2 mRNAs in the liver, which was dependent on 
the presence of Kuppfer cells, and a transient infiltration 
of neutrophils and CD11b+ cells224. Although binding 
of AAV to the co-factor complement regulatory protein 
factor H, results in conversion of C3b in iC3b and ab-
rogation of further complement activation223,225, the AAV 
capsid-iC3b complexes are still subject to some immune 
vigilance and binding of the complement receptor comp-
lex with the B-cell receptors (BCRs) activates B-cells. The 
expression of viral peptides by B-cells in the context of 
MHC class II molecules results in stimulation of CD4+ 
Th cells. Interactions between CD40L on the Th cells 
and CD40 on B-cells then leads to clonal expansion and 
production of antibody-producing plasma cells and me-
mory B-cells. Not only impairs a deficiency in C3 protein 
or complement receptors CR1/2 the humoral response 
to AAV significantly223,225, also the role of co-stimula-
tion and Th cells is important for an optimal immune 
response and CD8 cellular immunity to AAV vector 
capsids is ablated in the absence of CD4, CD40L, or 
CD28217,226. Approximately 30-60% of the humans carries 
neutralizing antibodies against AAV2 and cross-reacting 
antibodies against many other serotypes227,228. The extent 
of cross-reactivity between some AAV serotypes ap-
pears to be species specific and dependent on tissue type 
and route of administration. In mice, even low titers of 
neutralizingantibodieswereabletoimpairtheefficacyof
AAV-mediated gene transfer to liver229 or brain81 and in 
clinical trials, the induced IgG response to the AAV cap-
sid was shown to be inversely proportional to the level of 
pre-existing anti-AAV antibody and independent of the 
vector dose230. However, in immune privileged sites, such 
as the brain, it was shown that circulating anti-AAV2 
antibodies can inhibit AAV2-mediated, but not AAV5-
mediated gene transfer81. In contrast to the long-term ex-
pression of therapeutic levels of fIX after treatment with 
AAV vector in mice and dogs231-233, despite the formation 
of anti-hF.IX antibodies234, AAV2-fIX in men with severe 
hemophilia B at a dose of 2x1012 vg/kg resulted in only 
short-lived therapeutic levels of fIX expression49 likely as 
aresultofananti-AAVcapsidCD8+T-cellresponse235. 
It was shown in hemophilia B dogs that not only the total 
vector dose administered plays an important role in the 
formation of antibodies236, but also the vector dose per 
injection site234. Analysis from immunoglobulin classes 
showed that noninhibitory antibodies consisted of IgG2 
only, whereas inhibitory antibodies were found to be both 
IgG1 and IgG2. In addition, it was shown that AAV1 vec-
tors were much more potent in induction of inhibitory 
antibody formation than AAV2-CMV-F.IX234.
Also AAV vectors used as vaccine carriers were shown 
to induce transgene-specific T- and B-cell responses,
although mild in comparison to Ad vaccines, and may 
be due to lack of transgene product expression by DCs213. 
Normal human subjects were shown to carry wt AAV-
specificmemoryCD8+Tcells,whichcanexpandupon
re-exposure to capsid antigens and induce a rapid clear-
ance of transduced cells56,218,235. Pseudotyping of AAV2 
with capsid proteins from other less prevalent or animal 
type serotypes can circumvent pre-existing immunity. 
In a clinical trial forAATdeficiency, bothneutralizing
antibodies and cross-reacting antibodies against other 
serotypes increased after intramuscular administration 
of AAV2/1-AAT237. Despite induction of neutralizing 
antibodies, long-term low level expression ofAATwas
found in all patients, suggesting that after intramuscular 
injection some transduced may escape immune-media-
ted elimination. In contrast, animal models, such as the 
mdx mouse model, display substantial immune responses 
upon intramuscular injection of AAV, possibly due to 
leakage of neoantigens from affected muscle cells238. Ad-
ministration of AAV vectors to immune-privileged sites, 
such as the brain, in adults appears not to be negatively 
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affected by (pre-existing) immunity. In a phase I trial to 
test the safety of a single local infusion of up to 0.5x1011 
vg AAV2-GAD (AAV-glutamic acid decarboxylase) in 
patients with Parkinson’s disease (PD), an increase in 
anti-AAV2-antibodies or anti-GAD antibodies could 
not be detected239. In contrast, in another phase I trial for 
PD, 4 out of 6 adult patients injected with 5.4x1011 vg of 
AAV-NTN (Neurturin, CERE-120) atmultiple sites in
the putamen, showed an increase in anti-AAV2 antibodi-
es, but no humoral response against Neurturin, whereas 
6/6 patients, who received a lower dose of 1.3x1011 vg did 
not show any meaningful increases in anti-AAV or anti-
Neurturin antibodies240. A study in young children with 
Canavan disease, showed the appearance of detectable 
neutralizing antibodies to AAV in 3 out of 10 children 
after treatment241. The reason for the discrepancy between 
these studies is not clear, but may be related with the age 
of the patients, the total viral dose of the vector, whether 
the patients received a single or multiple injections and 
whether the patients suffered from postoperative compli-
cations, such as fever and/or hematomas. 
Thus, although mild, immune responses against AAV 
can hamper the efficacy of the treatment and methods to 
circumvent some of the major key players in the immune 
response include the use of alternative serotypes145, 
pseudopackaging149 and the selection of immune-escape 
mutants242. Although these methods can all delay or 
diminish the primary immune response, they cannot 
completely prevent induction of an immune response and 
therefore, other methods such as induction of tolerance, 
for exampleby increasingTregsor targeting liver cells,
using a different ROA and immune modulation may be 
needed for optimal use in vivo. For AAV, immune modu-
lation focused on Kuppfer cell depletion, complement 
inactivation or blocking of the CD8+ T-cell response
could considerably improve transgene expression. Inter-
estingly, it was shown that the anthracycline antibiotics, 
such as doxorubicin, daunorubicin and epirubicin, and 
platinum compounds, which are both commonly used as 
cancer chemotherapeutics and have an immune suppres-
sive effect, can augment AAV2 mediated gene transfer, by 
promoting nuclear accumulation of AAV2243,244. 
Immune response to other parvoviruses
Some rodent parvoviruses (PV), currently explored for 
their use as an oncolytic virus, are rat H-1PV, an autono-
mously replicating, non-integrating virus245 and parvovi-
rus Minute Virus of Mice (MVMp)246. After translocation 
to the nucleus, H-1PV is dependent on proliferation and 
transformation of host cells for conversion of ssDNA 
into dsDNA, gene expression and cytotoxic activity (J. 
Rommelaere,ESGCT2009).ThePVadaptorproteinNS1
affects cellular kinases and is responsible for oncolysis. 
Although H-1PV is infectious for normal mammal cells, 
it does not result in cell killing or significant pathol-
ogy in humans. Recognition of H-1PV and MVMp by 
PRRs results in a type I IFN response and clearance of 
the virus. The inability of transformed cells to induce 
such an innate immune response, allows completion 
of the lytic cycle and results in enhanced oncotropism. 
Oncolytic virotherapy was shown to be feasible in vitro 
and in vivo immuno-deficient animal cancer models 
for glioblastoma multiforme247, pancreatic cancer248 and 
lymphomas245. The anti-tumor effects of H1-PV can be 
improved by arming the virus with immunogenic CpG 
sequences or immune-stimulating molecules, such as 
MCP-3, or by combination treatment with the antibiotic 
norfloxacin249. H-1PV is currently tested in a phase I/Iia 
study for patients with glioblastoma multiforme. 
herpes viruses
Herpes viruses are characterized by their tendency to re-
main latent after primary infection and reactivate at later 
time points. Herpes Simplex Virus (HSV) is an enveloped 
dsDNA virus with a genome size of 152 kb, encoding 84 
viral genes, approximately half of which are dispensable 
for replication in vitro, but may affect virus virulence in 
vivo.
Replication-competent (RC) vectors, although at-
tenuated, carry the risk for pathogenesis, mutation or 
recombination, shedding and germ-line transmission154. 
The replicative ability of ICP34.5-deleted HSV is cell type 
and state dependent250. In general, dividing cells support 
replication of ICP34.5-null HSV, whereas non-dividing 
cells cannot support its growth. In non-permissive cells, 
failure to express ICP34.5 results in a defect in virus 
maturation and transportation from the nuclei of in-
fected cells251. In contrast, malignant cells allow selective 
replication of ICP34.5-null HSV-mutants252.
The first generation oncolytic HSV vectors contain 
a single gene mutation to prevent replication in non-
dividing cells. The HSV-1 F based, highly neuroattenu-
ated strain R3616 contains a deletion of both copies of 
ICP34.5 and has a good safety profile as demonstrated by 
the lack of encephalitis in an experimental glioma mouse 
model, while the virus can still replicate in actively divid-
ing cells and exert antitumor effects253. Strain HSV1716, 
derived from HSV-1 Glasgow strain 17+, has a similar 
ICP34.5-deletion254 and was tested in a Phase I clinical 
trial demonstrating lack of toxicity in immune compe-
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tent patients255,256. However, intraventricular treatment 
of nude mice with even a low dose of 103 pfu HSV1716 
demonstrated significant lethality257 and indicate that 
treatment of patients who are immune compromised 
may suffer from severe viral pathogenesis.
Second generation HSV vectors contain multiple 
mutations, to prevent reversion of the strains into wt and 
ensure a better safety profile. Vector G207, was derived 
from the R3616 by insertion of the lacZ gene into the 
UL39gene,encoding the largesubunitofRR(ICP6)258. 
In a Phase I and Phase Ib study, it was demonstrated that 
multiple doses of G207 were well tolerated, with no signs 
of toxicity or encephalitis259,260. Animal studies demon-
strated a localized distribution of G207 viral DNA after 
injection in the brain and absence of viral DNA in excreta 
up to one month after injection261. 
The replication-defective (RD) HSVs lack genes 
essential for in vitro viral replication, such as the imme-
diate-early (IE) genes encoding ICP4 and ICP27 shortly 
after viral entry262. The first generation defective genomic 
vectors contained deletions in a single encoding ICP4263, 
but were still neurotoxic in culture. Second generation 
RD vectors, deleted for various combinations of IE genes, 
showed reduced cytotoxicity in comparison to the first 
generation and allowed long-term gene expression in 
neurons264. 
Amplicon vectors are similar to HSV-1 particles in 
structure, immunogenicity and host-range, but do not 
carry any viral genes, nor induce synthesis of viral genes, 
rendering it fully nontoxic and nonpathogenic265 and 
can accommodate foreign genes up to 130 kb of a total 
packaging capacity of 152 kb265,266. Amplicon plasmids are 
dependent upon helper virus function to provide the rep-
lication machinery and structural proteins necessary for 
packaging amplicon vector DNA into viral particles267. 
Although the risks of reactivation, complementation or 
recombination with latent HSV-1 are considerably lower 
than with any of the other HSV-based vectors, its high-
titerproductionisfarmoredifficult,withtitersranging
in the order of 107 to 108 virus particles/mL267. 
Immunogenicity of HSV and HSV-based vectors
Wild-type HSV-1 and HSV-2 are highly immunogenic 
and induce rapid activation of the innate immune sys-
tem as well as cellular and humoral immunity against 
HSV antigens and transgenes. More than half of the 
population already possesses neutralizing antibody 
activity against viral envelope glycoproteins gB, gD 
and gH-gL58,268. CD4+ T-cell responses are broad and
directed against immediate early, early and late proteins, 
envelope proteins gB-E and gH,  tegument, capsid and 
nonstructural antigens present within infected cells58. 
Epitopes recognized by CD8+ cells include gB, RR1269, 
ICP0, tegument proteins VP13/14 and VP22270. However, 
some subjectsmaydisplay apersistent anti-HSVT-cell
response, in the absence of detectable antibodies, indicat-
ing either undetected infection or acquired immunity in 
the absence of infection271. The main difference between 
immune and non-immune individuals appears to be the 
velocity and the magnitude of the acquired response. As a 
first line of defense, factors in saliva272, tears and blood268 
bind and attempt to neutralize HSV. Rapid activation of 
the complement cascade273 is followed by local inflam-
mation,infiltrationofneutrophils,macrophages,T-cells
and NK-cells274. The type I IFN response is mediated by 
activationofTLR2275,TLR3andTLR9276. Viral particles, 
which succeed in entering the neuronal axons, travel by 
means of retrograde transfer to sensory ganglia, where 
they remain out-of-reach for the host adaptive immune 
responses. Cytokines affecting the course of the HSV 
infection include IFNa, b, g, IL-1, -2, -4, -5, -6, -10, -12 
and -23 and TNFa277. Initially, IFNa/b and TNFa are 
produced and effectively limit the early acute replication 
and spread of HSV278 and activate macrophages. Shortly 
thereafter, IL-12 in consert with other of the above cy-
tokines induces production of IFN-γ in CD4+ Th1 cells, 
CTLsandNKcells279,280. IFNg can be detected throughout 
the infection and is associated with improved survival, re-
sistance from encephalitis and prevention from reactiva-
tion274. Inactivation of the IFNs leads to elevation of viral 
replication and an increased viral load281. IL-23, produced 
by dendritic cells, is also upregulated during infection282, 
stimulates IFNg and plays a role in the control of memory 
T-cells283 residing in regional lymphnodes284, as well as in 
maintenance and induction of the type I cytokine and Th1 
response285.  Other mediators of the Th1 response include 
IL-1b, which regulates inflammatory responses, IL-6, 
which has predominantly antiviral effects and TNFa, 
the expression of which continues during latency274. 
Exposure of macrophages to IFNg results in induction of 
the enzyme inducible nitric oxide synthetase (iNOS) and 
production of NO, which has a strong antiviral activity, 
but when overproduced might result in damage to DNA, 
proteins and lipids in host cells and tissues279. The Th2 
cells are the primary producers of IL-4 and IL-13, which 
repress the induction of IL-12 and can halt the positive 
feed-back loop of IFN-γ production to prevent an ongo-
ing pro-inflammatory response and potentially harmful 
actions of macrophages and NK cells279. Whereas CD4+ 
T-cells and NK-like cytotoxic responses are present
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during all stages of infection, the infiltration ofCTL is
associated with actual viral clearance286.
The same host responses that are activated by wild-
type HSV-1 infection are also operational in limiting the 
anti-cancer effects of HSV-1-based oncolytic vectors268. 
Within hours of exposure, activation of the innate im-
mune reponse results in upregulation of anti-viral cyto-
kines and chemokines. It was demonstrated that plasma 
factors from naïve athymic and immunocompetent rats 
and humans can in vitro impede transduction with the 
oncolytic replication-conditional HSV mutant hrR3 
and that this activity could be quenched by mild heating 
of the plasma67. Treatment of rats with cobra venom
factor (CVF) to deplete complement factors or with 
cyclophosphamide, which decreases neutrophil levels 
in the peripheral blood and inhibits immunoglobulin 
production by B-cells, resulted in increased transduction 
efficiencyofbraintumorsafterintra-arterialinjectionof
hrR368,268. Mice with intracranial melanoma were treated 
with intratumoral injections of HSV1716 (see above) and 
showed an anti-tumor and anti-vector CTL response
and a tumor-specific proliferative T-cell response, but
absence of a (neutralizing) antibody response against the 
tumor or the vector and it was suggested that an optimal 
antitumor effect required the presence of an integrated, 
complete immune response287. Despite pre-existing 
antibodies against HSV, melanoma patients treated with 
intralesional injection of HSV1716, showed viral rep-
lication within the boundaries of the tumor and tumor 
flattening, without shedding/reactivation of endogenous 
latent virus or effects on serum IgG or IgM levels288. 
Although in both HSV seronegative and seropositive 
patients intratumoral injection of HSV1716 showed viral 
replication in high grade gliomas without causing toxic-
ity, injection resulted in increased serum levels of IgG 
and IgM and seroconversion two seronegative patients289. 
As a safety measure, however, some level of neutralizing 
activity against HSV-1 may be partially protective in 
inhibiting spread of a replicating virus.
RD-HSV vectors own a virtually intact HSV genome 
and immune responses may arise from viral particle 
components, co-purified packaging debris, low-level de 
novo viral gene product expression and expression of 
the transgene267. As is the case with the OV, preexisting 
immunity does not appear to negatively affect im-
munity elicited against RD-HSV-1 vaccine vectors or 
transgenes290. However, no detailed assessments of any 
of these confounding factors have been performed up to 
date. More information is present on immune responses 
against amplicons. The earlier amplicons, contaminated 
with helper virus allowed low level expression of viral 
proteins267. These amplicons induced a strong inflamma-
toryresponsewithMHCclassIandIIexpression,T-cell
activation and an influx of macrophages291. Although 
mice injected stereotacticly with helper-free preparations 
of b-galactosidase-expressing amplicon (HSVlac) dis-
played a similar innate immune response to mice injected 
with preparations contaminated with helper virus, this 
response fully resolved within 5 days, demonstrating that 
helper virus-free amplicon preparations exhibit a safer 
innate immune response profile292. Furthermore, it was 
shown that infection with HSV amplicons triggers an 
IRF3andIRF7-dependent,butTLR-independentantivi-
ral response, which results in only a mild and contained 
type I IFN response293. 
As mentioned before, the pathogenic effects of rep-
lication competent HSV vectors, when administered to 
athymic nude mice are major and can result in lethality, 
depending on the dose of the vector. In addition, immune 
compromised patients, in particular patients with defects 
in cell-mediated immunity may suffer extensively from 
a HSV infection, resulting in severe local infections, 
encephalitis, and even generalized infection. Thus, im-
mune modulation in a patient treated with a RC-HSV 
vector should be carefully chosen and preferably not 
target cellular immunity, but for example the IFNa and b 
response, which limits the early acute replication of HSV. 
Rather than suppression of the innate or cellular immune 
response, stimulation of elements regulating the Th2 
reponse can be an alternative route to achieve immune 
modulation. Broberg et al. used linomide to facilitate 
viral infection and found an increased expression of IL-4 
and IL-10 transgenes, but no effect on the clinical course 
of infections294.
vaccinia virus
The poxviruses are the largest known DNA viruses and 
are distinguished from other viruses by their ability to 
replicate entirely in the cytoplasm of infected cells: Since 
poxviruses do not require nuclear factors for replication, 
they can even replicate with little hindrance in enucleated 
cells. Vaccinia virus (VACV) belongs to the orthopox-
virus subfamily and has been used as a vaccine for the 
eradication of smallpox295. Important strains of VACV 
are derived from the New York City Board of Health 
(NYCBH) strain, which was used to develop the Dryvax 
and ACAM2000 vaccine strains, as well as the Western 
Reserve (WR) strain79. NYVAC is another attenuated 
form of VACV derived from the Copenhagen vaccine 
strain and has a deletion of 18 open reading frames from 
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the viral genome296,297. VACV is highly immunogenic 
andinducesastrongCTLandlong-lastingneutralizing
antibody response. This long-lasting response was the 
basis for the use of VACV as a vaccine for the eradication 
of smallpox and has resulted in extended experience with 
Vaccinia and a thorough knowledge of its side effects. 
VACV has also been used as a vaccine vector to present 
antigens from other pathogens and in the treatment of 
cancer298-301 and new strategies include methods to boost 
rather than decrease the immune response, eg by using 
different poxviruses302, or through co-expression of 
combinations of co-stimulatory factors303. The rationale 
behind the use of Vaccinia for cancer treatment is clear: 
VACV replicates and lyses cells rapidly; has a broad 
tumor tropism and does not require specific receptors for 
cell entrance; does not integrate into host DNA; displays 
efficient spreading, allowing systemic administration;
can be treated, if needed, with experimental anti-viral 
agents304 or Vaccinia immunoglobulin305; and can accom-
modate large genes up to 25 kb295. Vaccinia vaccine strains 
inherently target tumors306, as these are more susceptible 
to viral replication due to blocks in apoptosis and deregu-
lation of the cell cycle and conceal the virus from the im-
mune system295. In addition, Vaccinia expresses an EGF 
homologue, Vaccinia growth factor (VGF), that activates 
the EGFR-Ras pathway and anti-viral agents designed to 
block this pathway307 inhibit Vaccinia replication. Onco-
lytic Vaccinia vectors with increased tumor-specificity 
can be constructed by deletion of genes expendable for 
viralreplicationintumorcells,suchastheTK308,309 and 
VGF.The TK- andVGF-deleted vvDD vectors display
selective replication in tumors with activated EGFR-Ras 
pathways310. Increased tumor-selective replication can be 
achieved by deleting several other genes, including two 
serpins and an inhibitor of cytochrome c release295.
Immunogenicity of Vaccinia
Vaccinia-induced cell lysis results in the release of PAMPs 
and both virus- and tumor-associated antigens and can be 
used to boost the immune responses against a tumor302,303. 
In non-immunized patients, circulating virus is encoun-
tered by complement and reticulo-endothelial cell-based 
mechanisms, leading to phagocytosis of viral particles by 
tissue macrophages or liver Kuppfer cells, induction of 
type I IFNs through TLR-dependent and independent
mechanisms311, activation of NK cells by type I IFNs312 
andclonalexpansionofCD8+T-cellsthroughdirectsig-
naling ofTLR2-MyD88313. For recovery and protection 
from secondary infection, B-cell function and production 
of neutralizing antibodies are critical314, whereas type I 
IFNs315andCD8T-celleffectorfunctionsarenotessen-
tial166. The rapid and robust immune response in previ-
ously immunized patients can considerably decrease the 
anti-tumor effects of Vaccinia and must be circumvented. 
Although systemic immune suppression or B-cell deple-
tion can enhance viral infection of tumor cells, it may 
simultaneously decrease the immune response against 
the tumor. Rather, simultaneous shielding of the vector 
from the immune system, while maintaining the host 
immune responses against the tumor, can enhance the 
efficacy of oncolyticVaccinia virus40. A single systemic 
dose of replicating, double deleted vaccinia virus vvDD-
EGFP inhibited growth of malignant glioma cells in athy-
mic mice and increased survival in immune competent 
mice. Combination treatment of vvDD with rapamycine 
and cyclophosphamide enhanced viral replication and 
further increased survival40. Cyclooxygenase-2 (Cox-2) 
inhibitors represent a new class of non-steroidal anti-
inflammatory drugs that reduce inflammation and can 
attenuate antibody production by inhibiting antibody 
induction316. Furthermore, it was shown that treatment 
with Cox-2 inhibitors allowed the repeated administra-
tion of Vaccinia virus for the treatment of ovarian can-
cer317. Simultaneously, other groups attempt to use the 
strongcytotoxicT-cellresponseinducedbyVacciniato
induce a local anti-tumor response295.
retroviruses
Retroviruses are divided into two subfamilies, the 
orthoretrovirinae, including gammaretroviruses (MLV, 
HTLV-1andHTLV-II)andlentiviruses(HIV-1,HIV-2
and SIV-2), and the spumaretrovirinae (foamy viruses, 
FV)20. 
Gammaretroviruses
In the early eighties, the development of the ‘traditional’ 
retroviral vectors from MLV commenced. One of the 
major drawbacks of the onco-retroviral derived vectors 
is their inability to transduce non-dividing or quiescent 
cells and their preferred integration in promoter regions, 
which may lead to insertional mutagenesis, as was shown 
in a recent clinical trial for X-linked SCID318. In the cases 
of SCID-X1 it is now believed that an initial aberrant 
expression of an oncogene (mainly LMO2) led to prolif-
eration of specific clones and the addition of other genetic 
events, eventually resulting in leukemic transformation319. 
Immune responses to lentiviral vectors
In contrast to the retroviral vectors, the lentiviral vectors 
(LV)havebeen shown to efficiently transducedividing
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and non-dividing cells and therefore have a better safety 
profile than the retroviral vectors. The most commonly 
used LVs are derived from proviral DNA of the human 
immune deficiency virus type I (HIV-1). The LV vectors, 
similar to high-capacity Ad vectors and AAV vectors, 
do not encode viral genes. In contrast to the HCAd and 
AAV vectors, which despite a lack of expression of viral 
genes induce an effective anti-vector immune response 
due to highly immunogenic epitopes on the viral capsid, 
immune responses against LV vectors appear to occur 
only in the presence of an antigenic (foreign) transgene69. 
This difference between the induced immune response 
against HCAd, AAV and LV vectors, was suggested to 
be mediated by differences in viral capsid turnover: slow 
uncoating of antigenic capsid proteins, such as observed 
with AAV, allows longer interaction with the immune 
system to direct an anti-capsid response, whereas rapid 
capsid turnover, such as with LV, prevents recognition 
of immunogenic epitopes by activated effector T-cells,
rendering the transduced cells invisible to the immune 
system69. LV vectors are a promising tool for gene therapy 
of CNS diseases due to the ability to transduce quiescent 
cells. Injections of LV-GFP in the CNS of Sprague 
Dawley rats or systemically did not induce an inflam-
matory response, but rats immunized subcutaneously 
with LV-GFP or LV-fIX displayed a significant immune 
response against lentivirus virion (p17 and p24) and 
envelope (VSV-G) proteins69. Although LV-mediated 
gene transfer allowed sustained transgene expression, 
even in presence of a pre-existing immune response 
against the vector, peripheral immunization against the 
transgene can lead to decreased transgene expression and 
increasedinflammationwithanincreaseofCD8+T-cells
in the CNS. Nevertheless, despite relatively low level im-
munogenicity of the parental virus, persistent high-level 
LV-mediated transgene expressionhas beendifficult to
achieve due to the fact that LV particles are pseudotyped 
with commonly used envelopes, such as VSV-G, which 
transduce and activate APCs (DCs) more efficiently
than wild type HIV-1. In vivo transduced DCs display 
a mature phenotype, produce TNF-a and stimulate 
activationoftheadaptivehumoralandCTLresponseto
the transgene320,321. The lentiviral activation of DCs was 
foundtobemediatedbyTLR3andTLR7320. Importantly, 
although the potential immune response against LV 
is of no great concern, stable transduction of cells and 
long-term expression of transgenes may elicit a potent 
anti-transgene immune response, which may result in 
clearance of transduced cells, particularly if the transgene 
is foreign to the host. Although unwelcome when long-
term expression of transgenes is needed, the ability of 
LV vectors to efficiently transduceDCs and induce an
anti-transgene immuneresponsecanbeefficientlyused
as a tool to stimulate antigen-specific CTLs for cancer
immunotherapy322-325, or as a vaccine vector326. 
Integration deficient lentiviral vectors (IDLV) carry 
mutations in integrase, preventing proviral integration 
into the host genome and resulting in episomal persis-
tence of vectors in transduced cells327. Due to the lack of 
replication signals, the lentiviral episomes are gradually 
lost in dividing cells resulting in transient gene expres-
sion, but remain stable in quiescent cells. From a safety 
perspective IDLVs are preferred, as they display a much 
reduced risk for insertional mutagenesis as well as for the 
generation of replication competent recombinants.
Foamy Viruses
Although foamy viruses share their basic genetic order 
ofLTR-gag-pol-env-accessorygenes-LTRwiththegam-
maretroviruses and lentiviruses, they differ with respect 
to their replication mechanisms. Most notably is the 
feature to reverse-transcribe the RNA pre-genome late 
in replication before the virus buds from the cell mem-
brane328. Like the the gammaretroviruses, they are able 
to integrate into the genome, but the FV vectors display 
a distinct integration profile329,330. The FV vectors do not 
integrate preferentially within genes, despite a modest 
preference for integration near transcription start sites 
and a significant preference for CpG islands329. FV vector 
integrations in human hematopoietic cells were shown to 
occur both in introns and intergenic regions331. Humans 
are not natural hosts of FV and do not have any pre-
existing immunity332.
other viruses
Reovirus
Reovirus is a naturally occurring, non-pathogenic, 
double-stranded RNA virus. Attachment of reovirus to 
target cells is mediated by the reovirus sigma1 protein. 
Junctional adhesion molecule-1 (JAM-1) is a serotype-
independent receptor for reovirus, and sialic acid is a 
coreceptor for serotype 3 strains333. After binding to 
receptors on the cell surface, reovirus is internalized via 
receptor-mediated endocytosis. Viral infections of respi-
ratory and gastrointestinal tract the may occur in child-
hood334 without causing clinical disease335, resulting in a 
high prevalence of neutralizing anti-reovirus antibodies 
in adults. 
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In non-transformed cells, infection with reovirus 
results in phosphorylation of cellular PKR (dsRNA-
activated protein kinase) and arrest of viral protein 
translation and replication. In contrast, in Ras-activated 
cells, PKR remains unphosphorylated and is incapable 
of aborting viral translation, replication and cytolysis336. 
Therefore, Reoviruses are able to selectively kill cells 
with an activated Ras signaling pathway, which can 
occur through Ras mutation or aberrant expression of 
upstream mitogenic signals, such as overexpressed or 
mutated receptor tyrosine kinases337. 
SinceRT3D is in essence a non-modifiedwild-type
virus (ie it carries no transgenes), immune responses are 
only directed at the virus itself. Immune responses are 
mediated by RIG-1 and MDA-5, although either helicase 
is dispensible for innate immune signaling338. In animals 
a neutralizing antibody response occurs within 3-7 days 
and plateaus at day 914. In a clinical trial, it was shown 
that even heavily pretreated patients with advanced 
cancer were capable of inducing a dynamic immune 
responseduring treatmentwithReovirusType3Dear-
ing (RT3D)335. Before Reovirus treatment, CD3+CD4+ 
levels in patients were relatively decreased, whereas 
CD3+CD8+ levels were relatively increased in com-
parison to normal subjects. Levels of CD56+ NK cells in 
addition to both types of lymphocytes rapidly increased 
in response to reoviral therapy335. Inflammatory cytokine 
responses differed between patients and combined Th1 
and Th2 cytokine responses were observed in 8 (38%) 
patients, as well as a cyclical increase in IL-5 (4 patients), 
IL-2 (3 patients) and IL-6,  IL-8 and IL-12p40 in 2 pa-
tients335. Patients developed high titers of anti-Reovirus 
neutralizing antibodies despite previous chemotherapy 
and/or radiotherapy and reached plateau levels after 
7-14 days335,339. Promising data from animal studies 
showed the efficacy of Cyclophosphamide in blunting
the neutralizing antibody response against RT3D, but
demonstrated that high doses of Cyclophosphamide may 
result in unwanted replication of virus in normal tissue 
and toxicity14. In addition, although non-pathogenic in 
healthy persons, in immune compromised animal mod-
els,suchasimmunedeficientandneonatalmice,RT3D
may cause severe neurovirulence and death340.RT3D is
currently undergoing extensive evaluation in phase I and 
II clinical trials, either as a single agent or in combination 
with radiotherapy or cytotoxic chemotherapy.
Measles virus
Measles virus (Morbillivirus) belongs to the fam-
ily of paramyxovidae, as do respiratory syncytial virus 
(Pneumovirus), mumps and parainfluenza viruses (both 
paramyxoviruses). However, in contrast to the mumps 
and parainfluenza, measles and RSV do not possess 
neuraminidase. All members of this family are envel-
oped, negative-stranded RNA viruses.  The virus consists 
of eight proteins encoded within a 16 kb genome. The 
measles F envelope glycoprotein mediates fusion after 
cell attachment; the measles Hemaglutinin (H) protein 
is involved in the attachment and entry of measles virus 
into cells via binding to the cell surface receptors, CD46 
and signaling lymphocyte-activation molecule (SLAM, 
CD150)341. CD46 is involved in regulation of complement 
activation, is ubiquitously expressed on all nucleated cells 
and acts as a receptor for the measles Edmonston and 
Halle strains. SLAM is selectively expressedon someT
and B cells and is used by both the Edmonston strain and 
wild-type measles strains that cannot use CD46 for cell 
entry342. Spontaneous tumor regression observed during 
wt measles infection can be explained by the relative 
overexpression of CD46 on human tumor cells and has 
resulted in the engineering of attenuated measles viruses 
derived from the Edmonston strain as selective onco-
lytic agents53,341. The high prevalence of preexisting anti-
measles immunity as a result of world wide vaccination 
programs with live attenuated MMR (Measles, Mumps 
and Rubella) vaccine hampers the clinical use of oncolytic 
measles strains. However, from a safety perspective the 
use of oncolytic measles strains shows great potential 
as reversion of attenuated measles strains to pathogenic 
phenotypes has never been observed and population 
immunity provides the best protection from measles 
vector spread from patient to medical personal and close 
relatives341. The F and H proteins are the primary targets 
for the host immune response and induce a neutralizing 
antibodyandcytotoxicT-cellresponse.TheHproteinof
wild-type,butnotvaccinestrainMeasles,activatesTLR2
and stimulates production of IL-6343. Humoral and cel-
lular immunity is mediated by induction of the Th1 and 
Th2 cytokines, IFN-g and IL-4344. Measles virus clearance 
and long-lasting immunity is mediated predominantly 
by CTLs, as patients with agamma-globulinemia re-
cover normally. However, in patients with an impaired 
cell-mediated immune response Measles pneumonia, 
although rare, is often fatal. Measles disease typically is 
more severe in adults and very young children (<5 yrs 
of age). The P gene of wild-type Measles virus encodes 
P/V/C proteins and antagonizes the IFN response. 
Phosphopolymerase (P) protein is a basic component 
of viral RNA polymerase, whereas the C and V proteins 
are non-structural accessory proteins345. Suppression of 
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immunity by MV can result in an increased susceptibility 
for secondary bacterial infectionPhosphopolymerase (P) 
protein is a basic component of viral RNA polymerase, 
whereas the C and V proteins are non-structural acces-
sory proteins312. Suppression of immunity by MV can 
result in an increased susceptibility for secondary bacte-
rial infection
New Castle Disease Virus
Newcastle disease virus (NDV) is a member of the Avu-
lavirus genus in the Paramyxoviridae family, which has 
been shown to infect a number of avian species. NDV 
has a single-stranded negative sense RNA genome, which 
consists of six genes346 and does not undergo recombina-
tion with the host genome or with other viruses347. NDV 
has a lipid–glycoprotein envelope and its spikes come 
from the hemagglutinin-neuraminidase (HN) and the fu-
sion (F) genes. Attachment is mediated through the sialic 
acid cell receptor(s) and results in fusion with the cell 
membrane346. In response to NDV, IFNaandTNFa are 
released by peripheral blood mononuclear cells348. NDV 
inducesastrongneutralizingantibodyresponseandCTL
response against HN and F protein complexes, which 
limit spread of oncolytic NDV strains to other tumor cells 
within the host346. 
Vesicular stomatitis virus 
Vesicular stomatitis virus (VSV) infection of normal 
cells induces a potent type 1 interferon, which blocks viral 
replication. In contrast, many tumor cells have defects in 
their IFN response, allowing for selective lysis of tumors 
andtheassociatedprimingofTcellsagainsttumor-asso-
ciated antigens349,350. 
VIRAL EVASION MECHANISMS
Viral evasion mechanisms can be grossly divided into 
four categories: 1. Strategies to inhibit the innate im-
mune response; 2. Strategies to evade recognition by the 
humoral immunity: These are mostly used by smaller 
viruses with a limited capacity to harbor genes, such 
as the picornaviruses, myxoviruses and retroviruses, 
which depend on the continuous modification of their 
viral envelope glycoproteins to prevent recognition of 
immunodominant epitopes by the immune system; 3. 
Interference with the processes of the cellular immune re-
sponse. This is the main strategy applied by DNA viruses, 
including the poxvirus, herpesviruses and adenoviruses, 
which have a variety of mechanisms to prevent presenta-
tion by APCs to immune cells and use this to increase 
their chances for viral replication and shedding; and 4. 
Interference with immune effector functions, for example 
through expression of certain inhibiting cytokines or 
prevention of apoptosis351. 
evasion of the innate immune response
Theinnate immuneresponseis initiatedwhenToll-like
receptors TLR3, TLR7/8, and TLR9 recognize their
respective endosomal patterns associated with the viral 
genome, ie. dsRNA, ssRNA and CpG DNA, or when the 
RNA helicases, RIG-1 and Mda-5, recognize foreign cy-
toplasmic RNA molecules, which results through a series 
of intermediates in the production of type I interferons. 
Interference with these pathways results in modula-
tion of the innate immune response. Vaccinia virus 
(VACV) employs a variety of distinct pathways to evade 
the immune response and regulate virulence, includ-
ing expression of a wide range of immune modulatory 
proteins, such asA39R andA41L.Twoother proteins,
expressed by VACV, A52R and A46R, interfere with the 
host defense by modulating TLR pathways. Whereas
A52R blocks the activation of NF-kBbymultipleTLRs,
inparticularTLR3,bybindingtoIRAK2andTRAF6352, 
A46R, which is expressed by VACV early during infec-
tion,containsaToll-like–interleukin-1resistance (TIR)
domain and acts as a decoy protein by targeting myeloid 
differentiation factor 88 (MyD88), MyD88 adaptor-like, 
TIRdomain-containingadaptorinducingIFN-b(TRIF)
and the TRIF-related adaptor molecule, and inhibits
downstream activation of NF-kB and MAP kinase353. 
A46R thus disrupts TRIF-induced interferon (IFN)
regulatory factor 3 (IRF3) activation and induction 
of TRIF-dependent genes. The HCV serine protease
NS3/4AinhibitsactivationofIRF-3bycleavingTRIFand
IPS-1downstreamofTLR3/TLR4andtheRNAhelicases
and blocks type I interferon production in response to 
dsRNA354. Most paramyxoviruses V-proteins can inhibit 
induction of IFN-b through direct interaction with Mda-
5, thereby blocking dsRNA binding355,356. In addition, 
select paramyxovirus V proteins from the genus Rubula 
virus inhibit dsRNA mediated signaling by mimicking 
IRF3,andactasalternativesubstratesforTBK1/IKKe357.
Immune evasion mechanisms operated by HSV-1 in-
clude 1) management of humoral immunity: Viral glyco-
protein gC can bind to and inactivate the C3 component 
of complement358, viral glycoproteins gE and gI form a 
receptor complex that binds to the Fc portion of IgG359; 
2) resistance against type I interferons: Immediate early 
protein ICP0 antagonizes type I IFN-induced STAT1-
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 201074 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Appendix A Immune response against vectors
dependent repression of viral replication360-362, blocks the 
nuclear accumulation of activated IRF-3, required for 
transcription of type I IFN genes363, and is necessary for 
efficientreactivationfromlatency362, and ICP34.5 medi-
ates dephosphorylation of eIF2a364, as described above. 
The HSV-1 ICP47 protein, encoded by a47,blocksTAP,
preventing viral peptides from being transported to the 
ER and assembling with MHC class I molecules365,366. 
The natural tropism of HSV-1 for epithelial cells and 
neuronal cells makes it an outstanding vehicle to use as a 
vector for neuronal gene transfer274. Interestingly, muta-
tions in ICP47 result in a less neurovirulent HSV-1 strain, 
whereas replication in epithelial cells occurs normally365. 
evasion of the humoral immune response
All RNA viruses are subject to a relatively high muta-
tion rate as a result of the lack of proofreading control 
mechanisms of RNA polymerase. Influenza virus type A 
uses these mutations, which may result in antigenic drift 
or antigenic shift, to its own advantage, to evade the hu-
moral immune surveillance system and ensure survival. 
Antigenic drift occurs due to accumulation of random 
point mutations in viral genes, coding for immune 
dominant epitopes, presented at the cell surface, such 
as hemagglutinin and neuraminidase. Antigenic shift, a 
consequence of exchange of large RNA segments between 
viral chains, may result in considerable changes in surface 
proteins367. These cell surface modifications affect the 
pre-existing host humoral immunity and new encounters 
with the virus will result in a primary immune response.
Other viruses, such as herpes viruses and corona 
viruses, express IgG Fc binding proteins that inhibit IgG 
activity368: HSV-1 glycoproteins gE and gI form an IgG 
Fc receptor, which upon binding inhibits Fc-mediated 
immune functions, enabling the virus or infected cell 
to evade an antibody attack359. Herpes viruses, Vaccinia 
virus and HIV-l each have the capacity to interfere with 
complement, either by incorporation of cellular comple-
ment regulatory proteins into the virion envelope or 
cell membrane, or by expression of viral molecules that 
mimic functions of complement regulatory proteins368: 
HSV-1 expresses glycoprotein gC, which can bind and 
inactivate the C3 component of complement358.
Modulation of the cellular immune response
Viruses have developed multiple mechanisms to interfere 
withtheactivationofCD8+andCD4+T-cellsbyMHC
class I and II molecules, respectively. Interference can 
occur from the moment the virus penetrates the cell, dur-
ing degradation into small peptides, during association 
with the MHC molecules, till the moment of transport 
tothecellmembraneandpresentationtoT-cells.Protea-
somal degradation of specific sequences within the viral 
proteins results in the formation of smaller peptides with 
specific epitopes, which can be recognized by cytotoxic 
lymphocytes (CTL).Minimalmodifications in the viral
genome, affecting just a single amino acid, can prevent 
the degradation of the viral protein into immunodomi-
nantCTLepitopes369. As mentioned above, herpes viruses 
can persist in a latent state for longer periods of time and 
reactivate at later moments. The EBV encoded nuclear 
antigen-1 (EBNA-1) is essential for viral latency and is 
expressed in infected B cells of healthy EBV carriers370. 
The Gly-Ala repeat (Gar) of EBNA-1 is responsible for 
the in cis inhibition of ubiquitin/proteasome dependent 
proteolysisandpreventspresentationofCTLepitopesby
MHC class I molecules370-372,thuspreventingefficientrec-
ognition and killing of EBNA-1 positive cells. In addition, 
translation of EBNA-1 mRNA from an alternative open 
reading frame (ORF), results in a 40.7 kDa strongly acidic 
protein with a glycine, glutamin and glutamic acid-rich 
repeat (GZr)373, which was also shown to inhibit antigen 
processing. The latency-associated nuclear antigen-1 
(LANA-1) from Kaposi Sarcoma herpesvirus (KSHV or 
HHV8), which  contains an acidic protein domain with 
high resemblance to GZr374,375 and ORF73, a protein from 
the murine gamma-herpesvirus 68, are functional equiv-
alents of EBNA-1 and both inhibit antigen processing376. 
Phosphorylation of specific viral proteins, such as matrix 
proteinpp65(UL83)ofhumanCMVorphosphorylation
of threonin residues in the immediate early (IE) proteins 
can inhibit proteosomal degradation as well377.
Endosomal and lysosomal proteins are enzymatically 
degraded into smaller peptides, which bind to MHC class 
II molecules. The MHC class I-associated peptides are 
produced in the proteasome by proteolytic degradation 
of cytosolic proteins and are transported to the ER. Here, 
the peptides are linked with transporter associated with 
antigenprocessing(TAP)tonewlysynthesizedMHCclass
Imolecules.Competitiveinhibitionwiththepeptid/TAP
complex, such as by the herpes simplex virus immediate-
early (IE) gene transcript ICP47377 and BHV1 UL49.5
proteins378, hinders transport of antigenic viral peptides 
to the ER and assembly with MHC class I molecules and 
prevents CD8+ T-cell recognition of infected cells365.
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aPPendiX B iMMune ModuLation and 
induCtion of toLeranCe
The viral vectors that are being used in gene therapy are 
able to induce the full range of host innate and adaptive 
immune responses. Removal of redundant viral genes 
in order to create vacant areas for transgenes and make 
vectors less immunogenic, may have in fact reciprocally 
contributed to the immunogenicity of the constructs by 
removal of viral genes that modulate immune responses 
and viral evasion mechanisms.
immune modulation
Systemic immune suppression in pre-clinical animal 
models and gene therapy trials is used ideally to prevent 
induction of or, less ideally, tamper an existing immune 
response. A temporary incapacitated immune system 
could possibly 1) prevent early clearance of vector; 2) gain 
time to allow complete clearance of viral capsids from 
the circulation; 3) induce tolerance for the transgene 
by preventing a cellular immune response and the ap-
pearance of neutralizing antibodies. Improved and new 
generations of immunosuppressive agents developed for 
induction or maintenance therapy in hematological and 
solid malignancies and transplantation are jeopardized 
by a potential increase in infectious complications. 
Linking the risk of a particular infection to the use of 
a specific immunosuppressive agent has proven com-
plicated, as many of the agents are used serially or in 
conjunction with each other and often in combination 
with other prophylactic and preemptive treatment strate-
gies. An overview of immune suppressive and immune 
modulatory agents is given below and summarized in 
TableIII.However,thedegreeanddurationofimmune
suppression required to avoid allograft rejection or used 
for treatment of malignancies is likely to be lower and 
shorter for immune modulation of gene therapy, and 
depends largely on the amounts of antigen presented (eg 
transduction of antigen-presenting cells, targeted tissue 
and route of administration), the nature of the antigen 
(neoantigen)andnumberofantigen-specificTcells. In
the case of transplant rejection, prophylaxis of rejection 
is generally more successful than attempts to eradicate 
an existing adaptive immune response. However, in gene 
therapy this is often not possible due to preexisting im-
munity present in the normal population. Nevertheless, 
the widespread use of immune suppressive treatments 
provides the gene therapist with a vast array of immune 
modulatory agents, the choice of which depends on the 
intended effects and observed side effects.
Systemic immune suppression
Glucocorticoids are among the most commonly used 
transient immune suppressive agents. In the C57Bl/6 
mouse model, using intravenous injections of 0,75x1011 
E1-deleted human Ad5-derived replication-deficient 
vector particles encoding the highly immunogenic 
b-galactosidase (lacZ), it was demonstrated that pre-
treatmentwith dexamethasone (DEX)was sufficient to
significantly reduce most Ad-induced innate immune 
responses and dampen the adaptive immune response 
withoutaffectingtheefficacyoftheAdvectormediated
gene transduction or levels of transgene expresssion197. 
Pre-emptive treatment with DEX resulted in a dose-
dependent decrease in release of systemic cytokines, such 
as IL-6, IL-12, G-CSF, keratinocyte-derived cytokine 
(KC), monocyte chemoattractant protein 1 (MCP-1) 
and macrophage inflammatory protein 1b (MIB-1b), a 
decrease inRANTES at doses as low as 0.1mg/kg and
completely prevented Ad-induced acute thrombocyto-
penia, endothelial cell activation, pro-inflammatory gene 
induction, and leukocyte infiltration into transduced 
organs at a dose of 10 mg/kg. Similarly, mice treated 
with 0.5-4 mg methylprednisolone (MP) before intra-
venous injection of 1011 particles of E1/E3/E4-deleted 
AdAT4 expressing human apolipoprotein A-I (ApoA-I), 
displayed reduced levels of inflammatory cytokines IL-6, 
MIB-1b, MIB-2, interferon-inducible protein-10 (IP-10), 
lipopolysaccharide-induced CXC chemokine (LIX) and 
KC and decreased thrombocytopenia and leukocyte 
infiltration55.  In a small pilot study involving 5 patients 
withmesothelioma,safetyandefficacyofintrapleuralad-
ministration of 1.5x1013 replication-incompetent E1/E3 
deletedAd5-basedvectorparticlescarryingtheHSV-TK
suicide gene (H5.010RSVtk) and concurrent treatment 
with iv 60 or 125 mg MP, starting at 10 hours before gene 
transfer, every 6 hours for 3 days, was assessed379. The 
study showed that, although the short course of high-dose 
corticosteroids to patients receiving intrapleural gene 
therapydidnotaffecttheefficacyofgenetransfertothe
tumor, in contrast to the animal studies, it showed that it 
only moderately affects the cellular response and could 
not prevent the development of a strong anti-Ad humoral 
immune response. Although some of the acute systemic 
inflammatory responses, such as fever and hypoxemia, 
were decreased in the MP-treated group, the overall 
vector-related toxicity was similar to the control group 
of patients receiving no corticosteroids, and consisted 
of liver enzyme elevation, mild-moderate anemia, fever 
after vector infusion and bullous exanthema surrounding 
the thoracic access site. Reversible mental-status changes 
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in 3 patients using high-dose MP required lowering of the 
dose from 125 mg to 60 mg per infusion, but the overall 
treatment with MP appeared safe, with no evidence of 
increased viral shedding, other organ toxicity or dissemi-
nated viral infections379. 
Clearance of Ad, AAV and LV vectors is crucially 
dependentontheinductionofaCD8+T-cellresponse.
Current regimens used in animal studies to block this 
response are loosely based on the immunosuppressive 
regimens used in organ transplantation for two reasons: 
the first one being that the organ transplant regimens 
are typically developed to block or diminish the CTL
responses, the second one being the vast experience 
obtained with these drugs in the clinical setting. Immu-
nosuppressive regimens commonly used include either 
monotherapy with Cyclosporine A (CSA), methotrex-
ate (MTX) and cyclophosphamide (CY), sirolimus or
daclizumabtorepresstheCTLreponsebyinhibitionof
IL-2 production380, or combination therapy with Myco-
phenolate Mofetil (MMF) or anti-thymocyte globulin 
(ATG) or tacrolimus. CSA is a calcineurin inhibitor,
which specifically and reversibly inhibits proliferation of 
T-lymphocytes, without suppressing hematopoiesis or
affecting the function of phagocytic cells. It inhibits lym-
phokine production and release from activated T-cells.
This inhibiton is however not absolute and virus-specific 
responses can occur even in stem cell transplant recipi-
ents (personal communication with Marco Schilham). 
Thus, a very strong anti-viral response will not be suf-
ficiently repressed by the use of CSA alone. It was found 
that neither the frequency nor the spectrum of infections 
in organ transplant recipients was remarkably affected by 
the type of calcineurin inhibitory agents per se, the most 
commonly observed viral infectious complication being 
CMV381. Rather, susceptibility appeared more dependent 
on the presence or absence of additional immune sup-
pressants.
Due to its structural similarity to folic acid, MTX
functions as a folic acid antagonist and inhibits synthesis 
ofnucleicacidsandproliferation.TheuseofMTXina
gene therapy setting has been limited to use in combina-
tionwithtransferoftheMTXdrug-resistancegene,dihy-
drofolate reductase (DHFR)382-384 to confer myeloprotec-
tion to bone marrow cells. Gene modified hematopoietic 
stem cells, carrying the DHFR are resistant to subsequent 
treatment withMTX, whereas malignant cells in solid
tumors or metastases are sensitive to the cytotoxic effects 
of MTX. Although patients with rheumatoid arthritis
are commonly treated with immunosuppressive agents, 
reactivation of latent EBV in these patients is uniquely 
associatedwithtreatmentwithMTX385.
CY is a DNA-alkylating agent and blocks progression 
through the cell cycle. Although it can result in full bone 
marrow depression, most of its immunosuppressive ef-
fectsaremediatedviainhibitionofB-cells,CD4+T-cells
andtoalesserextentCD8+T-cells.Italsomightfunction
by inhibiting suppressor cells. In a muscular dystrophy 
mouse model, different regimens of transient immune 
modulation were used to prevent anti-AAV1 vector 
directed responses386. Although a five day blockade of co-
stimulationwithCTLA4Igor anti-CD40 antibodies (as
describedinthenextsection)wassufficienttototallyab-
rogate the formation of anti-AAV1 antibodies and allow 
correction of muscular dystrophy in injected muscles, 
‘conventional’ immunosuppressive treatment consisting 
of combinations of FK506, MMF and cyclosporine with 
or without Prednisone failed to inhibit formation of 
AAV1-specific neutralizing antibodies386. However, in a 
non-human primate model of hemophilia A, transient 
treatment with FK506 and MMF for up to 6 weeks, 
resulted in 2 out of 3 animals in effective prevention of 
formation of anti-AAV8 capsid antigens, and although 
upon withdrawal of the immune suppressive agents an 
increase in anti-AAV8 IgG was observed, none of the 
animals developed anti-hFIX antibodies54. A dose-related 
risk for (disseminated) Herpes Zoster and CMV infec-
tions is observed in SLE patients, a patient population 
already at a high risk of infections, when treated with CY, 
particularly if the immunosuppressive regimen is used in 
combination with high-dose glucocorticoids387.
inhibition of specific immune responses
Specific immune responses can be inhibited by immune 
signal blocking depleting (Alemtuzumab, Rituximab, 
Muronomab) or non-depleting antibodies (Daclizumab, 
Basiliximab), or by blockage of co-stimulation signals 
with, anti-ICOS, anti-CD80, anti-CD86, anti-CD40L, 
IDOandCTLA4-Igor less specifically, butmore effec-
tivelywithanti-thymocyteglobulin(ATG).
Depleting and non-depleting antibodies
Alemtuzumab (Campath-1H) is a humanized monoclo-
nalantibodyagainstCD52,expressedbyBandTlympho-
cytes, monocytes/macrophages and natural killer cells, 
which is predominantly used for the treatment of CLL. 
Alemtuzumab gives long lasting, profound lymphocyte 
depletion, which is associated with an increased occur-
rence of CMV and BK infections in solid organ transplant 
recipients, when used to prevent transplant rejection, but 
not when used as induction therapy388 and with increased 
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CMV389 and Ad390 infections in hematopoietic stem cell 
transplant recipients in comparison to similar immune 
suppressive regimens without Alemtuzumab. The risk 
for viral infections in pediatric hematopoietic stem cell 
transplantation patients appears not to be increased in 
comparison to regimens using anti-thymocyte globulin 
(ATG)391.  The absence of anti-murine or anti-canine 
CD52 antibodies reflects a lack in acquisition of pre-
clinical animal data and might explain reluctance of 
initiating human studies using Alemtuzumab as immune 
modulation in gene therapy. 
Rituximab is a chimeric human/mouse monoclonal 
antibody against CD20, and can be used for long last-
ing (9-12 months) depletion of B-lymphocytes. The 
use of Rituximab in solid organ transplant recipients 
was not associated with increased risks for CMV or BK 
infections392, but rituximab treatment for post-transplant 
lymphoproliferative disorders (PTLD) has been associ-
ated with occasional fatal CMV reactivation393 and with 
an increased risk for CMV in NHL patients receiving 
autologous stem cell transplantations394 and both 
increased risks for CMV and HBV and reactivation of 
VZV in lymphoma patients receiving chemotherapy, but 
no stem cell transplantation395. Treatment of a rhesus
monkey, that developed neutralizing antibodies against 
human coagulation factor IX in a non-human primate 
model of gene therapy for hemophilia B, with two doses 
of rituximab and daily doses of cyclosporine for four 
weeks, demonstrated that this regimen was sufficient
to eradicate anti-hFIX antibodies, which appeared after 
treatment with a self-complementary AAV-based vector 
with a codon-optimized gene for human coagulation 
factor IX396.
The murine monoclonal antibody Muromonab 
(OKT3) is directed against the T-cell surfacemolecule
CD3 antigen, which is responsible for signal transduc-
tion.Treatmentwithmuromonab results in short-term
depletionofT-cellsandrecoveryofT-cellsoccurswithin
a week after withdrawal of treatment. Muromonab is 
most commonly used to prevent (renal) transplant rejec-
tion and in the treatment of GvHD. In comparison to 
treatment with high dose MP (2 mg/kg) alone for treat-
ment of GvHD following allogeneic hematopoietic stem 
cell transplantationin, treatment regiments consisting of 
high dose MP in conjunction with Muronomab resulted 
in considerably less viral infectious complications, with 
an observed decrease in CMV, EBV and HHV6, but a 
slight increase in incidence of Parvovirus B19 and ad-
enovirus infections397. In a mouse study investigating the 
effects of the immune response on Ad vector clearance, a 
hamster-anti-mouse CD3 monoclonal antibody was used 
todepleteT-cellsandpreventimmuneresponsesagainst
the LacZ transgene398. A first generation E1-deleted Ad5 
vector coding for the LacZ gene under control of the 
murine pancreatic amylase promoter (Ad5-AmyLacZ) 
was directly injected iv in C57Bl/6 mice. Both immune 
deficient NOD-SCID mice and C57Bl/6 mice treated with 
anti-CD3 antibody displayed lack of liver inflammation 
and produced stable lacZ expression in over 80% of 
hepatocytes at 3 weeks in contrast to immune competent 
control animals, which developed an inflammatory 
response and lost transgene expression398.
Treatment with anti-thymocyte globulin (ATG) in
humans results in a profound and long-lasting depletion 
ofleukocytes.ATGisnonspecificandleukocytes,aswell
as certain subsets of NK cells, DC cells and monocytes 
are depleted from peripheral blood and lymphoid tissues 
through complement-mediated lysis and induction of 
apoptosis399. In solid organ transplant, the use of ATG
is associated with an increased risk for CMV, EBV, and 
BK polyomavirus infections, in comparison with treat-
ment with interleukin (IL)-2a receptor antagonists400. 
However, the risk for adenovirus infections appears to 
be lower in bone marrow transplant recipients treated 
with ATG than patients receiving Alemtuzumab390. In 
general, the risk for EBV and CMV infections appears to 
be related to the level anddurationofT-celldepletion,
which in turndependson thedoseofATGused401, the 
manufacturer (Fresenius versus Sangstat-Genzyme)402, 
and the animal source (horse versus rabbit)403. In a mouse 
model of gene therapy for hemophilia A, different non-
myeloablative regimens were tested, consisting of 5 Gy 
TBIwithorwithoutanti-murinethymocyteserum(ATS)
andacombinationsofBUandFLUwithorwithoutCY,
CTLA4Ig,anti-CD40IgandATS404.  After myelosuppres-
sion, mice were transplanted with HSCs carrying the por-
cinefVIIIgene.ItwasdemonstratedthatadditionofATS
toeithertheTBIorBUregimenwassufficienttoachieve
adequate and sustained levels of porcine fVIII, even if 
the mice were pre-immunized with human fVIII404. In 
a X-linked muscular dystrophy (cxmd) canine model, 
dogs were intramuscularly injected with rAAV6-CMV-
h-m-dys, carrying a human dystrophin gene405. Immune 
suppressive treatment consisting of CsA and MMF was 
notsufficienttosuppresslocalT-cellresponsestoAAVin
injected muscles. In contrast, triple immunosuppressive 
treatmentwithCsA,MMFandATGallowedlong-term
expression of both human dystrophin and canine micro-
dystrophin in cxmd dogs405.
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 201078
Appendix B Immune modulation and induction of tolerance
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Daclizumab and Basiliximab are non-depleting 
antibodies, directed against the IL-2 receptor alpha 
chain (CD25) of activated T-lymphocytes and prevent
T-cell proliferation.Their actions last up to 3 months
and infectious complications associated with these agents 
are largely dependent on the duration of treatment. 
Induction or short-term therapy generally results in a 
decreased risk of viral infections, whereas maintenance 
or long-term therapy in transplant patients is associated 
with an increased risk of CMV infections and death406. 
Rhesus macaques were used to study the effects of im-
mune modulation on transgene expression after direct 
infusion of AAV2-fIX into the hepatic artery407. As many 
hemophilia and renal transplant patients are HCV+, the 
immune suppressive drugs chosen for this study were 
based on a regimen, commonly used in renal transplan-
tation, which had been previously shown to offer an 
excellent long-term safety profile in HCV+ patients408. 
They compared the effects of combination treatment 
of MMF and sirolimus with or without daclizumab. It 
was previously shown that the immunologic tolerance 
to the transgene, achieved in hepatic gene transfer, is 
mediated by CD4+CD25+FoxP3+ regulatory T-cells409 
and therefore immune suppressive regimens should be 
designedtoblockthefunctionofCTLs,whilemaintain-
inginductionofTregs.Hereitwasshownthataregimen
consisting of MMF and sirolimus resulted in low level 
transgene expression and low levels of non-neutralizing 
anti-fIX antibodies, whereas addition of daclizumab to 
the regimen resulted in the formation of high levels of 
inhibitory antibodies directed against fIX and complete 
loss of transgene expression407. The use of 2 or 3 drug regi-
mendidnotaffectthetransductionefficiency,butitwas
found that the addition of daclizumab resulted in an in-
creased B-cell response to the AAV capsid and a marked 
reductionofCD4+CD25+FoxP3+regulatoryT-cells.Da-
clizumab and Basiliximab are non-depleting antibodies, 
directed against the IL-2 receptor alpha chain (CD25) of 
activatedT-lymphocytesandpreventT-cellproliferation.
Their actions last up to 3 months and infectious compli-
cations associated with these agents are largely dependent 
on the duration of treatment. Induction or short-term 
therapy generally results in a decreased risk of viral 
infections, whereas maintenance or long-term therapy 
in transplant patients is associated with an increased risk 
of CMV infections and death354. Rhesus macaques were 
used to study the effects of immune modulation on 
transgene expression after direct infusion of AAV2-fIX 
into the hepatic artery355. As many hemophilia and renal 
transplant patients are HCV+, the immune suppressive 
drugs chosen for this study were based on a regimen, 
commonly used in renal transplantation, which had been 
previously shown to offer an excellent long-term safety 
profile in HCV+ patients356. They compared the effects 
of combination treatment of MMF and sirolimus with 
or without daclizumab. It was previously shown that the 
immunologic tolerance to the transgene, achieved in he-
patic gene transfer, is mediated by CD4+CD25+FoxP3+ 
regulatory T-cells357 and therefore immune suppressive 
regimens should be designed to block the function of 
CTLs,whilemaintaininginductionofTregs.Hereitwas
shown that a regimen consisting of MMF and sirolimus 
resulted in low level transgene expression and low levels 
of non-neutralizing anti-fIX antibodies, whereas addition 
of daclizumab to the regimen resulted in the formation of 
high levels of inhibitory antibodies directed against fIX 
and complete loss of transgene expression355. The use of 
2 or 3 drug regimen did not affect the transduction ef-
ficiency, but it was found that the addition of daclizumab 
resulted in an increased B-cell response to the AAV 
capsid and a marked reduction of CD4+CD25+FoxP3+ 
regulatoryT-cells.
Blockade of co-stimulation
An alternative approach to inhibition of specific immune 
responses is blockade of co-stimulatory signals delivered 
by the B7-CD28 or CD40-CD40L (CD154) pathways. 
CD28,CTLA4andICOSallbelongtotheCD28receptor
superfamily410.
Cytotoxic T-lymphocyte–associated antigen 4
(CTLA4)isacellsurfaceproteinpresentonT-lympho-
cytes. CTLA4 is endogenously responsible for regulat-
ing T-lymphocyte activation and is upregulated after
T-lymphocyte activation. CTLA4 competes with CD28
and binds to CD80/CD86 (B7) with greater avidity than 
CD28, thereby blocking CD28 binding. This results in the 
production of IFN-g and upregulation of indoleamine 2,3 
dioxygenase (IDO)386 and down-regulation of the acti-
vatedT-lymphocytesandtheimmuneresponse.Abata-
cept is a recombinant fusion protein, which consists of 
theextracellulardomainofCTLA4andtheFcdomainof
IgG(CTLA4Ig),and ismainlyused in the treatmentof
rheumatoid arthritis patients with inadequate responses 
toMTXorTNFa-inhibitors411. The use of Abatacept in 
these patients is not associated with an increased risk in 
viral infections and is generally well tolerated412. In in vivo 
Advectorgenetherapyanimalmodels,CTLA4Igiscom-
monly used as an immune modulatory agent, either as 
direct intraperitoneal or intramuscular injections386,413-417 
or inbedded in the vector contruct413,418. Whereas the 
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former is used for gene therapy of a wide range of dis-
easemodels (seeTable II), ranging fromhemophilia to
muscular dystrophy, the latter is predominantly used as 
gene therapy to prevent solid organ (xeno) transplant 
rejection in animals418-423.IncontrasttoCTLA4Ig,which
blocksbothCTLA4andCD28mediatedco-stimulation,
anti-CD28antibodiesmayprovemorespecific.CTLA4Ig
reducesT-cellco-stimulationthroughcompetitionwith
CD28,butalsopreventsCTLA4fromtransmittingnega-
tive signals, which are important for the development 
of regulatory T-cells and are required for induction
of tolerance424. Anti-CD28 antibodies were shown to 
prolong allograft survival in rats425, in particular when 
combined with CD40Ig426. Although humanized anti-
CD28 antibodies have been developed427, currently effects 
of anti-CD28 antibodies on risk for specific infections in 
a human setting are unknown.
CD40Ig is a secretable fusion protein, which blocks 
the CD40-CD40L pathway. Similar to CTLA4Ig and
anti-CD28 antibodies, CD40Ig is mainly used in animal 
gene transfer models to facilitate and induce tolerance 
to allografts428,429. CD40Ig expression is most commonly 
achieved by gene transfer using adenoviral vectors and is 
often used in combination with another adenoviral vec-
torcarryingtheCTLA4Iggene430-433. There are no reports 
on the use of CD40Ig in a clinical setting. 
The effects of transient inhibition of co-stimulation 
using anti-human CD40 with or without anti-human 
CD86 chimeric antibodies were tested in a non-human 
primate model434. Administration of anti-CD40 and anti-
CD86 antibodies delayed or blocked the development 
of neutralizing antibodies against the adenoviral vector 
and prevented infiltration of CD8+ cells in the liver, 
resulting in prolonged persistence of transduced cells 
and efficient re-administration of adenoviral vector. In
agreement with data from other studies involving block-
ade of co-stimulation, administration of both anti-CD40 
andanti-CD86resultedinmoreefficienttreatmentthan
with anti-CD40 antibodies alone, demonstrating that 
inhibition of multiple pathways of co-stimulation leads 
to enhanced immune suppression434. 
Although administration of anti-CD40L antibody for 
2 weeks, in order to block CD40-CD40L interactions, was 
shown to prolong expression of b-glucuronidase after 
intravenous delivery or brain injections of E1-deleted 
Ad5.bgluc in a mouse model of MPS type VII435.
Inducible co-stimulator (ICOS) is expressed by 
memory T cells, which undergo proliferation indepen-
dent of B7-CD28 or CD40-CD40L signaling. The ICOS 
ligand (ICOSL) is constitutively expressed on B cells and 
is inducible on monocytes, dendritic cells, fibroblasts, 
and endothelial cells. Blockade of ICOS-ICOSL interac-
tionsblocksnotonlyT-helper(Th)type2signaling,but
also Th1-dependent responses. Anti-ICOS antibodies 
wereused in combinationwithAdCTLA4Ig toprevent
cardiac allograft rejection in rats418. Although treatment 
withAdCTLA4Igalonecouldpreventacuteheartrejec-
tion, signs of chronic rejection, including myocyte and 
vessel injury, as well as transplant arteriosclerosis, were 
found 100 days after transplantation. Addition of mouse-
anti-rat ICOS antibodies resulted in a dramatic reduction 
of affected vessels and mononuclear cell infiltration and 
prevention of chronic rejection. However, anti-ICOS an-
tibodies could not prevent hyperacute rejection. Combi-
nationtreatmentwitheitherAdCTLA4Ig418 or CD40Ig436 
could prevent rejection, underlining the importance of 
inhibiting multiple pathways for effective co-stimulation 
blockade resulting in induction of tolerance and preven-
tion of rejection. Recently, the immune modulatory 
effects of a fully human monoclonal antibody against hu-
manICOS(JTA-009)werestudiedinagraft-versus-host
model, where human peripheral blood mononuclear cells 
were engrafted in SCID mice437. JTA-009was shown to
significantly prolong mouse survival. There are no avail-
able data of the use of anti-ICOS antibody in a clinical 
setting.
Tryptophan is an amino acid essential for protein
synthesisandvitalmetabolicfunctions.Twoenzymesare
involved in the catabolism of tryptophan along the kyn-
urenine pathway, Tryptophan 2,3-dioxygenase (TDO),
which is mainly expressed in the liver and Indoleamine 
2,3-dioxygenase (IDO), which is present in many tissues 
and is induced by inflammatory signals. IDO catalyzes 
the rate-limiting step in tryptophan degradation and 
has been shown to play a critical role in the regulation of 
immune tolerance to foreign antigens within the tissue 
microenvironment438.WhereIDOitselfsuppressesT-cell
proliferation, the formed tryptophan metabolites induce 
T-cellapoptosis439. IDO also mediates the tolerogenic ef-
fectsofCTLA4IgandCD40Igbyincreasingthelevelsof
circulatingregulatoryT-cells440 and by specifically inhib-
iting the generation and function of allo-specific central 
memory CD8+ T cells, while effector memory CD8+
T-cell function remains unaffected439. The immunosup-
pressive effects and mechanisms of induction of graft 
tolerance by IDO have been studied by IDO induction 
with IFN-g or local overexpression after gene transfer in 
allo- or xenografts in animal transplantation models441,442, 
but not in a clinical setting.
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Use of anti-inflammatory cytokines
Immune modulation can also be achieved by interfering 
with the inflammatory cascades using either anti-inflam-
matorycytokines,suchasIL-10orTGFb, or by using spe-
cific antibodies directed against inflammatory cytokines, 
including anti-IFNa and anti-IFNb189. Adenoviral vec-
tors induce both innate and adaptive immune responses 
through the induction of high levels of type I IFNs189,443. 
Administration of neutralizing antibodies against mouse 
IFN-a and IFN-b, 6 hours before infusion of Ad-LacZ 
vector and again 5 days after infection to healthy C57Bl/6, 
resulted in a diminished immune response against the 
vector, more stable transgene expression and reduction 
of inflammation189.  
Proteasome inhibitors
Proteasome inhibitors, such as Bortezomib, are small 
molecules that are able to specifically inhibit the activity 
of the proteasome, resulting in an increase of ubiqui-
tinated proteins, increased intracellular reactive oxygen 
species444 and a decrease in presentation of MHC class I 
peptide complexes445. Bortezomib is predominantly used 
in the treatment of refractory multiple myeloma and may 
result in transient peripheral neuropathy, transfusion-
dependent thrombocytopenia and neutropenia with an 
increased risk for fungal, viral and bacterial infections. 
The use of Bortezomib is associated with the reactivation 
of Herpes Zoster (VZV)446, but may result in lethal herpes 
infections by CMV or HSV, particularly in cases where 
the agent is used in combination with Dexamethasone. In 
mice, Bortezomib was shown to enhance the susceptibility 
to viral infections with the lymphocytic choriomeningitis 
virus (LCMV), due to a decreased cytotoxic T-cell re-
sponse447. The administration of bortezomib to mice after 
infectionwithLCMVdidnot influence thecytotoxicT
cell response, suggesting that Bortezomib is effective dur-
ingtheinitialprimingofnaiveTcells447. More recently, 
Bortezomib was shown to facilitate AAV transduction 
both in vitro and in vivo and for multiple serotypes and 
cell types448,449. Possible mechanisms include changes in 
AAV intracellular processing due to modulation of the 
ubiquitin-proteasome system and decreased capsid-
derived peptide epitope presentation on MHC class I449.  
induction of tolerance
Immunological tolerance is the process in which the 
immune system is responsive to foreign antigens, while 
being tolerant to self-antigens. In gene therapy, the goal 
is to achieve tolerance towards exogenous neo-antigens, 
characterized by an antigen-specific nonreactivity of the 
immune system.Tolerance can be established centrally
at the site of primary lymphocyte development (thymus 
and bone marrow), or in the peripheral lymphoid tissues, 
where antigen recognition and processing occur. Cen-
tral tolerance is achieved through a process of positive 
and negative selection, whereas peripheral tolerance is 
broughtaboutthroughclonaldeletionofeffectorT-cells
(Teff),inductionofunresponsiveness(anergy),ignorance
andactivesuppressionbyregulatoryT-cells(Treg).
regulatory t-cells
CD4+/CD25+/FoxP3 regulatory T-cells are stimulated
byIL-10andTGFb, and induce tolerance by suppression 
of ongoing immune responses, through cell contact-
dependent suppression of IL-2 expression, in vivo secre-
tion of suppressive cytokines and even killing effector 
T-cellsorAPCs450.ActivationofTregsisusedforinduc-
tion of tolerance in transplant recipients, but can also be 
used to modulate immune responses against transgenes 
and genetically modified cells407. Regimens containing 
sirolimus are of great interest here, as the drug has been 
shown to promote induction of regulatory T cells451. 
Other immune modulating agents positively affecting 
Tregs are glucocorticoids, mTOR inhibitors, certain
depleting antibodies, including anti-CD3mAb (OKT3)
andAlemtuzumab,CTLA4IgandIvIg(reviewedbyAr-
ruda et al)452. In contrast, the use of immune modulating 
agents that negatively affect levels of immune response 
suppressing Tregs can result in an increased immune
response and loss of transgene expression. Examples 
are cyclophosphamide, the calineurin inhibitors cyclo-
sporineandtacrolimus,horseATGandthemonoclonal
antibodies daclizumab (anti-CD25) and basilixumab, 
whichbinds toactivatedT-cells.Theimportanceof the
Tregsfortolerancetowardsviralvectorsandtransgenes
was demonstrated by a study in non-human primates, 
in which animals were treated with an AAV2 vector 
expressing human fIX and simultaneously received 
immune suppression with MMF, rapamycin with or 
without daclizumab407. Animals treated with MMF and 
rapamycin displayed decreased anti-AAV2 antibodies, 
whereas animals treated with MMF, rapamycin and 
daclizumabdisplayeddecreased levelsofTregsandnot
only had increased antibody responses against the viral 
vector, but also developed neutralizing antibodies against 
the fIX transgene.
hepatic gene transfer
Daily, large amounts of blood flow through the liver and 
many foreign antigens are presented to hepatocytes, he-
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patic stellate cells, Kupffer cells, dendritic cells, sinusoidal 
endothelial cells and lymphocytes. These cells all play a 
different role in immune modulation and induction of 
tolerance. Hepatocytes express a range of immunomodu-
latory markers, including MHC-1, CD-1 and ICAM-1, 
they lack constitutive expression of co-stimulatory mol-
ecules453. Kupffer cells (KC) are scavengers of pathogens, 
including viral particles and express MHC-II molecules, 
ICAM-1, CD80 and CD86. Phagocytosis of pathogens 
by KC results in immediate production and release of 
proinflammatory cytokines, but in response to stimula-
tion with lipopolysaccharide, KC secrete IL-10, TGFb 
and prostanoids, known to promote tolerance. Hepatic 
DCs present foreign antigens to peripheral lymphoid 
tissues, but are also known to be important for tolerance 
following transplantation. Liver sinusoidal endothelial 
cells also have an antigen presenting function, but induce 
antigen-specific tolerance rather than immunity.
Ad vectors are rapidly phagocytosed by KCs and 
induce activation of IL-1b, release of proinflamma-
tory cytokines and a potent anti-viral IFN type I immune 
response. KC presentation of Ad antigens to CD4+ and 
CD8+ cells then result in an adaptive immune response. 
KC depletion results in increased bioavailability of vector 
DNA and transgene expression in the liver454. The use 
of a tightly regulated hepatocyte-specific promoter can 
further reduce transgene expression in APCs. AAV vec-
tors do not induce a potent immune response in the liver 
and are therefore preferred vectors for liver-targeting. 
However, a preexisting neutralizing antibody response 
against AAV or the transgene can complicate optimal 
liver transduction. In vivo liver-directed gene therapy 
with LV vectors induces an adaptive immune response 
against the transgene product as the result of an early 
type I IFN response to the RNA genome of the enveloped 
virus455 andactivationofT-cellsdue to transductionof
APCs456. Here, the use of a hepatocyte-specific promoter 
aloneisnotsufficienttopreventthisimmuneresponse321. 
After intramuscular injection of an AAV2 vector 
expressing the blood coagulation factor IX (fIX), in both 
normal immunocompetent mice457 and dog models of he-
mophilia B458 a rapid humoral immune responses against 
the fIX transgene was observed, preventing fIX from 
reaching therapeutic levels. In contrast, liver-directed 
gene transfer was shown to overcome neutralizing anti-
body formation by creating a tolerogenic environment 
for AAV2409. Thus, liver-targeting can also be used to treat 
non-liver diseases, where systemic delivery of a protein is 
needed, such as metabolic disorders and lysosomal stor-
age diseases453.Toleranceinductionthroughliver-specific
gene targeting requires the use of a minimally immuno-
genic vector, the presence of sufficiently high levels of
therapeutic transgene expression in hepatocytes321, and 
the absence of transgene expression in APCs. The latter 
can be achieved through the use of tightly regulated 
hepatocyte-specific promoters with or without a miRNA-
regulated transcript456. Under these circumstances full
tolerance can be achieved, as evident from the presence of 
transgenicprotein-specificCD4+T-cellsandtheabsence
ofneutralizingantibody formationandCTLresponses,
evenafterrepeatedchallenge.TheroleofTregsininduc-
tion of tolerance to the transgene product after in vivo 
hepatic gene transfer is clearly shown by Cao et al459. In-
ductionofTregsagainsthumanfIXwasobservedasearly
as two weeks after hepatic AAV-mediated gene transfer 
innormalmice.DepletionofTregsresultedinantibody
formation against fIX, whereas adoptive transfer of these 
cellstoTregnegativemicetreatedresultedinsuppression
of antibody formation to fIX459. Importantly, multiple 
studies have shown that immune tolerance to a foreign 
protein is maintained in other organs if that protein is 
expressed first in the liver. For example, after supplemen-
tary gene transfer with an AAV2 or E1/E3 deleted Ad 
vector to muscle after initial hepatic transduction with 
AAV2-fIX tolerance to fIX was maintained460. 
Muscle gene transfer
Immune tolerance to transgenic proteins can also be 
achieved following intramuscular gene transfer461,462. 
High expression of the transgene was shown to be 
critical for tolerance induction following intramuscular 
AAV injection463. The mechanism however appears to 
be distinct from immune tolerance induced by hepatic 
genetransferandnotmediatedbyTregs.Nosignificant
increaseinTregswasseenafterAAV1-fIXintramuscular
gene transfer and tolerance induction to fIX. Adoptive 
transfer of splenocytes from fIX-tolerant mice was not 
able to suppress anti-hfIX immunity in recipient mice 
anddepletion ofTregs in tolerizedmice did not result
in loss of tolerance to fIX462.Thus,itappearsthatT-cell
anergy plays a major role in achieving peripheral toler-
ance after intramuscular gene transfer.
Prevention of binding of ad to clotting factors
High-affinity interaction between coagulation factor X
(fX) and Ad hexons for a number of serotypes, including 
Ad5, mediates Ad uptake into hepatocytes after intrave-
nous Ad injection into mice464-466. Preinjection of snake 
venom factor X-binding protein (fX-bp) reduces hepato-
cyte transduction and thus prolongs the circulation time 
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of the fiber-chimeric Ad5/35 vector in peripheral blood467.
Prevention of immune detection
Stealth-mechanisms
Methods or “stealth mechanisms” employed by the vi-
ruses to evade recognition by the immune system, as de-
scribed by Zaldumbide et al468, and methods to engineer 
non-immunogenic or immune-escaping viral vectors are 
currently being explored to enable the use of common 
serotypes to which the majority of the population already 
has pre-exixting immunity, to enable the use of specific 
characteristics (eg tropism) of otherwise immunogenic 
serotypes and to allow the reuse and readministration 
of vector, when a single treatment does not result in suf-
ficient responses.
Adenoviral vectors display roughly 18000 amino 
groups on their cell surface. Modification of these amino 
groups with molecules, such as activated esters or large 
polysaccharides469,canbeusedtoefficientlymodifylarge
areas of the capsid surface. One of the most common 
methods to shield viruses is PEG-ylation of vectors. 
Polyethylene glycol (PEG) is an uncharged, nontoxic, 
hydrophilic, non-immunogenic polymer, which can be 
covalently attached to the Ad surface470.  Different types of 
PEG with respect to molecular weight, branches, or active 
groups, affect the level of vector shielding and tropism 
(F. Kreppel, ESGCT 2009), butmaintain the viral titer
of the Ad vectors after storage and positively influence 
the stability at various temperatures471-473. When adminis-
tered intravenously, the halflife of conventional Ad is less 
than 2 minutes, and most of the vector is accumulated in 
the liver. PEGylation of Ad vectors results in a four-fold 
decreased clearance and detargeting of the liver474. The 
amount of PEG coating on the surface of the Ad affects 
the characteristics of the vectors as well: the higher the 
modification ratio (ie PEG-coated surface area), and the 
largerthePEGmolecules,themoreefficienttheshielding
of immunogenic epitopes475 and the lower transduction 
of liver470. Decreased immune responses against PEG-Ad 
are the result of both reduced innate IL-6 responses, 
which parallel a similar reduction in vector uptake by 
macrophages476 and reduced humoral and cytotoxic T-
cell responses471.
Büning and collegues generated a capsid library 
by codon randomization at five known immunogenic 
sites152,477 of the structural proteins ORF (cap) of AAV-2 
and screened for viral mutants with an antibody escap-
ing phenotype242. They found that the replacement of 
large hydrophobic amino acids at immunogenic sites by 
smaller hydrophilic amino acids increased the likeliness 
of tolerance towards the AAV-2 capsid. In addition, 
substitution of a limited number of residues was found 
to result in immune-escaping mutants, which retained 
the packaging ability, infectivity and tropism of the 
original AAV2 serotype, whereas major capsid modifica-
tions result in dramatically altered tropism. Noteworthy 
however, despite increased antibody evasion, all mutants 
were fully neutralized at high concentrations of human 
serum, indicating that immune evasion in vivo by stealth 
mechanismsremainsdifficult.Anothermethodtoobtain
stealth phenotype may be by swapping entire antigenic 
domains between viral serotypes150,478,479. 
Prevention of early vector clearance
Complement depletion
It was previously shown that rodent plasma can inhibit 
cell transduction by replication-conditional (oncolytic) 
HSV, replication-defective HSV, and adenovirus vec-
tors68. In vitro depletion of complement with mild heat 
treatment or in vivo depletion by treatment of athymic 
rats with cobra venom factor (CVF) partially reverses this 
effect. CVF is a structural and functional analog of the 
C3 component of complement and through continuous 
activation of C3 leads to depletion of complement480. 
CVF has been successfully used in animal models of 
xenotransplantation in order to prevent the hyperacute 
rejection reaction caused by natural antibodies and 
complement481. New human C3/CVF hybrids have been 
developed for therapeutic complement depletion482. In 
animal studies it was shown that depletion of comple-
ment allowed enhanced initial infection of tumor cells 
by the intravascular HSV vector hrR3 and this effect was 
even more pronounced if the treatment was followed by 
treatment with Cyclophosphamide to inhibit both innate 
and neutralizing humoral antiviral responses68.
AAV capsid binding to C3 complement proteins 
enhances AAV uptake into macrophages, macrophage 
activation and induction of inflammatory cytokines and 
induction of neutralizing antibodies223. Complement 
receptor 1/2 and C3-deficient mice were shown to display 
impaired humoral immunity against AAV2 vectors and 
complement depletion may therefore delay the AAV-
induced antibody development.
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viral infections in patients with impaired immunity
immune deficiencies
The primary severe combined immune deficiencies 
(SCID) can be divided into two separate, but closely 
linked groups, i.e. the immune deficiencies predomi-
nantly involving B cells and hence immunoglobulin 
and antibody production, and the immune deficiencies 
mainlyaffectingTcellsandthereforecell-mediatedim-
munity. Sensitivity for specific viral infections is strongly 
correlated to the cytopathogenic effects caused by a cer-
tain type of virus. Lytic viruses, such as enteroviruses are 
generally encountered by antibody responses, whereas 
viruses creeping from cell-to-cell, such as herpes-, myxo- 
and paramyxoviruses encounter cell-mediated immu-
nity. The secondary or acquired immune deficiencies can 
be subdivided into secondary due to other diseases (eg 
AIDS), or secondary due to disease-related treatments 
(eg myelo- and/or immunosuppressive treatment for 
transplantation patients). 
Adenovirus infections are traditionally associated 
with mild respiratory, ocular, or gastrointestinal disease, 
occurring predominantly in children and U.S. military
recruits as endemic infections or during outbreaks15,176. 
During childhood these infections go often unnoticed, 
are usually self-limiting and result in serotype-specific 
immunity. The most prevalent serotypes belong to spe-
cies A, B and C, i.e. 1, 2, 3, 5, 7 and 41 among civilians 
and 4, 3 and 21 among militairy personnel176,483.Typically,
the patients infected with serotypes 5 or 21 had a higher 
risk of developing severe Ad disease483. In immunocom-
promised patients however, adenovirus infection can 
be more severe, give high morbidity and even result in 
mortality. Both primary infections or reactivation of 
latent Ad can occur. The serotypes described above ac-
count for approximately 50% of the infections in SCID 
patients, and other serotypes isolated from SCID patients 
include serotypes 11, 31, 34 and 35484(seeTableXIand
TableXII).CoinfectionwithmorethanoneAdserotype
is also more common in immunocompromised patients 
than in immunocompetent patients483. Importantly, these 
coinfections may be not only from different serotypes, but 
also from different species485. Most of the serotypes of Ad 
species D have been isolated from AIDS patients, whereas 
species D is rarely found in the normal population and 
does not cause illness (personal communication with 
Marco Schilham). It is conceivable that long-term Ad 
coinfections in AIDS patients with multiple strains may 
provide the opportunity for mutations within a strain and 
allowrecombinationbetweenserotypes.T-cell-mediated
immunity is important for recovery after an acute Ad 
infection. Consequently, immunocompromised patients, 
lacking effective cellular immunity are at higher risk of Ad 
infection. However, the humoral response against AdV is 
also very important for controlling the infection, leaving 
in particular pediatric hematopoietic stem cell trans-
plantation recipients prone to infection and to a lesser 
extent adult hematopoietic stem cell recipients (personal 
communication with Marco Schilham)176. Adenovirus 
infections occur in upto 3-47% of patients following stem 
cell transplantation (SCT),withanassociatedmortality
of up to 70%486,487. 
transplantation patients
The most commonly used immunosuppressive agents 
used to prevent rejection after kidney transplantation 
include (a combination of) corticosteroids, azathio-
prine, calcineurin inhibitors (CsA, tacrolimus), mTOR
inhibitors (sirolimus) and mycophenolate mofetil. Im-
munosuppressive treatment often renders the patients 
susceptible to a wide range of viral infections, as the 
result of reactivation of latent viruses or primary infec-
tions with members of the herpes virus family: HSV-1, 
VZV, EBV, CMV, HHV-6, HHV-7, HHV-8/KSHV; 
community-acquired respiratory viruses: Ad, RSV, influ-
enza, parainfluenza, Metapneumovirus;  Parvovirus B19; 
donor-derived viruses: West Nile virus (in endemic areas 
only), Rabies, Hepatitis B and C, HPV, Polyomavirus 
BK/JC, HIV and SARS (coronavirus)488. Viral infections 
after transplantation follow a general pattern, with in 
the first two months posttransplant most commonly 
acute infections with Herpes viruses (HSV, EBV, VZV 
and CMV) and donor-derived viruses (HBV, HCV), and 
after 2-6 months acute community acquired infections 
(influenza and RSV) and chronic infections with CMV, 
EBV, HCV, HBV, HPV and BK488. Different immunosup-
pressive drugs have been associated with a susceptibility 
to distinct viral infections, such as steroids with HBV and 
HCV, T-cell depleting antibodies with reactivation of
herpes viruses and HIV, tacrolimus with polyoma-related 
nephropathy489, anti-thymocyte globulin and mycophe-
nolate mofetil (MMF) with CMV490. Mycophenolate 
mofetil (MMF) is the prodrug of mycophenolic acid 
(MPA) and is used as an immunosuppressive agent in 
kidney transplant recipients491. MPA is a potent inhibitor 
of inosine monophosphate dehydrogenase (IMP-DH), 
whichresultsinadepletionoftheintracellularGTPand
dGTP in T and B-cells, preventing their proliferation
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and suppressing the cell-mediated and humoral immune 
response. MPA has been shown to inhibit the replication 
of a number of viruses, including arena viruses, yellow 
fever virus, reovirus-1, parainfluenza-3 virus, Coxsackie 
B4 virus, Epstein-Barr virus, Hepatitis B virus and human 
immunodeficiency virus492. 
recombination and shedding of live-attenuated vaccine 
viruses
From vaccination studies, it can be learned that
•adults are unlikely to transmit to other adults high
vaccine vector titers in pre-immune young children 
may increase the risk of transmission to other young 
children or even adults
•shedding and secondary/tertiary transmission most
often occur via direct contact with the site of vaccine 
inoculation 
•the risks of transmission depend on other envi-
ronmental factors including frequent contact with 
excreta from other young children and the level of 
immune competence
•transmissionmay occur due to breeches in precau-
tionary measures despite proper instruction
•risks of recombination between recombinant viral
vectors and related wild type viruses will be the highest 
in the pediatric pre-immune population
•the risk of shedding is likely affected by additional
handling, such as modification of vectors, immune 
modulation, the route of administration; the delivered 
viral vector load (single dose or/re-administration)
•Immune suppression ormodulationmay affect the
environmental risk by two mechanisms:
   -  longer persistence of the vector increases the dura-
tion of interaction with wild type viruses and recom-
bination
   -  immune suppressed individuals are more susceptible 
to infections, thus increasing the chances of interaction 
with specific wild type viruses 
gene therapy vector vaccines
HSV vaccines
Both live-attenuated and replication defective anti-HSV 
vaccines have been developed, but the live-attenuated 
viral vaccines have many advantages over the replication 
incompetent vaccines. Being able to present almost all 
viral antigens, lacking only those required for attenua-
tion, live-attenuated HSV vaccines stimulate both the 
humoral and cellular host immune system more effec-
tively. However, they also harbor the potential risk for 
neurovirulence, reactivation from latency, recombina-
tion with wt virus and possible shedding, the instability 
of the genotype during production258,493,494 (laboratory 
strains of mutant HSV strains are often more attenu-
ated than clinical isolates with the same mutation495) and 
oncogenesis58,154,496. Not all of the modifications made to 
achieve a safe live-attenuated HSV vaccine strain can 
be easily translated to the human situation due to spe-
ciesandvirus-specificdifferences:DeletionofTK from
HSV-1 reduced murine acute lethality and reactivation, 
whereasTK-deficientHSV-2couldstillcausediseasein
humans58,497; deletion of a portion of RR yielded an attenu-
ated HSV-2 strain with protective immunity in an animal 
model, but was not developed for human use due to 
high neurovirulence498; strain NV1020 (formerly R7020), 
based on HSV-1 strain F, was created by a deletion from 
UL54(ICP27) to thepromoterregionof ICP4499,500, but 
was found to be too attenuated to provide protection in 
humans. Vaccine strain RAV 9395, derived from HSV-2 
strainG,carriesdeletions in theUL55andUL56genes
and a deletion of both copies of the g34.5 gene and was 
found to be protective in guinea pigs, but has not been 
tested in a clinical setting501. Various replicative-defective 
HSV-based vectors have been developed to serve either as 
an anti-Herpes vaccine502,503 or as a vaccine vector. HSV-1 
mutants lacking either immediate-early gene ICP4 or 
ICP27 or early gene ICP8 were shown to be capable of 
inducingaT-cellresponseinBALB/cmiceandprotected
mice from challenge with wt HSV-1502. However, lack of 
production of significant levels of late proteins, many of 
which elicit protective immune responses, results in an 
incomplete suboptimal immune reponse. The discon-
tinuously replicating or disabled infectious single cycle 
(DISC) HSV vectors have a deletion of UL22, the late
gene encoding gH, and can infect a noncomplementing 
cell, but resulting viral progeny cannot infect a secondary 
cell503. Both HSV-1504 and HSV-2505 DISC vaccines were 
protective in a guinea pig model upon challenge, but 
more importantly, unlike some replication competent 
HSV vectors257, the HSV-2 DISC virus was shown to be 
avirulent in the nude athymic mouse model. Although in 
a randomized placebo controlled clinical trial treatment 
with a HSV-2 DISC vaccine was shown to be safe, no 
clinical benefit was achieved, whereas asymptomatic viral 
shedding was detected in 82% of the persons following 
completion of the vaccination506. Other clinical trials 
found the gH-deleted HSV vaccine safe and immunogen-
ic, whereas no live virus was found at the site of injection58.
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Ad vaccines
Ad vaccines have been used since the 1950s in military 
trainees. Adenoviruses among recruits were estimated to 
be the cause of about 70% of all respiratory illness and 
Ad was implicated in 90% of the pneumonia-related 
hospitalizations. Serotypes Ad4 and Ad7 were the first to 
be targeted for vaccination, due to their high prevalence 
among military personnel44. In the 1970s the first live oral 
Ad4 and Ad7 vaccines were tested and found to be safe 
and over 95% effective in preventing acute respiratory 
disease507. Studies with live adenovirus serotypes 4 and 
7 vaccines in military recruits have demonstrated little 
horizontal transmission among military personnel, but 
substantial transmission among family members42. Shed-
ding of oral Ad4 and Ad7 vaccine in stool samples was 
found from 7-21 days postvaccination43. Vaccines against 
Ad1, Ad2, Ad5508 and Ad21509 were next to be developed 
and although the effects were more modest in inducing 
neutralizing antibodies than natural infection, the overall 
immunogenicity, safety and shedding in stool samples 
were comparable to data from Ad4 and Ad7 studies. 
Due to their high immunogenicity, adenoviruses 
are also very popular as vaccine vectors for induction of 
immunity against transgenic proteins of other viruses, 
such as from HIV, hepatitis B and influenza, but also 
against tumor-associated neoantigens present in certain 
cancers510. However, oral delivery of the Ad vaccines 
results in a relatively weak adaptive immune responses 
to the transgenes, whereas a robust immune response is 
observed against replication competent Ad vaccine vec-
tors themselves44. 
Vaccinia-based vaccines
Poxvirus vector-based vaccines are being developed 
to protect against infectious diseases and treat cancer. 
As recombination between vaccine virus and naturally 
occuring orthopoxviruses in vivo might result in hybrid 
viruses with unpredictable characteristics. Recently, 
an in vitro study was performed assessing the effects of 
co-infection and possible recombination and demon-
strated that indeed homologous recombination between 
poxvirus-vectored vaccine and naturally circulating 
poxviruses occurred, resulting in genetic instability of 
the transgene, accumulation of non-transgene expressing 
vectors and hybrid virus progeny511. Follow-up of US
military personnel vaccinated with smallpox vaccine, 
showed that, despite provided printed information on 
prevention of transmission, including advice on hand 
washing, covering of the vaccination site and limited 
contact with infants, transmission of Vaccinia was 7.4 
per 100,000 primary vaccinees, as confirmed by viral 
culture or PCR. This included predominantly secondary 
transmission and in two cases tertiary transmission to 
persons with close contact (within the same household, 
intimate contacts and sports partners)52. In a subsequent 
study, it was shown that all of the environmental swabs 
taken from of the recently vaccinated Vaccinia-negative 
persons bed linen, bath towels, shirt sleeves adjacent to 
the vaccination bandages and the vaccinees’ hands were 
negative for live virus as determined by plaque infectivity 
assay, and only 0,78% of the injection-site bandages had 
measurable titers of Vaccinia165. These data underline 
that direct contact with live Vaccinia virus from the 
injection-site (bandages) is the main cause of secondary 
transmission.
In addition, Vaccinia virus (VACV) is commonly used 
in laboratories79 and has been known to cause occasional 
infection of non-vaccinated laboratory personnel167,512,513. 
Most recombinant VACV strains are generated through 
insertional recombination in the viral TK locus514,515. 
AlthoughTKisnon-essentialforviralreplication,dele-
tion results in a modest attenuation in virulence as shown 
in two mouse models309,516. Nevertheless, several human 
infectionswithTK-minusVACV following laboratory-
related exposure have occurred512,517-519, demonstrating 
the difference in virulence in animals and humans. Even 
more, some of the laboratory-acquired VACV infections 
have involved strains carrying foreign genes512,517-519. Ex-
posure to VACV was in most cases the result of a needle-
stick injury, an eye splash or while working with animals 
and resulted in fever, erythema and/or local swelling and 
needed in a few cases hospitalization79. These data consid-
ered,itisnowrecommended,atleastintheUSA,thatin
addition to appropriate laboratory measures, all labora-
tory personnel handling VACV be vaccinated, at least 
every 10 years520 as the benefits of vaccination outweigh 
the risks of infection. In addition, the usage of Biosafety 
level 2 practices and facilities are recommended for ma-
nipulation of viruses or animals with VACV strains79. 
non-gene therapy vaccines
Development of live attenuated vaccines to prevent se-
vere wild type infections in the population may occasion-
ally result in transmission of the lesser virulent vaccine 
virus strains from vaccinated children to unvaccinated 
contacts, thus contributing to herd immunity, but simul-
taneously also posing a possible risk of vaccine-derived 
disease in immunocompromised contacts.
Rotaviruses and orthoreoviruses are both members 
of the Reoviridae (Respiratory Enteric Orphan viruses). 
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The reoviruses differ from all other RNA viruses in that 
their genomes are double stranded. Rotavirus is a com-
mon cause of gastroenteritis in young children (<5 years 
of age), but since immunity to rotavirus is incomplete, 
outbreaks and recurrent infections during adult life may 
occur, especially in institutionalized elderly. Vaccine 
studies have shown that viral shedding and transmission 
to bystanders was more pronounced with the old tetrava-
lent rhesus rotavirus vaccine in comparison to the newer 
human attenuated monovalent rotavirus vaccine, Rotarix 
(GlaxoSmithKline) and the pentavalent bovine-human 
reassortant vaccine, RotaTeq (Merck)521. However, 
Rotarix still has a much greater tendency to shed vaccine 
virus into the stools and is measured, depending on the 
dose, at 7 days after the first dose in 35-80% of the vaccine 
recipients, whereas only about 13% of recipients of Ro-
taTeqwerefoundtoshedanycomponentofthevaccine
virus from day 4-6522. In two trials in infants conducted 
in Singapore523andtheUSA524 transfer of Rotarix vaccine 
occurred to 3 and 2 placebo recipients, respectively. In 
contrast, shedding of live virus was not found in any of 
the healthy adults, who were administered a single dose 
of Rotarix525.
The family of Picornaviridae consists of some of the 
smallest viruses, including Poliovirus, Coxsackie A and 
B virus, Echovirus and Enterovirus. Poliovirus is trans-
mitted primarily by the fecal-oral route, but can also be 
excreted through respiratory droplets. When the virus 
invades the central nervous system, it causes paralysis 
due to destruction of motor neurons. The OPV vaccine 
strains are live attenuated and can replicate in the gas-
trointestinal tract, but not in the central nervous system. 
Tenrecentoutbreaksofpoliomyelitiswereshowntobe
caused by pathogenic circulating vaccine-derived polio-
viruses526. Most of these virulent viruses were found to be 
recombinants of mutated poliovaccine strains and other 
unidentified enteroviruses of species C. In addition some 
sequences in the 3’ half of the recombinants was shown 
to bare homology to sequences of the co-circulating 
Coxsackie A17 strain. In vitro data demonstrated that 
recombination between the live attenuated polio vaccine 
and Coxsackie A17 resulted in viable and virulent hybrid 
progeny. These data emphasize that co-circulation of 
different viruses in the pediatric population can result in 
genetic recombination of viruses, despite differences in 
their pathogenicity and biological properties, including 
receptor usage, and lead to the generation of pathogenic 
recombinants526. Furthermore, a recent study compared 
the immunogenicity of monovalent type 1 oral poliovirus 
(mOPV1) vaccine and trivalent oral poliovirus (tOPV) 
in newborns and found that 36% of the children receiv-
ing mOPV1 and 42% of the newborns receiving tOPV 
shed vaccine strains in stool at any time527. Analysis of 
the vaccine strains showed intratypic differentiation 
with high numbers of antigenically divergent (AD) P1 
isolates, including substitutions of amino acid 60 of the 
VP3 region and residue 99 of the VP1 region, particularly 
in the mOPV1 study group. Substitutions of residues in 
the capsid region as a result from high immunogenic 
pressure may play a role in reversion of attenuation and 
evolution of a neuro-virulent vaccine-derived polio virus 
(VDPV). Therefore, it was stressed that in areas with low 
vaccination coverage528, vaccination with mOPV1 could 
potentially lead to transmission of AD P1 isolates and 
increase the risk for the development of VDPV527. 
Live attenuated influenza vaccine (LAIV1) is a trivalent 
nasal vaccine for active immunization and prevention of 
influenza, which consists of 3 cold-adapted, temperature-
sensitive, attenuated virus strains. The influenza A and B 
master donor virus (MDV) strains used to develop this 
vaccine are genetically and phenotypically stable and 
undergo regular antigenic updating by replacing the 2 
hemagglutinin and neuraminidase genes of the MDV 
strains with those of contemporary influenza strains529. 
Shedding and transmission of LAIV1 was tested in chil-
dren aged 9-36 months, going to primary day-care. This 
setting was chosen to serve as a “worst-case” transmission 
scenario as it was previously shown that young children 
without prior immunity to influenza shed vaccine virus at 
higher titers and for longer duration than older children 
or adults, and because rates of transmission of wild-type 
influenza viruses and other infectious agents in the day-
care environment are high530. It was found that 80% of 
the vaccinated children shed at least one virus strain for 
an average of 8 days during the 3-week post-vaccination 
period, which resulted in the confirmed transmission of 
vaccine strain to one placebo treated toddler, making the 
probability of vaccine strain transmission to a child after 
contact with a single vaccinated child 0.58%531.
Transmissionofvaccinestrainsfromliveattenuated
Varicella vaccine (Oka strain) has been reported on few 
occasions. These included secondary transfer from a 
primary vaccinee to two immune competent patients in 
a chronic care facility for children532, from a vaccinated 
mother to her two susceptible children533, from a healthy 
12-month old infant to his pregnant mother534, and from 
a 5-year old boy in remission from ALL, but receiving 
maintenance anti-cancer chemotherapy, to his two sib-
lings535. The latter is an excellent example of the risks of 
transmission after vaccination of immune compromised 
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patients. A study performed in children with leukemia, 
immunized with Varicella vaccine, demonstrated the 
importance of skin lesions in transmission to healthy sus-
ceptible siblings536. Out of 482 immunized children, 156 
developed a rash, which resulted in secondary transmis-
sion to 17% of the exposed healthy susceptible siblings 
with mild disease and one case of tertiary transmission. 
The risk for transmission of the varicella vaccine to the 
exposed siblings was directly correlated to the number 
of skin lesions of the vaccinee536. Current recommenda-
tions from the Infectious Diseases Working Party of 
the EBMT for immunization of recipients of stem cell
transplantation with Varicella vaccine therefore include 
either vaccination of seronegative patients before stem 
cell transplantationorat twoyearsafterSCTaswellas
vaccination of seronegative family members537. 
All together, these data suggest that 1) live attenuated 
vaccine shedding is associated with a low degree of 
immunity and a larger vaccine dose; 2) transmission 
is associated with intensive contact and most likely to 
occur in pre-immune children in daycare centers or 
within the same household, elderly and disabled people 
with suboptimal immunity housed in nursing homes 
and chronic care facilities, and among military trainees; 
3) shedding and transfer is more likely to occur from 
the primary site of vaccination or vaccine-induced 
skin lesions; 4) recombination risk is associated with 
a low degree of immunity and occurrence of multiple 
simultaneous infections, and may result in viable and 
(more) virulent virus strains with different tropism. 
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munity Amsterdam, The Netherlands: HIV and use of 
lentiviral vectors
•Dr. Chiara Bonini, Experimental Hematology, HSR,
Milan, Italy: Immune responses in bone marrow trans-
plantation patients and immunotherapy
•Drs.AnnadeGoede,DepartmentofVirology,Erasmus
MC, Rotterdam, The Netherlands: Shedding and trans-
mission
•Prof.Dr.RobHoeben,DepartmentofMolecularCell
Biology,LUMC:Stealthmechanismsandvectors
•Dr.PetervanderLey,LaboratoryofVaccineResearch,
Netherlands Vaccination Institute, Bilthoven, The 
Netherlands: Risks associated with vaccinations
•Dr.PerLjungman,DepartmentofMedicine,Karolin-
ska Institute, Sweden: Risk of infection after stem cell 
transplantation
•Dr.MarcoSchilham,DepartmentofPediatrics,LUMC,
Leiden, The Netherlands: Immunity and infections with 
Adenoviral vectors
Meetings with the supervisory committee and project 
progress
During the three meetings with the supervisory commit-
tee, the contents and progress of the report were discussed 
and adapted, where necessary.
•January 2009: Initiation project and discussion initial
project plan by executers results in inclusion all relevant 
viral vectors, both replication deficient and replication 
competent, information on risks of immune modula-
tion, shedding and recombination from non-gene 
therapy studies, such as vaccination and transplantation 
studies, as suggested by Prof. Dr. Rob Hoeben, and ef-
fects of currently used immune modulation in relevant 
preclinical gene therapy studies.
•May 2009: Data from clinical non-gene therapy are
presented and discussion on project scope and focus
•September2009:Presentationprefinalreport
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List of abbreviations
AAV Adeno-associated virus
Ad Adenovirus
ADA Adenosine deaminase
APC Antigen Presenting Cell
ATG Anti-thymocyteglobulin
Bu Busulfan
CAR Coxsackie-adenovirus receptor
CMV Cytomegalovirus
CR Conditionally replicating
CsA Cyclosporin A
CTL CytotoxicTcell
CTLA4 CytotoxicTcellantigen-4
CY Cyclophosphamide
DC Dendritic Cell
EBV Eppstein Barr Virus
ERA Environmental Risk Assessment
FDA Food and Drug Administration
GALV Gibbon Ape Leukemia Virus
GFP Green Fluorescent Protein
HIV Human Immune deficiency Virus
Hd-Ad Helper dependent Adenovirus
HSV Herpes Simplex Virus
IA Intra arterial
IFN Interferon
IL Interleukin
IP Intraperitoneal
IRES Internal ribosomal entry site
IT Intratumoral
IV Intravenous
lacZ b-galactosidase
LV Lentivirus
M Φ Macrophage
MHC Major Histocompatibility Complex
MLV Murine leukemia Virus
MMF Mycophenolate Mofetil
MMP Matrix metalloproteinases
MTX Methotrexate
LiSt of aBBreviationS
MV Measles Virus
NAb Neutralizing antibody
NDV Newcastle Disease Virus
NK Natural Killer cell
OV Oncolytic Virus
PAMP Pathogen activated molecular patterns
PCR Polymerase Chain Reaction
pfu plaque forming unit
Polio Poliovirus
PPR Pattern Recognition Receptor
RC Replication Competent
Reo Reovirus
RV Retrovirus
SCID Severe Combined Immune Deficiency
Th T-helpercell
TK ThymidineKinase
TLR Toll-likereceptor
TNF TumorNecrosisFactor
VACV Vaccinia Virus
vp viral particles
VSV Vesicular Stomatitis Virus
WNV West Nile Virus
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table v. Categories of transgenes
Category example environmental risk increased
Structural proteins Actin, myosin No
Enzymatic proteins Proteases, phosphatases No
Metabolic enzymes No
Cell growth and
house keeping proteins
Possible
Cell cycle and division proteins No
Proteins involved in DNA 
replication
Yes
Membrane proteins Ion channels, G-coupled receptors, 
transporters
Possible
Proteins enhancing cytotoxic or 
lytic activity
Fusogenic membrane proteins Yes
Tracking eGFP, luciferase No
Selection MGMT No
Antibiotic resistance Neomycin Possible 
Prodrug activating f-FC/CD No
Toxins Botulin Yes
Regulatory genes, transcription 
factors
Yes
Growth factors, cytokines, 
chemokines
Yes
Immune modulatory molecules CTLA4Ig,B7.1 Possible
Oncogenes Yes
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010 101
Figures and Tables
ta
bl
ev
i. 
Pr
op
er
tie
s o
f v
ir
al
 ve
ct
or
s
ve
ct
or
s
ve
ct
or
 m
od
ifi
-
ca
tio
ns
h
os
t r
an
ge
ve
ct
or
 y
ie
ld
 
(t
u
/m
L)
in
fla
m
m
at
or
y 
po
te
nt
ia
l
tr
op
ism
en
tr
y p
at
hw
ay
ve
ct
or
 g
en
om
e 
fo
rm
s
tr
an
sg
en
e 
ex
pr
es
sio
n
ge
no
to
xi
ci
ty
sh
ed
di
ng
Ad
V
-A
d2
, 5
, 7
E1
 an
d 
E3
/E
4-
de
le
te
d
Br
oa
d,
 
de
pe
nd
in
g 
on
 
se
ro
ty
pe
H
ig
h 
10
12
 
P
FU
/m
L
H
ig
h
Br
oa
d,
 
de
pe
nd
in
g 
on
 
se
ro
ty
pe
Re
ce
pt
or
-m
ed
ia
te
d 
en
do
cy
to
sis
ep
iso
m
al
Sh
or
t-t
er
m
 
(w
ks
)
lo
w
m
od
er
at
e
RV - M
M
LV
ga
g, 
po
l, 
en
v-
de
le
te
d
Ec
ot
ro
pi
c
A
m
ph
ot
ro
pi
c
VS
V-
G
 Ψ
M
od
er
at
e 1
01
0
Lo
w
D
iv
id
in
g 
ce
lls
Br
oa
d
Re
ce
pt
or
–b
in
di
ng
, 
m
em
br
an
e f
us
io
n
in
te
gr
at
ed
Lo
ng
-te
rm
 
(y
rs
)
In
se
rt
io
na
l 
m
ut
ag
en
es
is
lo
w
LV - H
IV
, S
IV
, 
EI
AV
, F
IV
ga
g, 
po
l, 
en
v, 
ne
f, 
vp
r-
de
le
te
d
Ec
ot
ro
pi
c
A
m
ph
ot
ro
pi
c
VS
V-
G
 Ψ
Lo
w
-
M
od
er
at
e
Lo
w,
 d
ep
en
ds
 o
n 
en
ve
lo
pe
 p
ro
te
in
s
D
ep
en
ds
 
on
 en
ve
lo
pe
 
pr
ot
ei
ns
in
te
gr
at
ed
Lo
ng
-te
rm
 
(y
rs
)
In
se
rt
io
na
l 
m
ut
ag
en
es
is
lo
w
H
er
pe
s
- H
SV
-1
no
n-
ly
tic
Br
oa
d
M
od
er
at
e –
 
H
ig
h
10
10
-1
01
2
H
ig
h
N
eu
ro
ns
Re
ce
pt
or
-b
in
di
ng
, 
m
em
br
an
e f
us
io
n
ep
iso
m
al
Tr
an
si
en
t
lo
w
hi
gh
 
A
AV
-A
AV
1,
 6
-9
-A
AV
8,
 9
-A
AV
1,
 4
, 5
-A
AV
2
-A
AV
8
-A
AV
9
re
p-
, c
ap
-
Br
oa
d
H
ig
h 
10
12
Lo
w
Br
oa
d
M
us
cle
Li
ve
r
CN
S
Ki
dn
ey
Pa
nc
re
as
Lu
ng
Re
ce
pt
or
-m
ed
ia
te
d 
en
do
cy
to
sis
, 
en
do
so
m
al
 es
ca
pe
ep
iso
m
al
 (9
0%
), 
in
te
gr
at
ed
 (1
0%
)
M
ed
iu
m
 to
 
lo
ng
-te
rm
 
(y
rs
)
Lo
w,
 b
ut
 
co
nc
ei
va
bl
e 
in
se
rt
io
na
l 
m
ut
ag
en
es
is 
up
on
 in
te
gr
at
io
n 
m
od
er
at
e
Po
x
- V
ac
ci
ni
a
- C
an
ar
y
Br
oa
d
10
8 P
FU
/m
L
H
ig
h
ep
iso
m
al
Tr
an
si
en
t
lo
w
hi
gh
M
ea
sle
s
Ba
cu
lo
vi
ru
s
M
am
m
al
ia
n
H
ig
h 
tit
er
Br
oa
d
Re
ov
iru
s
ty
pe
 3
10
8 
– 
10
9 P
FU
/
m
L
Br
oa
d,
 tu
m
or
 
ce
lls
Re
ce
pt
or
-m
ed
ia
te
d 
en
do
cy
to
sis
ep
iso
m
al
no
ne
A
da
pt
ed
fr
om
v
ir
al
v
ec
to
rs
,f
ro
m
v
ir
ol
og
y
to
tr
an
sg
en
e
ex
pr
es
si
on
.T
U
 :
tr
an
sd
uc
in
g
un
it
s h
ttp
://
ww
w.
sta
nf
or
d.
ed
u/
de
pt
/E
H
S/
pr
od
/re
se
ar
ch
la
b/
bi
o/
do
cs
/v
ira
l_
ve
ct
or
s.p
df
Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010102 Immune modulation in gene therapy studies - Points to consider for Environmental Risk Assessment - 2010
Figures and Tables
table vii. Properties of viruses that determine transmissibility
Property feature
Survivabililty outside host Resistancetoambienttemperatures,drying,UVlight,pH,physicalor
chemical agents
Existence of an alternative host Mosquito, pets
Portal of entry Skin, mucous membranes (respiratory tract, gastrointestinal tract, 
conjunctiva, genital tract)
Evasiveness Rapid multiplication before induction immune response,
high variability in antigenic structure
Pathogenesis Incubation period
Route of excretion Respiratory, conjunctival, skin/mucosa, faeces, blood, semen
table viii. risk factors for infections
risk of infections example
Primary or secondary immune deficiency SCID, HIV
Immune suppressive treatment TBI,chemotherapy
Immune modulation ImmunemodulatoryagentsotherthanTBIandchemotherapy,orin
significantly lower doses
Young age pre-immune children, typically < 5 yrs
Old age >60 yrs
Predisposing diseases Diabetes Mellitus
Disability Immobilization
Intensive contact Military personnel, day care centers, nursing homes, kindergarten, 
dormitories
Low socio-economic status Lack of vaccination, malnutrition
Other Stress, nutrition, alcoholism
table iX. adenovirus species, serotypes and receptors
Species Serotype(s) receptor177,564 features 486
A 12,18,31 CAR Pneumonia, enteritis
B1 3,7,
16,21,50
sBAR
CD46
Hemorrhagic cystitis
B2 11,
14,
34,
35
sBAR, CD46
sBAR
CD46
Hemorrhagic cystitis
C 1,2,5,6 CAR Hepatitis, pneumonia, disseminated, high risk 
post-SCTx
D 9,10,13,15,17,20,22-30,
32,33,36,38,39,42-49,51
8, 19a,37, 53, 54
CAR
CAR
sialic acid
Eye, gastrointestinal tract
E 4 CAR Respiratory tract
F 40,41 CAR Gastrointestinal tract
G  (proposed) 52 Gastrointestinal tract 565 
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table X. aav serotypes and receptors
Serotype host receptors organ tropism
AAV-1 Human/non-human primates Sialic acid Muscle, CNS, liver
AAV-2 Human HSPG, heparin, FGFR1, HGF, 
integrins anb5, a5b1
Kidney, liver, muscle, lung, CNS
AAV-3 Human HSPG, heparin
AAV-4 Non-human primates Sialic acid CNS (eye)
AAV-5 Human Sialic acid, PDGF-R CNS (eye)
AAV-6 Human and non-human primates HSPG, sialic acid, heparin Skeletal muscle, liver
AAV-7 Human and non-human primates Skeletal muscle
AAV-8 Human and non-human primates Heart, liver, skeletal muscle, 
pancreas
AAV-9 Human and non-human primates Liver, skeletal muscle, lung
AAV-10 Non-human primates
AAV-11 Non-human primates
table Xi. Prevalence and severity of virusinfections in immunocompromised patients
virus SCid aidS Cytotoxic agents/
Malignancies566
Stem cell / organ transplantion488,566
HSV* ++ ++ 15% 90% 
CMV ++ +++ 32-58% 3-17%
VZV* +++ ++ 2-15% 25-60%
HHV6*, HHV8   +++ ++ +
EBV +++ + ++ +++
Measles ++  +  +  +
AdV* B D, B ++ 5-29% 
A,B,C(SCT)486, B (kidney), C (liver)
HBV, HCV   ++   ++
Reovirus, rotavirus ++      
Papova virus 
(HPV, BK, JC)
++ + ++ ++,upto95%inSCT
HIV   +++   +
Adapted from Human Virology by Leslie Collier and John Oxford (1993): +++ very common and often severe;
++ common, moderately severe; + infrequent or mild; +/- rare; * mostly reactivation.
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